§4.30

- (d) On these total ratings Department of Veterans Affairs regulations governing effective dates for increased benefits will control.
- (e) The total hospital rating if convalescence is required may be continued for periods of 1, 2, or 3 months in addition to the period provided in paragraph (a) of this section.
- (f) Extension of periods of 1, 2 or 3 months beyond the initial 3 months may be made upon approval of the Veterans Service Center Manager.
- (g) Meritorious claims of veterans who are discharged from the hospital with less than the required number of days but need post-hospital care and a prolonged period of convalescence will be referred to the Director, Compensation Service, under §3.321(b)(1) of this chapter.

[29 FR 6718, May 22, 1964, as amended at 41 FR 11294, Mar. 18, 1976; 41 FR 34256, Aug. 13, 1976; 54 FR 4281, Jan. 30, 1989; 54 FR 34981, Aug. 23, 1989; 71 FR 28586, May 17, 2006; 79 FR 2100, Jan. 13, 2014]

§ 4.30 Convalescent ratings.

A total disability rating (100 percent) will be assigned without regard to other provisions of the rating schedule when it is established by report at hospital discharge (regular discharge or release to non-bed care) or outpatient release that entitlement is warranted under paragraph (a) (1), (2) or (3) of this section effective the date of hospital admission or outpatient treatment and continuing for a period of 1, 2, or 3 months from the first day of the month following such hospital discharge or outpatient release. The termination of these total ratings will not be subject to §3.105(e) of this chapter. Such total rating will be followed by appropriate schedular evaluations. When the evidence is inadequate to assign a schedular evaluation, a physical examination will be scheduled and considered prior to the termination of a total rating under this section.

- (a) Total ratings will be assigned under this section if treatment of a service-connected disability resulted in:
- (1) Surgery necessitating at least one month of convalescence (Effective as to outpatient surgery March 1, 1989.)

- (2) Surgery with severe postoperative residuals such as incompletely healed surgical wounds, stumps of recent amputations, therapeutic immobilization of one major joint or more, application of a body cast, or the necessity for house confinement, or the necessity for continued use of a wheelchair or crutches (regular weight-bearing prohibited). (Effective as to outpatient surgery March 1, 1989.)
- (3) Immobilization by cast, without surgery, of one major joint or more. (Effective as to outpatient treatment March 10, 1976.)

A reduction in the total rating will not be subject to §3.105(e) of this chapter. The total rating will be followed by an open rating reflecting the appropriate schedular evaluation; where the evidence is inadequate to assign the schedular evaluation, a physcial examination will be scheduled prior to the end of the total rating period.

- (b) A total rating under this section will require full justification on the rating sheet and may be extended as follows:
- (1) Extensions of 1, 2 or 3 months beyond the initial 3 months may be made under paragraph (a) (1), (2) or (3) of this section.
- (2) Extensions of 1 or more months up to 6 months beyond the initial 6 months period may be made under paragraph (a) (2) or (3) of this section upon approval of the Veterans Service Center Manager.

[41 FR 34256, Aug. 13, 1976, as amended at 54 FR 4281, Jan. 30, 1989; 71 FR 28586, May 17, 2006]

§4.31 Zero percent evaluations.

In every instance where the schedule does not provide a zero percent evaluation for a diagnostic code, a zero percent evaluation shall be assigned when the requirements for a compensable evaluation are not met.

[58 FR 52018, Oct. 6, 1993]

Subpart B—Disability Ratings

THE MUSCULOSKELETAL SYSTEM

§ 4.40 Functional loss.

Disability of the musculoskeletal system is primarily the inability, due

to damage or infection in parts of the system, to perform the normal working movements of the body with normal excursion, strength, speed, coordination and endurance. It is essential that the examination on which ratings are based adequately portray the anatomical damage, and the functional loss, with respect to all these elements. The functional loss may be due to absence of part, or all, of the necessary bones, joints and muscles, or associated structures, or to deformity, adhesions, defective innervation, or other pathology, or it may be due to pain, supported by adequate pathology and evidenced by the visible behavior of the claimant undertaking the motion. Weakness is as important as limitation of motion, and a part which becomes painful on use must be regarded as seriously disabled. A little used part of the musculoskeletal system may be expected to show evidence of disuse, either through atrophy, the condition of the skin, absence of normal callosity or the like.

§ 4.41 History of injury.

In considering the residuals of injury, it is essential to trace the medical-industrial history of the disabled person from the original injury, considering the nature of the injury and the attendant circumstances, and the requirements for, and the effect of, treatment over past periods, and the course of the recovery to date. The duration of the initial, and any subsequent, period of total incapacity, especially periods reflecting delayed union, inflammation, swelling, drainage, or operative intervention, should be given close attention. This consideration, or the absence of clear cut evidence of injury, may result in classifying the disability as not of traumatic origin, either reflecting congenital or developmental etiology, or the effects of healed dis-

§ 4.42 Complete medical examination of injury cases.

The importance of complete medical examination of injury cases at the time of first medical examination by the Department of Veterans Affairs cannot be overemphasized. When possible, this should include complete neurological

and psychiatric examination, and other special examinations indicated by the physical condition, in addition to the required general and orthopedic or surgical examinations. When complete examinations are not conducted covering all systems of the body affected by disease or injury, it is impossible to visualize the nature and extent of the service connected disability. Incomplete examination is a common cause of incorrect diagnosis, especially in the neurological and psychiatric fields, and frequently leaves the Department of Veterans Affairs in doubt as to the presence or absence of disabling conditions at the time of the examination.

§ 4.43 Osteomyelitis.

Chronic, or recurring, suppurative osteomyelitis, once clinically identified, including chronic inflammation of bone marrow, cortex, or periosteum, should be considered as a continuously disabling process, whether or not an actively discharging sinus or other obvious evidence of infection is manifest from time to time, and unless the focus is entirely removed by amputation will entitle to a permanent rating to be combined with other ratings for residual conditions, however, not exceeding amputation ratings at the site of election.

§ 4.44 The bones.

The osseous abnormalities incident to trauma or disease, such as malunion with deformity throwing abnormal stress upon, and causing malalignment of joint surfaces, should be depicted from study and observation of all available data, beginning with inception of injury or disease, its nature, degree of prostration, treatment and duration of convalescence, and progress of recovery with development of permanent residuals. With shortening of a long bone, some degree of angulation is to be expected; the extent and direction should be brought out by X-ray and observation. The direction of angulation and extent of deformity should be carefully related to strain on the neighboring joints, especially those connected with weight-bearing.

§ 4.45

§ 4.45 The joints.

As regards the joints the factors of disability reside in reductions of their normal excursion of movements in different planes. Inquiry will be directed to these considerations:

- (a) Less movement than normal (due to ankylosis, limitation or blocking, adhesions, tendon-tie-up, contracted scars, etc.).
- (b) More movement than normal (from flail joint, resections, nonunion of fracture, relaxation of ligaments, etc.).
- (c) Weakened movement (due to muscle injury, disease or injury of peripheral nerves, divided or lengthened tendons, etc.).
 - (d) Excess fatigability.
- (e) Incoordination, impaired ability to execute skilled movements smoothly.
- (f) Pain on movement, swelling, deformity or atrophy of disuse. Instability of station, disturbance of locomotion, interference with standing and weight-bearing are related considerations. For the purpose of rating disability from arthritis, the shoulder, elbow, wrist, hip, knee, and ankle are considered major joints; multiple involvements of the interphalangeal, metacarpal and carpal joints of the upper extremities, the interphalangeal, metatarsal and tarsal joints of the lower extremities, the cervical vertebrae, the dorsal vertebrae, and the vertebrae, lumbar are considered groups of minor joints, ratable on a parity with major joints. lumbosacral articulation and both sacroiliac joints are considered to be a group of minor joints, ratable on disturbance of lumbar spine functions.

§ 4.46 Accurate measurement.

Accurate measurement of the length of stumps, excursion of joints, dimensions and location of scars with respect to landmarks, should be insisted on. The use of a goniometer in the measurement of limitation of motion is indispensable in examinations conducted within the Department of Veterans Affairs. Muscle atrophy must also be accurately measured and reported.

[41 FR 11294, Mar. 18, 1976]

§§ 4.47-4.54 [Reserved]

§ 4.55 Principles of combined ratings for muscle injuries.

- (a) A muscle injury rating will not be combined with a peripheral nerve paralysis rating of the same body part, unless the injuries affect entirely different functions.
- (b) For rating purposes, the skeletal muscles of the body are divided into 23 muscle groups in 5 anatomical regions: 6 muscle groups for the shoulder girdle and arm (diagnostic codes 5301 through 5306); 3 muscle groups for the forearm and hand (diagnostic codes 5307 through 5309); 3 muscle groups for the foot and leg (diagnostic codes 5310 through 5312); 6 muscle groups for the pelvic girdle and thigh (diagnostic codes 5313 through 5318); and 5 muscle groups for the torso and neck (diagnostic codes 5319 through 5323).
- (c) There will be no rating assigned for muscle groups which act upon an ankylosed joint, with the following exceptions:
- (1) In the case of an ankylosed knee, if muscle group XIII is disabled, it will be rated, but at the next lower level than that which would otherwise be assigned.
- (2) In the case of an ankylosed shoulder, if muscle groups I and II are severely disabled, the evaluation of the shoulder joint under diagnostic code 5200 will be elevated to the level for unfavorable ankylosis, if not already assigned, but the muscle groups themselves will not be rated.
- (d) The combined evaluation of muscle groups acting upon a single unankylosed joint must be lower than the evaluation for unfavorable ankylosis of that joint, except in the case of muscle groups I and II acting upon the shoulder.
- (e) For compensable muscle group injuries which are in the same anatomical region but do not act on the same joint, the evaluation for the most severely injured muscle group will be increased by one level and used as the combined evaluation for the affected muscle groups.
- (f) For muscle group injuries in different anatomical regions which do not act upon ankylosed joints, each muscle group injury shall be separately rated

and the ratings combined under the provisions of § 4.25.

(Authority: 38 U.S.C. 1155) [62 FR 30237, June 3, 1997]

§ 4.56 Evaluation of muscle disabilities.

- (a) An open comminuted fracture with muscle or tendon damage will be rated as a severe injury of the muscle group involved unless, for locations such as in the wrist or over the tibia, evidence establishes that the muscle damage is minimal.
- (b) A through-and-through injury with muscle damage shall be evaluated as no less than a moderate injury for each group of muscles damaged.
- (c) For VA rating purposes, the cardinal signs and symptoms of muscle disability are loss of power, weakness, lowered threshold of fatigue, fatigue-pain, impairment of coordination and uncertainty of movement.
- (d) Under diagnostic codes 5301 through 5323, disabilities resulting from muscle injuries shall be classified as slight, moderate, moderately severe or severe as follows:
- (1) Slight disability of muscles—(i) Type of injury. Simple wound of muscle without debridement or infection.
- (ii) History and complaint. Service department record of superficial wound with brief treatment and return to duty. Healing with good functional results. No cardinal signs or symptoms of muscle disability as defined in paragraph (c) of this section.
- (iii) Objective findings. Minimal scar. No evidence of fascial defect, atrophy, or impaired tonus. No impairment of function or metallic fragments retained in muscle tissue.
- (2) Moderate disability of muscles—(i) Type of injury. Through and through or deep penetrating wound of short track from a single bullet, small shell or shrapnel fragment, without explosive effect of high velocity missile, residuals of debridement, or prolonged infection
- (ii) History and complaint. Service department record or other evidence of in-service treatment for the wound. Record of consistent complaint of one or more of the cardinal signs and symptoms of muscle disability as defined in

- paragraph (c) of this section, particularly lowered threshold of fatigue after average use, affecting the particular functions controlled by the injured muscles.
- (iii) Objective findings. Entrance and (if present) exit scars, small or linear, indicating short track of missile through muscle tissue. Some loss of deep fascia or muscle substance or impairment of muscle tonus and loss of power or lowered threshold of fatigue when compared to the sound side.
- (3) Moderately severe disability of muscles—(i) Type of injury. Through and through or deep penetrating wound by small high velocity missile or large low-velocity missile, with debridement, prolonged infection, or sloughing of soft parts, and intermuscular scarring.
- (ii) History and complaint. Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section and, if present, evidence of inability to keep up with work requirements
- (iii) Objective findings. Entrance and (if present) exit scars indicating track of missile through one or more muscle groups. Indications on palpation of loss of deep fascia, muscle substance, or normal firm resistance of muscles compared with sound side. Tests of strength and endurance compared with sound side demonstrate positive evidence of impairment.
- (4) Severe disability of muscles—(i) Type of injury. Through and through or deep penetrating wound due to high-velocity missile, or large or multiple low velocity missiles, or with shattering bone fracture or open comminuted fracture with extensive debridement, prolonged infection, or sloughing of soft parts, intermuscular binding and scarring.
- (ii) History and complaint. Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section, worse than those shown for moderately severe muscle injuries,

§4.57

and, if present, evidence of inability to keep up with work requirements.

- (iIi) Objective findings. Ragged, depressed and adherent scars indicating wide damage to muscle groups in missile track. Palpation shows loss of deep fascia or muscle substance, or soft flabby muscles in wound area. Muscles swell and harden abnormally in contraction. Tests of strength, endurance, or coordinated movements compared with the corresponding muscles of the uninjured side indicate severe impairment of function. If present, the following are also signs of severe muscle disability:
- (A) X-ray evidence of minute multiple scattered foreign bodies indicating intermuscular trauma and explosive effect of the missile.
- (B) Adhesion of scar to one of the long bones, scapula, pelvic bones, sacrum or vertebrae, with epithelial sealing over the bone rather than true skin covering in an area where bone is normally protected by muscle.
- (C) Diminished muscle excitability to pulsed electrical current in electrodiagnostic tests.
 - (D) Visible or measurable atrophy.
- (E) Adaptive contraction of an opposing group of muscles.
- (F) Atrophy of muscle groups not in the track of the missile, particularly of the trapezius and serratus in wounds of the shoulder girdle.
- (G) Induration or atrophy of an entire muscle following simple piercing by a projectile.

(Authority: 38 U.S.C. 1155 [62 FR 30238, June 3, 1997]

§ 4.57 Static foot deformities.

It is essential to make an initial distinction between bilateral flatfoot as a congenital or as an acquired condition. The congenital condition, with depression of the arch, but no evidence of abnormal callosities, areas of pressure, strain or demonstrable tenderness, is a congenital abnormality which is not compensable or pensionable. In the acquired condition, it is to be remembered that depression of the longitudinal arch, or the degree of depression is not the essential feature. The attention should be given to anatomical changes, as compared to normal, in the

relationship of the foot and leg, particularly to the inward rotation of the superior portion of the os calcis, medial deviation of the insertion of the Achilles tendon, the medial tilting of the upper border of the astragalus. This is an unfavorable mechanical relationship of the parts. A plumb line dropped from the middle of the patella falls inside of the normal point. The forepart of the foot is abducted, and the foot everted. The plantar surface of the foot is painful and shows demonstrable tenderness, and manipulation of the foot produces spasm of the Achilles tendon, peroneal spasm due to adhesion about the peroneal sheaths, and other evidence of pain and limited motion. The symptoms should be apparent without regard to exercise. In severe cases there is gaping of bones on the inner border of the foot, and rigid valgus position with loss of the power of inversion and adduction. Exercise with undeveloped or unbalanced musculature, producing chronic irritation, can be an aggravating factor. In the absence of trauma or other definite evidence of aggravation, service connection is not in order for pes cavus which is a typically congenital or juvenile disease.

§4.58 Arthritis due to strain.

With service incurred lower extremity amputation or shortening, a disabling arthritis, developing in the same extremity, or in both lower extremities, with indications of earlier, or more severe, arthritis in the injured extremity, including also arthritis of the lumbosacral joints and lumbar spine, if associated with the leg amputation or shortening, will be considered as service incurred, provided, however, that arthritis affecting joints not directly subject to strain as a result of the service incurred amputation will not be granted service connection. This will generally require separate evaluation of the arthritis in the joints directly subject to strain. Amputation, or injury to an upper extremity, is not considered as a causative factor with subsequently developing arthritis, except in joints subject to direct strain or actually injured.

§4.59 Painful motion.

With any form of arthritis, painful motion is an important factor of disability, the facial expression, wincing, etc., on pressure or manipulation, should be carefully noted and definitely related to affected joints. Muscle spasm will greatly assist the identification. Sciatic neuritis is not uncommonly caused by arthritis of the spine. The intent of the schedule is to recognize painful motion with joint or periarticular pathology as productive of disability. It is the intention to recognize actually painful, unstable, or malaligned joints, due to healed injury, as entitled to at least the minimum compensable rating for the joint. Crepitation either in the soft tissues such as the tendons or ligaments, or crepitation within the joint structures should be noted carefully as points of contact which are diseased. Flexion elicits such manifestations. The joints involved should be tested for pain on both active and passive motion, in weight-bearing and nonweight-bearing and, if possible, with the range of the opposite undamaged joint.

§4.60 [Reserved]

§4.61 Examination.

With any form of arthritis (except traumatic arthritis) it is essential that the examination for rating purposes cover all major joints, with especial reference to Heberden's or Haygarth's nodes.

§ 4.62 Circulatory disturbances.

The circulatory disturbances, especially of the lower extremity following injury in the popliteal space, must not be overlooked, and require rating generally as phlebitis.

§4.63 Loss of use of hand or foot.

Loss of use of a hand or a foot, for the purpose of special monthly compensation, will be held to exist when no effective function remains other than that which would be equally well served by an amputation stump at the site of election below elbow or knee with use of a suitable prosthetic appliance. The determination will be made on the basis of the actual remaining function of the hand or foot, whether the acts of grasping, manipulation, etc., in the case of the hand, or of balance and propulsion, etc., in the case of the foot, could be accomplished equally well by an amputation stump with prosthesis.

- (a) Extremely unfavorable complete ankylosis of the knee, or complete ankylosis of 2 major joints of an extremity, or shortening of the lower extremity of $3\frac{1}{2}$ inches (8.9 cms.) or more, will be taken as loss of use of the hand or foot involved.
- (b) Complete paralysis of the external popliteal nerve (common peroneal) and consequent, footdrop, accompanied by characteristic organic changes including trophic and circulatory disturbances and other concomitants confirmatory of complete paralysis of this nerve, will be taken as loss of use of the foot.

[29 FR 6718, May 22, 1964, as amended at 43 FR 45349, Oct. 2, 1978]

§ 4.64 Loss of use of both buttocks.

Loss of use of both buttocks shall be deemed to exist when there is severe damage to muscle Group XVII, bilateral (diagnostic code number 5317) and additional disability rendering it impossible for the disabled person, without assistance, to rise from a seated position and from a stooped position (fingers to toes position) and to maintain postural stability (the pelvis upon head of femur). The assistance may be rendered by the person's own hands or arms, and, in the matter of postural stability, by a special appliance.

§4.65 [Reserved]

§4.66 Sacroiliac joint.

The common cause of disability in this region is arthritis, to be identified in the usual manner. The lumbosacral and sacroiliac joints should be considered as one anatomical segment for rating purposes. X-ray changes from arthritis in this location are decrease or obliteration of the joint space, with the appearance of increased bone density of the sacrum and ilium and sharpening of the margins of the joint. Disability is manifest from erector spinae spasm (not accounted for by other pathology), tenderness on deep palpation and percussion over these joints, loss of

§4.67

normal quickness of motion and resiliency, and postural defects often accompanied by limitation of flexion and extension of the hip. Traumatism is a rare cause of disability in this connection, except when superimposed upon congenital defect or upon an existent arthritis; to permit assumption of pure traumatic origin, objective evidence of damage to the joint, and history of trauma sufficiently severe to injure this extremely strong and practically immovable joint is required. There should be careful consideration of lumbosacral sprain, and the various symptoms of pain and paralysis attributable to disease affecting the lumbar vertebrae and the intervertebral disc.

§ 4.67 Pelvic bones.

The variability of residuals following these fractures necessitates rating on specific residuals, faulty posture, limitation of motion, muscle injury, painful motion of the lumbar spine, manifest by muscle spasm, mild to moderate sciatic neuritis, peripheral nerve injury, or limitation of hip motion.

§ 4.68 Amputation rule.

The combined rating for disabilities of an extremity shall not exceed the rating for the amputation at the elective level, were amputation to be performed. For example, the combined evaluations for disabilities below the knee shall not exceed the 40 percent evaluation, diagnostic code 5165. This 40 percent rating may be further combined with evaluation for disabilities above the knee but not to exceed the above the knee amputation elective level. Painful neuroma of a stump after amputation shall be assigned the evaluation for the elective site of reamputation.

§ 4.69 Dominant hand.

Handedness for the purpose of a dominant rating will be determined by the evidence of record, or by testing on VA

examination. Only one hand shall be considered dominant. The injured hand, or the most severely injured hand, of an ambidextrous individual will be considered the dominant hand for rating purposes.

(Authority: 38 U.S.C. 1155) [62 FR 30239, June 3, 1997]

§4.70 Inadequate examinations.

If the report of examination is inadequate as a basis for the required consideration of service connection and evaluation, the rating agency may request a supplementary report from the examiner giving further details as to the limitations of the disabled person's ordinary activity imposed by the disease, injury, or residual condition, the prognosis for return to, or continuance of, useful work. When the best interests of the service will be advanced by personal conference with the examiner, such conference may be arranged through channels.

§4.71 Measurement of ankylosis and joint motion.

Plates I and II provide a standardized description of ankylosis and joint motion measurement. The anatomical position is considered as 0°, with two major exceptions: (a) Shoulder rotation—arm abducted to 90°, elbow flexed to 90° with the position of the forearm reflecting the midpoint 0° between internal and external rotation of the shoulder; and (b) supination and pronation—the arm next to the body, elbow flexed to 90°, and the forearm in midposition 0° between supination and pronation. Motion of the thumb and fingers should be described by appropriate reference to the joints (See Plate III) whose movement is limited, with a statement as to how near, in centimeters, the tip of the thumb can approximate the fingers, or how near the tips of the fingers can approximate the proximal transverse crease of palm.




PLATE I

§4.71a




PLATE II

 $[29 \ FR \ 6718, May \ 22, \ 1964, as amended at 43 \ FR \ 45349, Oct. \ 2, \ 1978; \ 67 \ FR \ 48785, July \ 26, \ 2002]$

§ 4.71a Schedule of ratings—musculoskeletal system.

ACUTE, SUBACUTE, OR CHRONIC DISEASES

	Rat- ing
5000 Osteomyelitis, acute, subacute, or chronic: Of the pelvis, vertebrae, or extending into major joints, or with multiple localization or with long history of intractability and debility, anemia, amyloid liver changes, or other continuous	
constitutional symptoms	100
Frequent episodes, with constitutional symptoms	60
With definite involucrum or sequestrum, with or without discharging sinus	30
	20
Inactive, following repeated episodes, without	10
With definite involucrum or sequestrum, with or without discharging sinus	2

ACUTE, SUBACUTE, OR CHRONIC DISEASES—Continued

Rat-

NOTE (1): A rating of 10 percent, as an exception to the amputation rule, is to be assigned in any case of active osteomyelitis where the amputation rating for the affected part is no percent. This 10 percent rating and the other partial ratings of 30 percent roless are to be combined with ratings for ankylosis, limited motion, nonunion or malunion, shortening, etc., subject, of course, to the amputation rule. The 60 percent rating, as it is based on constitutional symptoms, is not subject to the amputation rule. A rating for osteomyelitis will not be applied following cure by removal or radical resection of the affected bone.

§4.71a

ACUTE, SUBACUTE, OR CHRONIC DISEASES-

Continued	:5—
	Rat- ing
NOTE (2): The 20 percent rating on the basis of activity within the past 5 years is not assignable following the initial infection of active osteomyelitis with no subsequent reactivation. The prerequisite for this historical rating is an established recurrent osteomyelitis. To qualify for the 10 percent rating, 2 or more episodes following the initial infection are required. This 20 percent rating or the 10 percent rating, when applicable, will be assigned once only to cover disability at all sites of previously active infection with a future ending date in the case of the 20 percent rating. 5001 Bones and joints, tuberculosis of, active or inactive:	
Active	100
process: With constitutional manifestations associated with active joint involvement, totally incapaci-	
tating Less than criteria for 100% but with weight loss and anemia productive of severe impairment of health or severely incapacitating exacerbations occurring 4 or more times a year or a	100
lesser number over prolonged periods	60
bations occurring 3 or more times a year One or two exacerbations a year in a well-estab-	40
lished diagnosis. For chronic residuals: For residuals such as limitation of motion or ankylosis, favorable or unfavorable, rate under the appropriate diagnostic codes for the specific joints involved. Where, however, the limitation of motion of the specific joint or joints involved is noncompensable under the codes a rating of 10 percent is for application for each such major joint or group of minor joints affected by limitation of motion, to be combined, not added under diagnostic code 5002. Limitation of motion must be objectively confirmed by findings such as swelling, muscle spasm, or satisfactory evidence of painful motion.	20

NOTE: The ratings for the active process will not be combined with the residual ratings for limitation of motion or ankylosis. Assign the higher evaluation.
5003 Arthritis, degenerative (hypertrophic or osteo-

arthritis):

Degenerative arthritis established by X-ray find-ings will be rated on the basis of limitation of motion under the appropriate diagnostic codes for the specific joint or joints involved (DC 5200 etc.). When however, the limitation of motion of the specific joint or joints involved is motion of the specific joint or joints involved is noncompensable under the appropriate diagnostic codes, a rating of 10 pct is for application for each such major joint or group of minor joints affected by limitation of motion, to be combined, not added under diagnostic code 5003. Limitation of motion must be objectively confirmed by findings such as swelling, muscle spasm, or satisfactory evidence of painful motion. In the absence of limitation of motion, rate as below: motion, rate as below:

ACUTE, SUBACUTE, OR CHRONIC DISEASES-Continued

	Rat- ing
With X-ray evidence of involvement of 2 or	
more major joints or 2 or more minor joint groups, with occasional incapacitating ex-	
acerbations	20
groups	10
on X-ray findings, above, will not be combined with ratings based on limitation of motion. NOTE (2): The 20 pct and 10 pct ratings based	
on X-ray findings, above, will not be utilized in rating conditions listed under diagnostic codes 5013 to 5024, inclusive.	
5004 Arthritis, gonorrheal. 5005 Arthritis, pneumococcic.	
5006 Arthritis, typhoid. 5007 Arthritis, syphilitic.	
5008 Arthritis, streptococcic.	
With the types of arthritis, diagnostic codes 5004 through 5009, rate the disability as rheumatoid	
arthritis. 5010 Arthritis, due to trauma, substantiated by X-ray findings: Rate as arthritis, degenerative.	
5011 Bones, caisson disease of: Rate as arthritis, cord involvement, or deafness, depending on the	
severity of disabling manifestations. 5012 Bones, new growths of, malignant	100
Note: The 100 percent rating will be continued for 1 year following the cessation of surgical,	
X-ray, antineoplastic chemotherapy or other therapeutic procedure. At this point, if there has been no local recurrence or metastases, the rating will be made on residuals.	
5013 Osteoporosis, with joint manifestations.	
5014 Osteomalacia. 5015 Bones, new growths of, benign.	
5016 Osteitis deformans. 5017 Gout.	
5018 Hydrarthrosis, intermittent.	
5019 Bursitis. 5020 Synovitis.	
5021 Myositis.	
5022 Periostitis.	
5023 Myositis ossificans.	
5024 Tenosynovitis. The diseases under diagnostic codes 5013	
through 5024 will be rated on limitation of mo- tion of affected parts, as arthritis, degenera- tive, except gout which will be rated under di-	
agnostic code 5002. 5025 Fibromyalgia (fibrositis, primary fibromyalgia	
syndrome) With widespread musculoskeletal pain and ten-	
der points, with or without associated fatigue, sleep disturbance, stiffness, paresthesias, headache, irritable bowel symptoms, depres-	
sion, anxiety, or Raynaud's-like symptoms: That are constant, or nearly so, and refrac-	
tory to therapy	40
That are episodic, with exacerbations often precipitated by environmental or emo- tional stress or by overexertion, but that	
are present more than one-third of the time	20

38 CFR Ch. I (7-1-17 Edition)

§4.71a

ACUTE, SUBACUTE, OR CHRONIC DISEASES— Continued

	Rat- ing
NOTE: Widespread pain means pain in both the left and right sides of the body, that is both above and below the waist, and that affects both the axial skeleton (i.e., cervical spine, anterior chest, thoracic spine, or low back) and the extremities.	

PROSTHETIC IMPLANTS

	Rating	
	Major	Minor
5051 Shoulder replacement (prosthesis). Prosthetic replacement of the shoulder joint:		
For 1 year following implantation of prosthesis	100	100
severe, painful motion or weak- ness in the affected extremity With intermediate degrees of resid- ual weakness, pain or limitation	60	50
of motion, rate by analogy to di- agnostic codes 5200 and 5203. Minimum rating	30	20
For 1 year following implantation of prosthesis	100	100
severe painful motion or weak- ness in the affected extremity With intermediate degrees of resid- ual weakness, pain or limitation of motion rate by analogy to di- agnostic codes 5205 through 5208.	50	40
Minimum evaluation	30	20
prosthesis	100	100
ness in the affected extremity With intermediate degrees of residual weakness, pain or limitation of motion, rate by analogy to diagnostic code 5214.	40	30
Minimum rating	20	20
For 1 year following implantation of prosthesis		100
crutches		1 90

PROSTHETIC IMPLANTS—Continued

	Rat	ing
	Major	Mino
Markedly severe residual weak-		
ness, pain or limitation of motion		
following implantation of pros-		
thesis		7
Moderately severe residuals of		
weakness, pain or limitation of motion		5
Minimum rating		3
5055 Knee replacement (prosthesis).		١
Prosthetic replacement of knee joint:		
For 1 year following implantation of		
prosthesis		10
With chronic residuals consisting of		
severe painful motion or weak-		
ness in the affected extremity		6
With intermediate degrees of resid-		
ual weakness, pain or limitation		
of motion rate by analogy to di-		
agnostic codes 5256, 5261, or 5262.		
		3
Minimum rating5056 Ankle replacement (prosthesis).		٦
Prosthetic replacement of ankle joint:		
For 1 year following implantation of		
prosthesis		10
With chronic residuals consisting of		
severe painful motion or weak-		
ness		4
With intermediate degrees of resid-		
ual weakness, pain or limitation		
of motion rate by analogy to		
5270 or 5271.		,
Minimum rating		2
NOTE (1): The 100 pct rating for 1 year following implantation of prosthesis		
will commence after initial grant of the		
1-month total rating assigned under		
§ 4.30 following hospital discharge.		
NOTE (2): Special monthly compensa-		
tion is assignable during the 100 pct		
rating period the earliest date perma-		
nent use of crutches is established.		
COMBINATIONS OF DISABILITIES		
5104 Anatomical loss of one hand and loss		
of use of one foot		110
5105 Anatomical loss of one foot and loss		
of use of one hand		¹ 10
5106 Anatomical loss of both hands		¹ 10
5107 Anatomical loss of both feet		110
5108 Anatomical loss of one hand and one		٠
foot		110
5109 Loss of use of both hands		110
5110 Loss of use of both feet		110
5111 Loss of use of one hand and one foot		110
	1	110

codes 5051 through 5056 means a total replacement of the named joint. However, in DC 5054, "prosthetic replacement" means a total replacement of the head of the femur or of the acetabulum.

1 Also entitled to special monthly compensation.

TABLE II—RATINGS FOR MULTIPLE LOSSES OF EXTREMITIES WITH DICTATOR'S RATING CODE AND 38 CFR CITATION

		`	or it on another			
	Impairment of other extremity					
Impairment of one extremity	Anatomical loss or loss of use below elbow	Anatomical loss or loss of use below knee	Anatomical loss or loss of use above elbow (preventing use of prosthesis)	Anatomical loss or loss of use above knee (preventing use of prosthesis)	Anatomical loss near shoulder (preventing use of prosthesis)	Anatomical loss near hip (pre- venting use of prosthesis)
Anatomical loss or loss of use below elbow.	M Codes M-1 a, b, or c, 38 CFR 3.350 (c)(1)(i).	L Codes L-1 d, e, f, or g, 38 CFR 3.350(b).	M½ Code M-5, 38 CFR 3.350 (f)(1)(x).	L½ Code L-2 c, 38 CFR 3.350 (f)(1)(vi).	N Code N-3, 38 CFR 3.350 (f)(1)(xi).	M Code M-3 c, 38 CFR 3.350 (f)(1)(viii)
Anatomical loss or loss of use below knee.		L Codes L-1 a, b, or c, 38 CFR 3.350(b).	L½ Code L–2 b, 38 CFR 3.350	L½ Code L–2 a, 38 CFR 3.350 (f)(1)(i).	M Code M–3 b, 38 CFR 3.350	M Code M-3 a, 38 CFR 3.350 (f)(1)(ii)
Anatomical loss or loss of use above elbow			(f)(1)(iii). N Code N-1, 38 CFR 3.350 (d)(1).	M Code M–2 a, 38 CFR 3.350	(f)(1)(iv). N½ Code N–4, 38 CFR 3.350	M½ Code M-4 c, 38 CFR 3.350
(preventing use of prosthesis). Anatomical loss or loss of use above knee (preventing use				(c)(1)(iii). M Code M-2 a, 38 CFR 3.350 (c)(1)(ii).	(f)(1)(ix). M½ Code M-4 b, 38 CFR 3.350 (f)(1)(vii).	(f)(1)(xi) M½ Code M-4 a, 38 CFR 3.350 (f)(1)(v)
of prosthesis). Anatomical loss near shoulder (preventing use					O Code O-1, 38 CFR 3.350 (e)(1)(i).	N Code N-2 b, 38 CFR 3.350 (d)(3)
of prosthesis). Anatomical loss near hip (preventing use of prosthesis).						N Code N-2 a, 38 CFR 3.350 (d)(2)

Note.—Need for aid attendance or permanently bedridden qualifies for subpar. L. Code L-1 h, i (38 CFR 3.350(b)). Paraplegia with loss of use of both lower extremities and loss of anal and bladder sphincter control qualifies for subpar. O. Code O-2 (38 CFR 3.350(e)(2)). Where there are additional disabilities rated 50% or 100%, or anatomical or loss of use of a third extremity see 38 CFR 3.350(f) (3), (4) or (5).

(Authority: 38 U.S.C. 1115)

AMPUTATIONS: UPPER EXTREMITY—Continued

AMPUTATIONS: UPPER EXTREMITY				
		Rating		
		Major	Minor	
A	rm, amputation of:			
5120	Disarticulation	1 90	1 90	
5121	Above insertion of deltoid	1 90	180	
5122	Below insertion of deltoid	180	1 70	
F	orearm, amputation of:			
5123	Above insertion of pronator teres	¹ 80	¹ 70	
5124	Below insertion of pronator teres	1 70	1 60	
5125	Hand, loss of use of	170	¹ 60	
	MULTIPLE FINGER AMPUTATIONS			
5126 of	Five digits of one hand, amputation	1 70	¹ 60	
	our digits of one hand, amputation of:	. 70	. 60	
5127	Thumb, index, long and ring	1 70	160	
5128	Thumb, index, long and little	170	¹ 60	
5129	Thumb, index, ring and little	170	1 60	
5130	Thumb, long, ring and little	170	¹ 60	
5131	Index, long, ring and little	60	50	
T	hree digits of one hand, amputation of:			
5132	Thumb, index and long	60	50	
5133	Thumb, index and ring	60	50	
5134	Thumb, index and little	60	50	
5135	Thumb, long and ring	60	50	
5136	Thumb, long and little	60	50	

		Rating	
		Major	Minor
5137	Thumb, ring and little	60	50
5138	Index, long and ring	50	40
5139	Index, long and little	50	40
5140	Index, ring and little	50	40
5141	Long, ring and little	40	30
T	wo digits of one hand, amputation of:		
5142	Thumb and index	50	40
5143	Thumb and long	50	40
5144	Thumb and ring	50	40
5145	Thumb and little	50	40
5146	Index and long	40	30
5147	Index and ring	40	30
5148	Index and little	40	30
5149	Long and ring	30	20
5150	Long and little	30	20
5151	Ring and little	30	20
·	a) The ratings for multiple finger amputations apply to amputations at the proximal interphalangeal joints or through proximal phalanges. b) Amputation through middle phalanges will be rated as prescribed for unfavorable ankylosis of the fingers		

§4.71a

38 CFR Ch. I (7-1-17 Edition)

AMPUTATIONS: UPPER EXTREMITY—Continued

	Rati	Rating	
	Major	Minor	
(c) Amputations at distal joints, or through distal phalanges, other than negligible losses, will be rated as prescribed for favorable ankylosis of the fingers (d) Amputation or resection of metacarpal bones (more than one-half the bone lost) in multiple fingers injuries will require a rating of 10 percent added to (not combined with) the ratings, multiple finger amputations, subject to the amputation rule applied to the forearm. (e) Combinations of finger amputations at various levels, or finger amputations with ankylosis or limitation of motion of the fingers will be rated on the basis of the grade of disability, i.e., amputation, unfavorable ankylosis, most representative of the levels or combinations. With an even number of fingers involved, and adjacent grades of disability, select the higher of the two grades. (f) Loss of use of the hand will be held to exist when no effective function remains other than that which would be equally well served by an amputation stump with a suitable prosthetic appliance.			

5152 Thumb, amputation of:

AMPUTATIONS: UPPER EXTREMITY—Continued

	Rating	
	Major	Minor
With metacarpal resection At metacarpophalangeal joint or through	40	30
proximal phalanx	30	20
At distal joint or through distal phalanx 5153 Index finger, amputation of	20	20
With metacarpal resection (more than one-half the bone lost)	30	20
thereto	20	20
Through middle phalanx or at distal joint	10	10
5154 Long finger, amputation of: With metacarpal resection (more than one-half the bone lost) Without metacarpal resection, at proxi-	20	20
mal interphalangeal joint or proximal thereto	10	10
With metacarpal resection (more than one-half the bone lost)	20	20
mal interphalangeal joint or proximal thereto	10	10
With metacarpal resection (more than one-half the bone lost)	20	20
mal interphalangeal joint or proximal thereto	10	10

¹ Entitled to special monthly compensation.

SINGLE FINGER AMPUTATIONS




PLATE III

§4.71a

38 CFR Ch. I (7-1-17 Edition)

AMPUTATIONS: LOWER EXTREMITY

	Rat- ing
Thigh, amputation of:	
5160 Disarticulation, with loss of extrinsic pelvic gir-	
dle muscles	2 90
5161 Upper third, one-third of the distance from	
perineum to knee joint measured from perineum	2 80
5162 Middle or lower thirds	² 60
Leg, amputation of:	
5163 With defective stump, thigh amputation rec-	
ommended	² 60
5164 Amputation not improvable by prosthesis con-	
trolled by natural knee action	² 60
5165 At a lower level, permitting prosthesis	² 40
5166 Forefoot, amputation proximal to metatarsal	
bones (more than one-half of metatarsal loss)	² 40
5167 Foot, loss of use of	2 40

AMPUTATIONS: LOWER EXTREMITY—Continued

	Rat- ing
5170 Toes, all, amputation of, without metatarsal	
loss	30
5171 Toe, great, amputation of:	
With removal of metatarsal head	30
Without metatarsal involvement	10
5172 Toes, other than great, amputation of, with re-	
moval of metatarsal head:	
One or two	20
Without metatarsal involvement	0
5173 Toes, three or four, amputation of, without	
metatarsal involvement:	
Including great toe	20
Not including great toe	10

² Also entitled to special monthly compensation.

AMPUTATIONS: LOWER EXTREMITY




PLATE IV

38 CFR Ch. I (7-1-17 Edition)

§4.71a

THE SHOULDER AND ARM

THE ELBOW AND FOREARM—Continued

	Rating	
	Major	Minor
5200 Scapulohumeral articulation, anky-		
losis of:		
NOTE: The scapula and humerus move		
as one piece.		
Unfavorable, abduction limited to 25°		
from side	50	40
Intermediate between favorable and un-		
favorable	40	30
Favorable, abduction to 60°, can reach		
mouth and head	30	20
5201 Arm, limitation of motion of:		
To 25° from side	40	30
Midway between side and shoulder		
level	30	20
At shoulder level	20	20
5202 Humerus, other impairment of:		
Loss of head of (flail shoulder)	80	70
Nonunion of (false flail joint)	60	50
Fibrous union of	50	40
Recurrent dislocation of at		
scapulohumeral joint.		
With frequent episodes and guard-		
ing of all arm movements	30	20
With infrequent episodes, and		
guarding of movement only at		
shoulder level	20	20
Malunion of:	00	
Marked deformity	30	20
Moderate deformity	20	20
5203 Clavicle or scapula, impairment of:	00	
Dislocation of	20	20
Nonunion of: With loose movement	00	
Without loose movement	20	20
Malunion of	10 10	10 10
Or rate on impairment of function of	10	10
contiguous joint.		
contiguous joint.		

THE ELBOW AND FOREARM

	Rati	ng
	Major	Minor
5205 Elbow, ankylosis of:		
Unfavorable, at an angle of less than		
50° or with complete loss of		
supination or pronation	60	50
Intermediate, at an angle of more than		4.0
90°, or between 70° and 50°	50	40
Favorable, at an angle between 90° and	40	00
70°	40	30
5206 Forearm, limitation of flexion of: Flexion limited to 45°		40
	50 40	40 30
Flexion limited to 55° Flexion limited to 70°	30	20
Flexion limited to 70	20	20
Flexion limited to 90	10	10
Flexion limited to 100	0	0
5207 Forearm, limitation of extension of:	U	U
Extension limited to 110°	50	40
Extension limited to 110	40	30
Extension limited to 90°	30	20
Extension limited to 75°	20	20
Extension limited to 70°	10	10
Extension limited to 45°	10	10
5208 Forearm, flexion limited to 100° and		
extension to 45°	20	20
5209 Elbow, other impairment of Flail joint	60	50

	Rating	
	Major	Minor
Joint fracture, with marked cubitus varus or cubitus valgus deformity or with ununited fracture of head of ra-		
dius5210 Radius and ulna, nonunion of, with	20	20
flail false joint	50	40
Nonunion in upper half, with false movement:		
With loss of bone substance (1 inch (2.5 cms.) or more) and marked		
deformity	40	30
deformity	30	20
Nonunion in lower half	20	20
Malunion of, with bad alignment	10	10
5212 Radius, impairment of:	10	10
Nonunion in lower half, with false move- ment:		
With loss of bone substance (1 inch		
(2.5 cms.) or more) and marked		
deformity	40	30
Without loss of bone substance or		
deformity	30	20
Nonunion in upper half	20	20
Malunion of, with bad alignment	10	10
5213 Supination and pronation, impairment		
of:		
Loss of (bone fusion):		
The hand fixed in supination or		
hyperpronation	40	30
The hand fixed in full pronation	30	20
The hand fixed near the middle of	30	20
the arc or moderate pronation	20	20
Limitation of pronation:	20	20
Motion lost beyond middle of arc	30	20
Motion lost beyond last quarter of		
arc, the hand does not approach		
full pronation	20	20
Limitation of supination:		
To 30° or less	10	10
NOTE: In all the forearm and wrist inju-		
ries, codes 5205 through 5213, mul-		
tiple impaired finger movements due		
to tendon tie-up, muscle or nerve in-		
jury, are to be separately rated and		
combined not to exceed rating for		
loss of use of hand.		

THE WRIST

	Rating	
	Major	Minor
5214 Wrist, ankylosis of: Unfavorable, in any degree of palmar flexion, or with ulnar or radial deviation	50 40 30	40 30 20
Dorsiflexion less than 15°	10	10
arm	10	10

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

THE TIAND	_		THE TIAND CONTINUES		
	Rat	_		Rat	
	Major	Minor		Major	Mino
1) For the index, long, ring, and little fingers			(iv) If only the metacarpophalangeal		
(digits II, III, IV, and V), zero degrees of			or proximal interphalangeal joint		
flexion represents the fingers fully ex-			is ankylosed, and there is a gap		
tended, making a straight line with the rest			of two inches (5.1 cm.) or less		
of the hand. The position of function of the			between the fingertip(s) and the		
hand is with the wrist dorsiflexed 20 to 30			proximal transverse crease of the palm, with the finger(s) flexed to		
degrees, the metacarpophalangeal and			the extent possible, evaluate as		
proximal interphalangeal joints flexed to			favorable ankylosis		
30 degrees, and the thumb (digit I) abducted and rotated so that the thumb pad			(4) Evaluation of ankylosis of the thumb:		
faces the finger pads. Only joints in these			(i) If both the carpometacarpal and		
positions are considered to be in favorable			interphalangeal joints are		
position. For digits II through V, the			ankylosed, and either is in exten-		
metacarpophalangeal joint has a range of			sion or full flexion, or there is ro-		
zero to 90 degrees of flexion, the proximal			tation or angulation of a bone,		
interphalangeal joint has a range of zero			evaluate as amputation at		
to 100 degrees of flexion, and the distal			metacarpophalangeal joint or		
(terminal) interphalangeal joint has a			through proximal phalanx(ii) If both the carpometacarpal and		
range of zero to 70 or 80 degrees of flex-			interphalangeal joints are		
ion			ankylosed, evaluate as unfavor-		
2) When two or more digits of the same			able ankylosis, even if each joint		
hand are affected by any combination of			is individually fixed in a favorable		
amputation, ankylosis, or limitation of mo- tion that is not otherwise specified in the			position		
rating schedule, the evaluation level as-			(iii) If only the carpometacarpal or		
signed will be that which best represents			interphalangeal joint is		
the overall disability (i.e., amputation, un-			ankylosed, and there is a gap of		
favorable or favorable ankylosis, or limita-			more than two inches (5.1 cm.)		
tion of motion), assigning the higher level			between the thumb pad and the		
of evaluation when the level of disability is			fingers, with the thumb attempt-		
equally balanced between one level and			ing to oppose the fingers, evalu- ate as unfavorable ankylosis		
the next higher level			(iv) If only the carpometacarpal or		
3) Evaluation of ankylosis of the index,			interphalangeal joint is		
long, ring, and little fingers:			ankylosed, and there is a gap of		
(i) If both the metacarpophalangeal			two inches (5.1 cm.) or less be-		
and proximal interphalangeal			tween the thumb pad and the fin-		
joints of a digit are ankylosed,			gers, with the thumb attempting		
and either is in extension or full			to oppose the fingers, evaluate		
flexion, or there is rotation or an-			as favorable ankylosis		
gulation of a bone, evaluate as amputation without metacarpal			(5) If there is limitation of motion of two or		
resection, at proximal inter-			more digits, evaluate each digit separately		
phalangeal joint or proximal			and combine the evaluations		
thereto	l		I. Multiple Digits: Unfavorable Ank	cylosis	
(ii) If both the metacarpophalangeal				,	
and proximal interphalangeal			5216 Five digits of one hand, unfavorable		
joints of a digit are ankylosed,			ankylosis of	60	5
evaluate as unfavorable anky-			Note: Also consider whether evaluation as		
losis, even if each joint is individ-			amputation is warranted.		
ually fixed in a favorable position.			5217 Four digits of one hand, unfavorable		
(iii) If only the metacarpophalangeal			ankylosis of: Thumb and any three fingers	60	
or proximal interphalangeal joint			Index, long, ring, and little fingers	50	2
is ankylosed, and there is a gap			Note: Also consider whether evaluation as		
of more than two inches (5.1			amputation is warranted.		
cm.) between the fingertip(s) and			5218 Three digits of one hand, unfavorable		
the proximal transverse crease of the palm, with the finger(s) flexed			ankylosis of:		
to the extent possible, evaluate			Thumb and any two fingers	50	4
as unfavorable ankylosis			Index, long, and ring; index, long,		
ao amavorabio amyioolo		,	and little; or index, ring, and little		
			fingers	40	3
			Long, ring, and little fingers	30	2
			Note: Also consider whether evaluation as		
			amputation is warranted.		
			5219 Two digits of one hand, unfavorable ankylosis of:		
			Thumb and any finger	40	3
			mumb and any imger	. 40	

38 CFR Ch. I (7-1-17 Edition)

§4.71a

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

	Rati	Rating	
	Major	Minor	
Index and long; index and ring; or index and little fingers	30 20	20 20	
II. Multiple Digits: Favorable Anky	ylosis		
5220 Five digits of one hand, favorable ankylosis of	50	40	
Thumb and any three fingers Index, long, ring, and little fingers 5222 Three digits of one hand, favorable an-	50 40	40 30	
kylosis of: Thumb and any two fingers Index, long, and ring; index, long, and little; or index, ring, and little	40	30	
fingers	30 20	20 20	
Thumb and any finger	30	20	
Index and long; index and ring; or index and little fingers	20	20	
Long and ring; long and little; or ring and little fingers	10	10	
III. Ankylosis of Individual Dig	its		
5224 Thumb, ankylosis of: Unfavorable	20 10	20 10	
5225 Index finger, ankylosis of:	10	10	
hand. 5226 Long finger, ankylosis of:	10	10	
hand. 5227 Ring or little finger, ankylosis of: Unfavorable or favorable	0	0	

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

		Rati	ing
		Major	Mino
amp addi sulti	Also consider whether evaluation as utation is warranted and whether an tional evaluation is warranted for regilimitation of motion of other digits terference with overall function of the d.		
	IV. Limitation of Motion of Individua	al Digits	
5228	Thumb, limitation of motion:		
	With a gap of more than two inches (5.1 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers With a gap of one to two inches (2.5 to 5.1 cm.) between the thumb pad and the fingers, with	20	20
	the thumb attempting to oppose the fingers	10	10
5229	(2.5 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers Index or long finger, limitation of mo-	0	(
tion:			
	With a gap of one inch (2.5 cm.) or more between the fingertip and the proximal transverse crease of the palm, with the finger flexed to the extent possible, or; with extension limited by more than 30		
	degrees	10	10
5230	and; extension is limited by no more than 30 degrees	0	(
tion:	Any limitation of motion	0	,
	THE SPINE		
			Rat-
Gene	ral Rating Formula for Diseases and I	njuries	
(For d	of the Spine iagnostic codes 5235 to 5243 unless	5243 is	
eval Inte	uated under the Formula for vertebral Disc Syndrome Based on Ir g Episodes):	Rating ncapaci-	
	With or without symptoms such a (whther or not it radiates), stiffn aching in the area of the spine affer residuals of injury or disease	ess, or ected by	
	Unfavorable ankylosis of the spine		100
	thoracolumbar spine		50

THE SPINE—Continued

THE SPINE—Continued

	Rat- ing		Rat-
Unfavorable ankylosis of the entire cervical spine; or, forward flexion of the thoracolumbar spine 30 degrees or less; or, favorable ankylosis of the entire thoracolumbar spine		Note (2): (See also Plate V.) For VA compensation purposes, normal forward flexion of the cervical spine is zero to 45 degrees, extension is zero to 45 degrees, elft and right lateral flexion are zero to 45 degrees, and left and right lateral rotation are zero to 80 degrees. Normal forward flexion of the thoracolumbar spine is zero to 90 degrees, extension is zero to 30 degrees, left and right lateral flexion are zero to 30 degrees, left and right lateral flexion are zero to 30 degrees, and left and right lateral flexion, are zero to 30 degrees. The combined range of motion refers to the sum of the range of forward flexion, extension, left and right lateral flexion, and left and right rotation. The normal combined range of motion of the cervical spine is 340 degrees and of the thoracolumbar spine is 240 degrees. The normal ranges of motion for each component of spinal motion provided in this note are the maximum that can be used for calculation of the combined range of motion. Note (3): In exceptional cases, an examiner may state that because of age, body habitus, neurologic disease, or other factors not the result of disease or injury of the spine, the range of motion of the spine in a particular individual, even though it does not conform to the normal range of motion stated in Note (2). Provided that the examiner supplies an explanation, the examiner's assessment that the range of motion is normal for that individual will be accepted. Note (4): Round each range of motion measurement to the nearest five degrees. Note (5): For VA compensation purposes, unfavorable ankylosis is a condition in which the entire cervical spine, the entire thoracolumbar spine, or the entire spine is fixed in flexion or extension, and the ankylosis results in one or more of the following: difficulty walking because of a limited line of vision; restricted opening of the mouth and chewing; breathing limited to diaphragmatic respiration; gastrointestinal symptoms due to nerve root stretching. Fixation of a spinal segment in neutral	
		diagnostic code 5003)	


§4.71a

38 CFR Ch. I (7-1-17 Edition)

THE SPINE—Continued

THE SPINE—Continued

	Rat- ing
Note (1): For purposes of evaluations under diagnostic code 5243, an incapacitating episode is a period of acute signs and symptoms due to intervertebral disc syndrome that requires bed rest prescribed by a physician and treatment by a physician. Note (2): If intervertebral disc syndrome is present in more than one spinal segment, provided that the effects in each spinal segment are clearly distinct, evaluate each segment on the basis of incapacitating episodes or under the General Rating Formula for Diseases and Injuries of the Spine, whichever method results in a higher evaluation for that segment.	






PLATE V
RANGE OF MOTION OF CERVICAL AND THORACOLUMBAR SPINE

§4.71a

38 CFR Ch. I (7-1-17 Edition)

THE HIP AND THIGH

	Rat- ing
5250 Hip, ankylosis of:	
Unfavorable, extremely unfavorable ankylosis, the foot not reaching ground, crutches neces-	
sitated	₃90
Intermediate	70
Favorable, in flexion at an angle between 20°	
and 40°, and slight adduction or abduction	60
5251 Thigh, limitation of extension of:	
Extension limited to 5°	10
5252 Thigh, limitation of flexion of:	
Flexion limited to 10°	40
Flexion limited to 20°	30
Flexion limited to 30°	20
Flexion limited to 45°	10
5253 Thigh, impairment of:	
Limitation of abduction of, motion lost beyond	
10°	20
Limitation of adduction of, cannot cross legs	10
Limitation of rotation of, cannot toe-out more	
than 15°, affected leg	10
5254 Hip, flail joint	80
5255 Femur, impairment of:	
Fracture of shaft or anatomical neck of:	
With nonunion, with loose motion (spiral or	
oblique fracture)	80
With nonunion, without loose motion,	
weightbearing preserved with aid of brace	60
Fracture of surgical neck of, with false joint	60
Malunion of:	
With marked knee or hip disability	30
With moderate knee or hip disability	20
With slight knee or hip disability	10

³Entitled to special monthly compensation.

THE KNEE AND LEG

	Rat- ing
5256 Knee, ankylosis of:	
Extremely unfavorable, in flexion at an angle of	
45° or more	60
In flexion between 20° and 45°	50
In flexion between 10° and 20°	40
Favorable angle in full extension, or in slight	
flexion between 0° and 10°	30
5257 Knee, other impairment of:	
Recurrent subluxation or lateral instability:	
Severe	30
Moderate	20
Slight	10
5258 Cartilage, semilunar, dislocated, with frequent	
episodes of "locking," pain, and effusion into the	
joint	20
5259 Cartilage, semilunar, removal of, symptomatic	10
5260 Leg, limitation of flexion of:	
Flexion limited to 15°	30
Flexion limited to 30°	20
Flexion limited to 45°	10
Flexion limited to 60°	0
5261 Leg, limitation of extension of:	
Extension limited to 45°	50
Extension limited to 30°	40
Extension limited to 20°	30
Extension limited to 15°	20
Extension limited to 10°	10
Extension limited to 5°	0
5262 Tibia and fibula, impairment of:	١.,
Nonunion of, with loose motion, requiring brace	40
Malunion of:	
With marked knee or ankle disability	30

THE KNEE AND LEG—Continued

	Rat- ing
With moderate knee or ankle disability	20
With slight knee or ankle disability	10
tively demonstrated)	10

THE ANKLE

	Rat- ing
5270 Ankle, ankylosis of:	
In plantar flexion at more than 40°, or in	
dorsiflexion at more than 10° or with abduc-	
tion, adduction, inversion or eversion deformity	40
In plantar flexion, between 30° and 40°, or in	
dorsiflexion, between 0° and 10°	30
In plantar flexion, less than 30°	20
5271 Ankle, limited motion of:	
Marked	20
Moderate	10
5272 Subastragalar or tarsal joint, ankylosis of:	
In poor weight-bearing position	20
In good weight-bearing position	10
5273 Os calcis or astragalus, malunion of:	
Marked deformity	20
Moderate deformity	10
5274 Astragalectomy	20

SHORTENING OF THE LOWER EXTREMITY

	Rat- ing
5275 Bones, of the lower extremity, shortening of:	
Over 4 inches (10.2 cms.)	³ 60
31/2 to 4 inches (8.9 cms. to 10.2 cms.)	³ 50
3 to 31/2 inches (7.6 cms. to 8.9 cms.)	40
2½ to 3 inches (6.4 cms. to 7.6 cms.)	30
2 to 21/2 inches (5.1 cms. to 6.4 cms.)	20
11/4 to 2 inches (3.2 cms. to 5.1 cms.)	10
NOTE: Measure both lower extremities from ante-	
rior superior spine of the ilium to the internal	
malleolus of the tibia. Not to be combined with	
other ratings for fracture or faulty union in the	
same extremity.	

³ Also entitled to special monthly compensation.

THE FOOT

	Rat- ing
5276 Flatfoot, acquired: Pronounced; marked pronation, extreme tenderness of plantar surfaces of the feet, marked inward displacement and severe spasm of the tendo achillis on manipulation, not improved by orthopedic shoes or appliances.	
Bilateral	50
Unilateral	30
Severe; objective evidence of marked deformity (pronation, abduction, etc.), pain on manipula- tion and use accentuated, indication of swell- ing on use, characteristic callosities:	
Bilateral	30
Unilateral	20

THE FOOT—Continued

	Rat- ing
Moderate; weight-bearing line over or medial to great toe, inward bowing of the tendo achillis, pain on manipulation and use of the feet, bilateral or unilateral	10 0
constitutional conditions, characterized by at- rophy of the musculature, disturbed circulation, and weakness: Rate the underlying condition, minimum rat- ing	10
5278 Claw foot (pes cavus), acquired: Marked contraction of plantar fascia with dropped forefoot, all toes hammer toes, very painful callosities, marked varus deformity:	
Bilateral Unilateral All toes tending to dorsiflexion, limitation of dorsiflexion at ankle to right angle, shortened plantar fascia, and marked tenderness under metatarsal heads:	50 30
Bilateral	30 20
Bilateral	10 10 0
unilateral, or bilateral	10
Operated with resection of metatarsal head Severe, if equivalent to amputation of great toe 5281 Hallux rigidus, unilateral, severe: Rate as hallux valgus, severe. Note: Not to be combined with claw foot ratings.	10 10
5282 Hammer toe: All toes, unilateral without claw foot	10 0
Severe	30 20 10
5284 Foot injuries, other: Severe Moderately severe Moderate NOTE: With actual loss of use of the foot, rate 40 percent.	30 20 10

THE SKULL

	Rat- ing
5296 Skull, loss of part of, both inner and outer ta-	
bles:	
With brain hernia	80
Without brain hernia:	
Area larger than size of a 50-cent piece or	
1.140 in ² (7.355 cm ²)	50
Area intermediate	30
Area smaller than the size of a 25-cent	"
piece or 0.716 in 2 (4.619 cm ²)	10

THE SKULL—Continued

	Rat- ing
NOTE: Rate separately for intracranial complications.	

THE RIBS

	Rat- ing
5297 Ribs, removal of:	
More than six	50
Five or six	40
Three or four	30
Two	20
One or resection of two or more ribs without regeneration	10

THE COCCYX

	Rat- ing
5298 Coccyx, removal of: Partial or complete, with painful residuals Without painful residuals	10 0

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 40 FR 42536, Sept. 15, 1975; 41 FR 11294, Mar. 18, 1976; 43 FR 45350, Oct. 2, 1978; 51 FR 6411, Feb. 24, 1986; 61 FR 20439, May 7, 1996; 67 FR 48785, July 26, 2002; 67 FR 54349, Aug. 22, 2002; 68 FR 51456, Aug. 27, 2003; 69 FR 32450, June 10, 2004; 80 FR 42041, July 16, 2015]

§4.72 [Reserved]

§4.73 Schedule of ratings—muscle injuries.

NOTE: When evaluating any claim involving muscle injuries resulting in loss of use of any extremity or loss of use of both buttocks (diagnostic code 5317, Muscle Group XVII), refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation.

38 CFR Ch. I (7-1-17 Edition)

§4.73

THE SHOULDER GIRDLE AND ARM

THE FOREARM AND HAND

	Rating			Rati	ing
	Domi- nant	Non- domi- nant		Domi- nant	Non- domi- nant
5301 Group I. Function: Upward rotation of scapula; elevation of arm above shoulder level. Extrinsic muscles of shoulder girdle: (1) Trapezius; (2) levator scapulae; (3) serratus magnus. Severe	40 30 10 0	30 20 10 0	5307 Group VII. Function: Flexion of wrist and fingers. Muscles arising from internal condyle of humerus: Flexors of the carpus and long flexors of fingers and thumb; pronator. Severe Moderately Severe Moderately Severe Slight 5308 Group VIII. Function: Extension of wrist, fingers, and thumb; abduction of thumb. Muscles arising mainly from external condyle of humerus: Extensors of carpus, fingers, and thumb; supinator. Severe Moderately Severe	40 30 10 0	30 20 10 0
latissimus dorsi and teres major (teres major, although technically an intrinsic muscle, is included with latissimus dorsi); (3) pectoralis minor; (4) rhombold. Severe	40	30	Moderate	10 0	10 0
Moderately Severe Moderate Slight	30 20 0	20 20 0	sic muscles in delicate manipulative movements. <i>Intrinsic muscles of hand:</i> Thenar eminence; short flexor, opponens,		
5303 Group III. Function: Elevation and ab- duction of arm to level of shoulder, act with 1 and 2 of Group II in forward and backward swing of arm. Intrinsic muscles of shoulder girdle: (1) Pectoralis major I			abductor and adductor of thumb; hypothenar eminence; short flexor, opponens and abductor of little finger; 4 lumbricales; 4 dorsal and 3 palmar interossei.		
(clavicular); (2) deltoid. Severe	40 30 20	30 20 20 0	NOTE: The hand is so compact a structure that isolated muscle injuries are rare, being nearly always complicated with injuries of bones, joints, tendons, etc. Rate on limitation of motion, minimum 10 percent.		
Slight	U	U	THE FOOT AND LEG		
tation of arm. Intrinsic muscles of shoulder girdle: (1) Supraspinatus; (2) infraspinatus and teres minor; (3) subscapularis; (4) coracobrachialis.			5310 Group X. Function: Movements of		Rat- ing
Severe Moderately Severe Moderate	30 20 10	20 20 10	and toes; propulsion thrust in walking. muscles of the foot: Plantar: (1) Flexor d brevis; (2) abductor hallucis; (3) abduct minimi; (4) quadratus plantae; (5) lumbrica	gitorum or digiti iles; (6)	
Slight	40	30	flexor hallucis brevis; (7) adductor hallucis; or digiti minimi brevis; (9) dorsal and interossei. Other important plantar structure tar aponeurosis, long plantar calcaneonavicular ligament, tendons of ptibial, peroneus longus, and long flexors and little toes.	plantar s: Plan- and osterior	
Moderately Severe	30 10 0	20 10 0	Severe		30 20 10
5306 Group VI. Function: Extension of elbow (long head of triceps is stabilizer of shoulder joint). Extensor muscles of the elbow: (1) Triceps; (2) anconeus			Slight Dorsal: (1) Extensor hallucis brevis; (2) e digitorum brevis. Other important dorsal str cruciate, crural, deltoid, and other ligamer	extensor uctures: its; ten-	α
Severe Moderately Severe Moderate	40 30 10	30 20 10	dons of long extensors of toes and peron cles. Severe		20 10
Slight	0	0	Moderate		10

THE FOOT AND LEG—Continued

	Rat- ing
Note: Minimum rating for through-and-through wounds of the foot—10.	
5311 Group XI. Function: Propulsion, plantar flexion of foot (1); stabilization of arch (2, 3); flexion of toes (4, 5); Flexion of knee (6). Posterior and lateral crural muscles, and muscles of the calf: (1) Triceps surae (gastrocnemius and soleus); (2) tibialis posterior; (3) peroneus longus; (4) peroneus brevis; (5) flexor hallucis longus; (6) flexor digitorum longus; (7) popliteus; (8) plantaris. Severe	30 20 10 0
Severe	30 20 10
Slight	0

THE PELVIC GIRDLE AND THIGH

	Rat- ing
5313 Group XIII. Function: Extension of hip and flexion of knee; outward and inward rotation of flexed knee; acting with rectus femoris and sartorius (see XIV, 1, 2) synchronizing simultaneous flexion of hip and knee and extension of hip and knee by belt-over-pulley action at knee joint. Posterior thigh group, Hamstring complex of 2-joint muscles: (1) Biceps femoris; (2) semimembranosus; (3) semitendinosus. Severe Moderately Severe	40 30
Moderate	10 0
Severe Moderately Severe	40 30 10 0
brevis; (3) adductor magnus; (4) gracilis. Severe	30 20 10 0
pectineus. Severe Moderately Severe Moderate Slight	40 30 10 0

THE PELVIC GIRDLE AND THIGH—Continued

	Rat- ing
5317 Group XVII. Function: Extension of hip (1); abduction of thigh; elevation of opposite side of pelvis (2, 3); tension of fascia lata and iliotibial (Maissiat's) band, acting with XIV (6) in postural support of body steadying pelvis upon head of femur and condyles of femur on tibia (1). Pelvic girdle group 2: (1) Gluteus maximus; (2) gluteus medius; (3) gluteus minimus. Severe	*50 40 20 0
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

*If bilateral, see §3.350(a)(3) of this chapter to determine whether the veteran may be entitled to special monthly compensation.

THE TORSO AND NECK

THE TORSO AND NECK	
	Rat- ing
5319 Group XIX. Function: Support and compression of abdominal wall and lower thorax; flexion and lateral motions of spine; synergists in strong downward movements of arm (1). Muscles of the abdominal wall: (1) Rectus abdominis; (2) external oblique; (3) internal oblique; (4) transversalis; (5) quadratus lumborum.	
Severe Moderately Severe Moderate Slight	50 30 10 0
5320 Group XX. Function: Postural support of body; extension and lateral movements of spine. Spinal muscles: Sacrospinalis (erector spinae and its pro- longations in thoracic and cervical regions). Cervical and thoracic region:.	
Severe Moderately Severe Moderate Slight Lumbar region:	40 20 10 0
Severe	60 40 20 0
Severe or Moderately Severe Moderate Slight S322 Group XXII. Function: Rotary and forward movements of the head; respiration; deglutition. Muscles of the front of the neck: (Lateral, supra, and infrahyoid group.) (1) Trapezius I (clavicular insertion); (2) sternocleidomastoid; (3) the "hyoid" muscles: (4) sternothyroid; (5) digastric.	20 10 0
Severe Moderately Severe Moderate Slight	30 20 10 0

§4.75

THE TORSO AND NECK—Continued

	Rat- ing
5323 Group XXIII. Function: Movements of the head; fixation of shoulder movements. Muscles of the side and back of the neck: Suboccipital; lateral vertebral and anterior vertebral muscles. Severe	30 20 10 0

MISCELLANEOUS

	Rat- ing

5324 Diaphragm, rupture of, with herniation. Rate under diagnostic code 7346.

5325 Muscle injury, facial muscles. Evaluate functional impairment as seventh (facial) cranial nerve neuropathy (diagnostic code 8207), disfiguring scar (diagnostic code 7800), etc. Minimum, if interfering to any extent with mastication—10.

5326 Muscle hernia, extensive. Without other injury to the muscle—10.

5327 Muscle, neoplasm of, malignant (excluding soft tissue sarcoma)—100.

NOTE: A rating of 100 percent shall continue beyond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residual impairment of function.

5328 Muscle, neoplasm of, benign, postoperative. Rate on impairment of function, i.e., limitation of motion, or scars, diagnostic code 7805, etc.

5329 Sarcoma, soft tissue (of muscle, fat, or fibrous connective tissue)—100.

NOTE: A rating of 100 percent shall continue beyond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residual impairment of function.

(Authority: 38 U.S.C. 1155) [62 FR 30239, June 3, 1997]

THE ORGANS OF SPECIAL SENSE

§4.75 General considerations for evaluating visual impairment.

(a) Visual impairment. The evaluation of visual impairment is based on impairment of visual acuity (excluding developmental errors of refraction), visual field, and muscle function.

- (b) Examination for visual impairment. The examination must be conducted by a licensed optometrist or by a licensed ophthalmologist. The examiner must identify the disease, injury, or other pathologic process responsible for any visual impairment found. Examinations of visual fields or muscle function will be conducted only when there is a medical indication of disease or injury that may be associated with visual field defect or impaired muscle function. Unless medically contraindicated, the fundus must be examined with the claimant's pupils dilated.
- (c) Service-connected visual impairment of only one eye. Subject to the provisions of 38 CFR 3.383(a), if visual impairment of only one eye is service-connected, the visual acuity of the other eye will be considered to be 20/40 for purposes of evaluating the service-connected visual impairment.
- (d) Maximum evaluation for visual impairment of one eye. The evaluation for visual impairment of one eye must not exceed 30 percent unless there is anatomical loss of the eye. Combine the evaluation for visual impairment of one eye with evaluations for other disabilities of the same eye that are not based on visual impairment (e.g., disfigurement under diagnostic code 7800).
- (e) Anatomical loss of one eye with inability to wear a prosthesis. When the claimant has anatomical loss of one eye and is unable to wear a prosthesis, increase the evaluation for visual acuity under diagnostic code 6063 by 10 percent, but the maximum evaluation for visual impairment of both eyes must not exceed 100 percent. A 10-percent increase under this paragraph precludes an evaluation under diagnostic code 7800 based on gross distortion or asymmetry of the eye but not an evaluation under diagnostic code 7800 based on other characteristics of disfigurement.
- (f) Special monthly compensation. When evaluating visual impairment, refer to 38 CFR 3.350 to determine whether the claimant may be entitled to special monthly compensation. Footnotes in the schedule indicate levels of visual impairment that potentially establish entitlement to special monthly compensation; however, other levels of visual impairment combined

with disabilities of other body systems may also establish entitlement.

(Authority: 38 U.S.C. 1114 and 1155) [73 FR 66549, Nov. 10, 2008]

§4.76 Visual acuity.

- (a) Examination of visual acuity. Examination of visual acuity must include the central uncorrected and corrected visual acuity for distance and near vision using Snellen's test type or its equivalent.
- (b) Evaluation of visual acuity. (1) Evaluate central visual acuity on the basis of corrected distance vision with central fixation, even if a central scotoma is present. However, when the lens required to correct distance vision in the poorer eye differs by more than three diopters from the lens required to correct distance vision in the better eye (and the difference is not due to congenital or developmental refractive error), and either the poorer eye or both eyes are service connected, evaluate the visual acuity of the poorer eye using either its uncorrected or corrected visual acuity, whichever results in better combined visual acuity.
- (2) Provided that he or she customarily wears contact lenses, evaluate the visual acuity of any individual affected by a corneal disorder that results in severe irregular astigmatism that can be improved more by contact lenses than by eyeglass lenses, as corrected by contact lenses.


- (3) In any case where the examiner reports that there is a difference equal to two or more scheduled steps between near and distance corrected vision, with the near vision being worse, the examination report must include at least two recordings of near and distance corrected vision and an explanation of the reason for the difference. In these cases, evaluate based on corrected distance vision adjusted to one step poorer than measured.
- (4) To evaluate the impairment of visual acuity where a claimant has a reported visual acuity that is between two sequentially listed visual acuities, use the visual acuity which permits the higher evaluation.

(Authority: 38 U.S.C. 1155) [73 FR 66549, Nov. 10, 2008]

§ 4.76a Computation of average concentric contraction of visual fields.

TABLE III—NORMAL VISUAL FIELD EXTENT AT 8
PRINCIPAL MERIDIANS

Meridian	Normal de- grees
Temporally	85
Down temporally	85
Down	65
Down nasally	50
Nasally	60
Up nasally	55
Up	45
Up temporally	55
Total	500



TS-19

52a

Example of computation of concentric contraction under the schedule with abnormal findings taken from Figure 1.

Loss	Degrees
Temporally	55
Down temporally	55
Down	45

Loss	Degrees
Down nasally Nasally Up nasally Up top Up temporally	30 40 35 25 35
Total loss	320

Remaining field 500° minus 320° = 180°. $180^{\circ} \div 8 = 22\frac{1}{2}^{\circ}$

(Authority: 38 U.S.C. 1155)

[43 FR 45352, Oct. 2, 1978, as amended at 73 FR 66549, Nov. 10, 2008]

§ 4.77 Visual fields.

(a) Examination of visual fields. Examiners must use either Goldmann kinetic perimetry or automated perimetry using Humphrey Model 750, Octopus Model 101, or later versions of these perimetric devices with simulated kinetic Goldmann testing capability. For phakic (normal) individuals, as well as for pseudophakic or aphakic individuals who are well adapted to intraocular lens implant or contact lens correction, visual field examinations must be conducted using a standard target size and luminance, which is Goldmann's equivalent III/4e. For aphakic individuals not well adapted to correction contact lens Or pseudophakic individuals not adapted to intraocular lens implant. visual field examinations must be conducted using Goldmann's equivalent IV/4e. In all cases, the results must be recorded on a standard Goldmann chart

(see Figure 2), and the Goldmann chart must be included with the examination report. The examiner must chart at least 16 meridians 22½ degrees apart for each eye and indicate the Goldmann equivalent used. See Table III for the normal extent (in degrees) of the visual fields at the 8 principal meridians (45 degrees apart). When the examiner indicates that additional testing is necessary to evaluate visual fields, the additional testing must be conducted using either a tangent screen or a 30-degree threshold visual field with the Goldmann III stimulus size. The examination report must then include the tracing of either the tangent screen or of the 30-degree threshold visual field with the Goldmann III stimulus size.

- (b) Evaluation of visual fields. Determine the average concentric contraction of the visual field of each eye by measuring the remaining visual field (in degrees) at each of eight principal meridians 45 degrees apart, adding them, and dividing the sum by eight.
- (c) Combination of visual field defect and decreased visual acuity. To determine the evaluation for visual impairment when both decreased visual acuity and visual field defect are present in one or both eyes and are service connected, separately evaluate the visual acuity and visual field defect (expressed as a level of visual acuity), and combine them under the provisions of § 4.25.




Figure 2. Goldmann Perimeter Chart

52c

(Authority: 38 U.S.C. 1155)

 $[53~\mathrm{FR}~30262,~\mathrm{Aug}.~11,~1988,~\mathrm{as}~\mathrm{amended}~\mathrm{at}~73~\mathrm{FR}~66549,~\mathrm{Nov}.~10,~2008;~74~\mathrm{FR}~7648,~\mathrm{Feb}.~19,~2009]$

§ 4.78 Muscle function.

(a) Examination of muscle function. The examiner must use a Goldmann perimeter chart that identifies the four major quadrants (upward, downward, left and right lateral) and the central field (20 degrees or less) (see Figure 2). The examiner must chart the areas of diplopia and include the plotted chart with the examination report.

(b) Evaluation of muscle function. (1) An evaluation for diplopia will be assigned to only one eye. When a claimant has both diplopia and decreased visual acuity or visual field defect, assign a level of corrected visual acuity

for the poorer eye (or the affected eye, if disability of only one eye is serviceconnected) that is: one step poorer than it would otherwise warrant if the evaluation for diplopia under diagnostic code 6090 is 20/70 or 20/100; two steps poorer if the evaluation under diagnostic code 6090 is 20/200 or 15/200; or three steps poorer if the evaluation under diagnostic code 6090 is 5/200. This adjusted level of corrected visual acuity, however, must not exceed a level of 5/200. Use the adjusted visual acuity for the poorer eye (or the affected eye, if disability of only one eye is serviceconnected), and the corrected visual

acuity for the better eye (or visual acuity of 20/40 for the other eye, if only one eye is service-connected) to determine the percentage evaluation for visual impairment under diagnostic codes 6065 through 6066.

(2) When diplopia extends beyond more than one quadrant or range of degrees, evaluate diplopia based on the quadrant and degree range that provides the highest evaluation.

(3) When diplopia exists in two separate areas of the same eye, increase the equivalent visual acuity under diagnostic code 6090 to the next poorer level of visual acuity, not to exceed 5/200.

(Authority: 38 U.S.C. 1155) [73 FR 66550, Nov. 10, 2008]

§4.79 Schedule of ratings—eye.

DISEASES OF THE EYE

	BIGEROES OF THE ETE	
		Rating
	Choroidopathy, including uveitis, iritis, cyclitis, and choroiditis.	
	Keratopathy.	
	Scleritis.	
	Retinopathy or maculopathy. Intraocular hemorrhage.	
	Detachment of retina.	
	Unhealed eye injury.	
	General Rating Formula for Diagnostic Codes 6000 through 6009	
	Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation.	
	With incapacitating episodes having a total duration of at least 6 weeks during the past 12 months	60
	past 12 months	40
	past 12 months	20
	past 12 months	10
	For VA purposes, an incapacitating episode is a period of acute symptoms severe enough to require pre- bed bed rest and treatment by a physician or other healthcare provider.	
6010	Tuberculosis of eye:	
	Active	100
6011	Inactive: Evaluate under § 4.88c or § 4.89 of this part, whichever is appropriate. Retinal scars, atrophy, or irregularities:	
3011	Localized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and that result in an irregular, duplicated, enlarged, or diminished image	10
	Alternatively, evaluate based on visual impairment due to retinal scars, atrophy, or irregularities, if this	
	would result in a higher evaluation.	
6012	Angle-closure glaucoma:	
	Evaluate on the basis of either visual impairment due to angle-closure glaucoma or incapacitating episodes, whichever results in a higher evaluation.	
	With incapacitating episodes having a total duration of at least 6 weeks during the past 12 months	60
	past 12 months	40
	With incapacitating episodes having a total duration of at least 2 weeks, but less than 4 weeks, during the past 12 months	20
	Minimum evaluation if continuous medication is required	10
	For VA purposes, an incapacitating episode is a period of acute symptoms severe enough to require pre-	
	bed bed rest and treatment by a physician or other healthcare provider.	
6013	Open-angle glaucoma: Evaluate based on visual impairment due to open-angle glaucoma.	
	Minimum evaluation if continuous medication is required	10
6014	Malignant neoplasms (eyeball only):	
	Malignant neoplasm of the eyeball that requires therapy that is comparable to that used for systemic malig-	
	nancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation	100
Note:	Continue the 100-percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or	
will	er therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent mination will be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or	
	astasis, evaluate based on residuals.	
	Malignant neoplasm of the eyeball that does not require therapy comparable to that for systemic malignancies:	
0045	Separately evaluate visual impairment and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations.	
0015	Benign neoplasms (of eyeball and adnexa):	

Rating

DISEASES OF THE EYE—Continued

		namy
	Separately evaluate visual impairment and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations.	
6016	Nystagmus, central	10
6017	Trachomatous conjunctivitis:	30
	Active: Evaluate based on visual impairment, minimum	30
6018	Chronic conjunctivitis (nontrachomatous):	
	Active (with objective findings, such as red, thick conjunctivae, mucous secretion, etc.)	10
6019		
	Evaluate based on visual impairment or, in the absence of visual impairment, on disfigurement (diagnostic	
6020	code 7800). Ectropion:	
0020	Bilateral	20
0004	Unilateral	10
6021	Entropion: Bilateral	20
	Unilateral	10
6022	Lagophthalmos:	00
	Bilateral	20 10
6023	Loss of eyebrows, complete, unilateral or bilateral	10
6024	Loss of eyelashes, complete, unilateral or bilateral	10
0023	Bilateral	20
	Unilateral	10
6026	Optic neuropathy: Evaluate based on visual impairment.	
6027	Cataract of any type:	
Pre	operative:	
Pos	Evaluate based on visual impairment. toperative:	
1 03	If a replacement lens is present (pseudophakia), evaluate based on visual impairment. If there is no re-	
	placement lens, evaluate based on aphakia.	
6029	Aphakia or dislocation of crystalline lens: Evaluate based on visual impairment, and elevate the resulting level of visual impairment one step.	
	Minimum (unilateral or bilateral)	30
6030	Paralysis of accommodation (due to neuropathy of the Oculomotor Nerve (cranial nerve III)).	20
6032	Loss of eyelids, partial or complete: Separately evaluate both visual impairment due to eyelid loss and nonvisual impairment, e.g., disfigurement	
	(diagnostic code 7800), and combine the evaluations.	
6034	Pterygium:	
	Evaluate based on visual impairment, disfigurement (diagnostic code 7800), conjunctivitis (diagnostic code 6018), etc., depending on the particular findings.	
6035	Keratoconus:	
6036	Evaluate based on impairment of visual acuity. Status post corneal transplant:	
0030	Evaluate based on visual impairment.	
	Minimum, if there is pain, photophobia, and glare sensitivity	10
6037	Pinguecula: Evaluate based on disfigurement (diagnostic code 7800).	
	Evaluate based on disrigurement (diagnostic code 7000).	
	Impairment of Central Visual Acuity	
6061	Anatomical loss of both eyes 1	100
6062 6063	No more than light perception in both eyes 1	100
6003	Anatomical loss of one eye: 1 In the other eye 5/200 (1.5/60)	100
	In the other eye 10/200 (3/60)	90
	In the other eye 15/200 (4.5/60)	80
	In the other eye 20/200 (6/60)	70 60
	In the other eye 20/70 (6/21)	60
	In the other eye 20/50 (6/15)	50 40
6064	In the other eye 20/40 (6/12)	40
	In the other eye 5/200 (1.5/60)	100
	In the other eye 10/200 (3/60)	90
	In the other eye 15/200 (4.5/60)	80 70
	In the other eye 20/100 (6/30)	60
	In the other eye 20/70 (6/21)	50

DISEASES OF THE EYE-Continued

		Rating
	In the other eye 20/50 (6/15)	4
	In the other eye 20/40 (6/12)	3
3065	Vision in one eye 5/200 (1.5/60):	Ū
	In the other eye 5/200 (1.5/60)	¹ 10
	In the other eye 10/200 (3/60)	9
	In the other eye 15/200 (4.5/60)	8
	In the other eye 20/200 (6/60)	7
	In the other eye 20/100 (6/30)	6
	In the other eye 20/70 (6/21)	5
	In the other eye 20/50 (6/15)	4
	In the other eye 20/40 (6/12)	3
3066	Visual acuity in one eye 10/200 (3/60) or better:	
	n in one eye 10/200 (3/60):	
	In the other eye 10/200 (3/60)	9
	In the other eye 15/200 (4.5/60)	8
	In the other eye 20/200 (6/60)	7
	In the other eye 20/100 (6/30)	6
	In the other eye 20/70 (6/21)	5
	In the other eye 20/50 (6/15)	4
	In the other eye 20/40 (6/12)	3
/ieior	n one eye 15/200 (4.5/60):	
v iSiOi	In the other eye 15/200 (4.5/60)	8
	In the other eye 13/200 (4:3/00)	7
	In the other eye 20/100 (6/30)	6
	In the other eye 20/70 (6/21)	4
	In the other eye 20/70 (6/21) In the other eye 20/50 (6/15)	3
	In the other eye 20/40 (6/12)	2
/:a:a=	ni one eye 20/200 (6/60):	2
/15101	In the other eye 20/200 (6/60)	7
		6
	In the other eye 20/100 (6/30)	
	In the other eye 20/70 (6/21)	4
	In the other eye 20/50 (6/15)	3
/:a:a=	In the other eye 20/40 (6/12)	
/ISIO	n in one eye 20/100 (6/30):	
	In the other eye 20/100 (6/30)	5
	In the other eye 20/70 (6/21)	3
	In the other eye 20/50 (6/15)	2
	In the other eye 20/40 (6/12)	1
/isior	n in one eye 20/70 (6/21):	
	In the other eye 20/70 (6/21)	3
	In the other eye 20/50 (6/15)	2
	In the other eye 20/40 (6/12)	1
/isior	n in one eye 20/50 (6/15):	
	In the other eye 20/50 (6/15)	1
	In the other eye 20/40 (6/12)	1
/isior	n in one eye 20/40 (6/12):	
	In the other eye 20/40 (6/12)	

 $^{^{\}rm 1}\,\mbox{Review}$ for entitlement to special monthly compensation under 38 CFR 3.350.

RATINGS FOR IMPAIRMENT OF VISUAL FIELDS

	Rating
6080 Visual field defects:	
Homonymous hemianopsia	30
Loss of temporal half of visual field:	I
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	I
Loss of nasal half of visual field:	1
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	
Loss of inferior half of visual field:	
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	
Loss of superior half of visual field:	
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	i

§§ 4.80-4.84

RATINGS FOR IMPAIRMENT OF VISUAL FIELDS—Continued

	Rating
Concentric contraction of visual field:	
With remaining field of 5 degrees: 1	
Bilateral	100
Unilateral	30
Or evaluate each affected eye as 5/200 (1.5/60).	
With remaining field of 6 to 15 degrees:	
Bilateral	70
Unilateral	20
Or evaluate each affected eye as 20/200 (6/60).	
With remaining field of 16 to 30 degrees:	
Bilateral	50
Unilateral	10
Or evaluate each affected eye as 20/100 (6/30).	
With remaining field of 31 to 45 degrees:	
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	
With remaining field of 46 to 60 degrees:	
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	
6081 Scotoma, unilateral:	
Minimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally	
located scotoma of any size	10
Alternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evaluation.	

¹ Review for entitlement to special monthly compensation under 38 CFR 3.350.

RATINGS FOR IMPAIRMENT OF MUSCLE FUNCTION

Degree of diplopia	Equivalent visual acuity
6090 Diplopia (double vision): (a) Central 20 degrees (b) 21 degrees to 30 degrees (1) Down (2) Lateral (3) Up (c) 31 degrees to 40 degrees (1) Down (2) Lateral (3) Up (2) Lateral (3) Up (5) Lateral (6) Lateral (7) Down (9) Lateral (1) Down (1) Lateral (2) Lateral (3) Up (2) Lateral (3) Up (3) Up (4) Lateral (5) Lateral (6) Lateral (7) Lateral (8) Up (9) Lateral (10) Lateral (11) Lateral (12) Lateral (13) Lateral (23) Lateral (34) Lateral (45) Lateral (47) Lateral (48) Lateral (50) Lateral (60) Lateral (70)	5/200 (1.5/60) 15/200 (4.5/60) 20/100 (6/30) 20/70 (6/21) 20/200 (6/60) 20/70 (6/21) 20/40 (6/12)

(Authority: 38 U.S.C. 1155) [73 FR 66550, Nov. 10, 2008]

$\S\S4.80-4.84$ [Reserved]

IMPAIRMENT OF AUDITORY ACUITY

\$4.85 Evaluation of hearing impairment.

(a) An examination for hearing impairment for VA purposes must be conducted by a state-licensed audiologist and must include a controlled speech discrimination test (Maryland CNC) and a puretone audiometry test. Ex-

aminations will be conducted without the use of hearing aids.

(b) Table VI, "Numeric Designation of Hearing Impairment Based on Puretone Threshold Average and Speech Discrimination," is used to determine a Roman numeral designation (I through XI) for hearing impairment based on a combination of the percent of speech discrimination (horizontal

rows) and the puretone threshold average (vertical columns). The Roman numeral designation is located at the point where the percentage of speech discrimination and puretone threshold average intersect.

- (c) Table VIa, "Numeric Designation of Hearing Impairment Based Only on Puretone Threshold Average," is used to determine a Roman numeral designation (I through XI) for hearing impairment based only on the puretone threshold average. Table VIa will be used when the examiner certifies that use of the speech discrimination test is not appropriate because of language difficulties, inconsistent speech discrimination scores, etc., or when indicated under the provisions of §4.86.
- (d) "Puretone threshold average," as used in Tables VI and VIa, is the sum of the puretone thresholds at 1000, 2000, 3000 and 4000 Hertz, divided by four. This average is used in all cases (including those in §4.86) to determine the Roman numeral designation for hearing impairment from Table VI or VIa.
- (e) Table VII, "Percentage Evaluations for Hearing Impairment," is used to determine the percentage evaluation by combining the Roman numeral designations for hearing impairment of each ear. The horizontal rows represent the ear having the better hearing and the vertical columns the ear having the poorer hearing. The percentage evaluation is located at the point where the row and column intersect.
- (f) If impaired hearing is service-connected in only one ear, in order to determine the percentage evaluation from Table VII, the non-service-connected ear will be assigned a Roman Numeral designation for hearing impairment of I, subject to the provisions of § 3.383 of this chapter.
- (g) When evaluating any claim for impaired hearing, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation due either to deafness, or to deafness in combination with other specified disabilities.
 - (h) Numeric tables VI, VIA*, and VII.

TABLE VI

NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ON PURETONE THRESHOLD AVERAGE AND SPEECH DISCRIMINATION

Puretone Threshold Average

% of discrim- ination	0-41	42-49	50-57	58-65	66-73	74-81	82-89	90-97	98+
92-100	I	I	I	II	II	II	III	III	IV
84-90	II	II	II	III	III	III	IV	IV	IV
76-82	III	III	IV	IV	IV	V	V	V	V
68-74	IV	IV	V	V	VI	VI	VII	VII	VII
60-66	V	v	VI	VI	VII	VII	VIII	VIII	VIII
52-58	VI	VI	VII	VII	VIII	VIII	VIII	VIII	IX
44-50	VII	VII	VIII	VIII	VIII	IX	IX	IX	X
36-42	VIII	VIII	VIII	IX	IX	IX	X	X	X
0-34	IX	X	XI	XI	XI	XI	XI	XI	XI

TABLE VIA*

NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ONLY ON PURETONE THRESHOLD AVERAGE

Puretone Threshold Average

0-41	42-48	49-55	56-62	63-69	70-76	77-83	84-90	91-97	98-104	105+
I	II	III	IV	V	VI	VII	VIII	IX	X	XI

^{*} This table is for use only as specified in §§ 4.85 and 4.86.

TABLE VII

PERCENTAGE EVALUATION FOR HEARING IMPAIRMENT (DIAGNOSTIC CODE 6100)

Poorer Ear

	XI	100*										
	X	90	80									
	IX	80	70	60				MA II				
	VIII	70	60	50	50							
ar	VII	60	60	50	40	40						
Better Ear	VI	50	50	40	40	30	30	Procedural and an analysis of the second				
B	V	40	40	40	30	30	20	20				
	IV	30	30	30	20	20	20	10	10	-		
	III	20	20	20	20	20	10	10	10	0		
	II	10	10	10	10	10	10	10	0 -	0	0	
	I	10	10	0	0	0	0	0	0	. 0	0	0
	Reconstruction of the second	XI	X	IX	VIII	VII	VI	v	IV	III	II	I

^{*} Review for entitlement to special monthly compensation under §3.350 of this chapter.

 $[64~{\rm FR}~25206,~{\rm May}~11,~1999]$

§ 4.86 Exceptional patterns of hearing impairment.

(a) When the puretone threshold at each of the four specified frequencies (1000, 2000, 3000, and 4000 Hertz) is 55 decibels or more, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher nu-

meral. Each ear will be evaluated separately.

(b) When the puretone threshold is 30 decibels or less at 1000 Hertz, and 70 decibels or more at 2000 Hertz, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher numeral. That numeral will then be elevated to the next higher

Roman numeral. Each ear will be evaluated separately.

(Authority: 38 U.S.C. 1155) [64 FR 25209, May 11, 1999]

§4.87 Schedule of ratings—ear.

DISEASES OF THE EAR

Rating

10

100

60 30

10

DISEASES OF THE LAN
6200 Chronic suppurative otitis media, mastoiditis, or cholesteatoma (or any combination): During suppuration, or with aural polyps NOTE: Evaluate hearing impairment, and complications such as labyrinthitis, tinnitus, facial nerve paralysis, or bone loss of skull, separately.
6201 Chronic nonsuppurative otitis media with effusion (serous otitis media):
Rate hearing impairment 6202 Otosclerosis:
Rate hearing impairment 6204 Peripheral vestibular disorders: Dizziness and occasional staggering Occasional dizziness NOTE: Objective findings supporting the diagnosis of vestibular disequilibrium are required before a compensable evaluation can be assigned under this code. Hearing impairment or suppuration shall be separately rated and
combined. 6205 Meniere's syndrome (endolymphatic hydrops): Hearing impairment with attacks of vertigo and cerebellar gait occurring more than once weekly, with or without tinnitus Hearing impairment with attacks of vertigo and
cerebellar gait occurring from one to four times a month, with or without tinnitus
NOTE: Evaluate Meniere's syndrome either under these criteria or by separately evaluating vertigo (as a peripheral vestibular disorder), hearing impairment, and tinnitus, whichever method results in a higher overall evaluation. But do not combine an evaluation for hearing impairment, tinnitus, or vertigo with an evaluation under diagnostic code 6205.
6207 Loss of auricle: Complete loss of both Complete loss of one Deformity of one, with loss of one-third or more
of the substance
NoTE: A rating of 100 percent shall continue beyond the cessation of any surgical, radiation treatment, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based on that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.
only):

Rate on impairment of function.

6210 Chronic otitis externa:

38 CFR Ch. I (7-1-17 Edition)

DISEASES OF THE EAR—Continued

	Hat- ing
Swelling, dry and scaly or serous discharge, and itching requiring frequent and prolonged treatment	10 0 10

(Authority: 38 U.S.C. 1155)

[64 FR 25210, May 11, 1999, as amended at 68 FR 25823, May 14, 2003]

§4.87a Schedule ratings-other sense organs.

	Rat- ing
6275 Sense of smell, complete loss	10 10

(Authority: 38 U.S.C. 1155)

[64 FR 25210, May 11, 1999]

INFECTIOUS DISEASES, IMMUNE DIS-ORDERS AND NUTRITIONAL DEFI-CIENCIES

§4.88 [Reserved]

§ 4.88a Chronic fatigue syndrome.

- (a) For VA purposes, the diagnosis of chronic fatigue syndrome requires:
- (1) new onset of debilitating fatigue severe enough to reduce daily activity to less than 50 percent of the usual level for at least six months; and
- (2) the exclusion, by history, physical examination, and laboratory tests, of all other clinical conditions that may produce similar symptoms; and
 - (3) six or more of the following: (i) acute onset of the condition,

 - (ii) low grade fever,
 - (iii) nonexudative pharyngitis,

Department of Veterans Affairs

§4.88b

- (iv) palpable or tender cervical or axillary lymph nodes,
- (v) generalized muscle aches or weakness,
- (vi) fatigue lasting 24 hours or longer after exercise,
- (vii) headaches (of a type, severity, or pattern that is different from headaches in the pre-morbid state),
 - (viii) migratory joint pains,
 - (ix) neuropsychologic symptoms,
 - (x) sleep disturbance.
 - (b) [Reserved]

[59 FR 60902, Nov. 29, 1994]

$\$\,4.88b$ Schedule of ratings—infectious diseases, immune disorders and nutritional deficiencies.

		Ratir
300	Cholera, Asiatic:	
	As active disease, and for 3 months convalescence	1
	Thereafter rate residuals such as renal necrosis under the appropriate system	
301	Visceral Leishmaniasis:	
	During treatment for active disease	1
	Note: A 100 percent evaluation shall continue beyond the cessation of treatment for active disease. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Rate residuals such as liver damage or lymphadenopathy under the appropriate system.	
302	Leprosy (Hansen's Disease): As active disease	1
	NOTE: A 100 percent evaluation shall continue beyond the date that an examining physician has determined that this has become inactive. Six months after the date of inactivity, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. Rate residuals such as skin lesions or peripheral neuropathy under the appropriate system.	
304	Malaria: As active disease	1
	Note: The diagnosis of malaria depends on the identification of the malarial parasites in blood smears. If the veteran served in an endemic area and presents signs and symptoms compatible with malaria, the diagnosis may be based on clinical grounds alone. Relapses must be confirmed by the presence of malarial parasites in blood smears. Thereafter rate residuals such as liver or spleen damage under the appropriate system	
205	Lymphatic Filariasis:	
303	As active disease	
	Thereafter rate residuals such as epididymitis or lymphanqitis under the appropriate system	
306	Bartonellosis:	
,00	As active disease, and for 3 months convalescence	
	Thereafter rate residuals such as skin lesions under the appropriate system	
307	Plaque:	
	As active disease	
	Thereafter rate residuals such as lymphadenopathy under the appropriate system	
808	Relapsing Fever:	
	As active disease	
	Thereafter rate residuals such as liver or spleen damage or central nervous system involvement under the ap-	
	propriate system	
309	Rheumatic fever:	
	As active disease	
	Thereafter rate residuals such as heart damage under the appropriate system	
310	Syphilis, and other treponemal infections:	
	Rate the complications of nervous system, vascular system, eyes or ears. (See DC 7004, syphilitic heart disease, DC 8013, cerebrospinal syphilis, DC 8014, meningovascular syphilis, DC 8015, tabes dorsalis, and	
	DC 9301, dementia associated with central nervous system syphilis)	
111	Tuberculosis, miliary:	
	As active disease	
	Inactive: See §§ 4.88c and 4.89.	
313	Avitaminosis:	
	Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor	
	With stomatitis, diarrhea, and symmetrical dermatitis	
		l
	With stomatitis, or achlorhydria, or diarrhea	

§4.88b

		Rati
314	Beriberi:	
	As active disease:	
	With congestive heart failure, anasarca, or Wernicke-Korsakoff syndrome	1
	With cardiomegaly, or; with peripheral neuropathy with footdrop or atrophy of thigh or calf muscles	
	With peripheral neuropathy with absent knee or ankle jerks and loss of sensation, or; with symptoms such as weakness, fatigue, anorexia, dizziness, heaviness and stiffness of legs, headache or sleep disturbance	
	Thereafter rate residuals under the appropriate body system.	
315	Pellagra:	
0.0	Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor	
	With stomatitis, diarrhea, and symmetrical dermatitis	
	With stomatitis, or achlorhydria, or diarrhea	
	Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discom-	
	fort, weakness, inability to concentrate and irritability	
316	Brucellosis:	
	As active disease	-
317		
317	As active disease, and for 3 months convalescence	
	Thereafter rate residuals such as spleen damage or skin conditions under the appropriate system	
318		
-	As active disease	
	Thereafter rate residuals such as arthritis, lung lesions or meningitis under the appropriate system	
319		
	As active disease	
	Thereafter rate residuals such as arthritis under the appropriate system	
320	Parasitic diseases otherwise not specified:	
	As active disease	
350	Thereafter rate residuals such as spleen or liver damage under the appropriate system Lupus erythematosus, systemic (disseminated):	
3330	Not to be combined with ratings under DC 7809 Acute, with frequent exacerbations, producing severe impair-	
	ment of health	
	Exacerbations lasting a week or more, 2 or 3 times per year	
	Exacerbations once or twice a year or symptomatic during the past 2 years	
	NOTE: Evaluate this condition either by combining the evaluations for residuals under the appropriate system,	
	or by evaluating DC 6350, whichever method results in a higher evaluation.	
3351	· · · · · · · · · · · · · · · · · · ·	
0001	AIDS with recurrent opportunistic infections or with secondary diseases afflicting multiple body systems; HIV-	
	related illness with debility and progressive weight loss, without remission, or few or brief remissions	
	Refractory constitutional symptoms, diarrhea, and pathological weight loss, or; minimum rating following de-	
	velopment of AIDS-related opportunistic infection or neoplasm	
	Recurrent constitutional symptoms, intermittent diarrhea, and on approved medication(s), or; minimum rating	
	with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	
	Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on ap-	
	proved medication(s), or; with evidence of depression or memory loss with employment limitations	
	Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4	
	cell count	
	NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protocol	
	at an accredited medical institution.	
	NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms may be rated separately under appropriate codes if higher overall evaluation results, but not in combination with	
	percentages otherwise assignable above.	
6354	Chronic Fatique Syndrome (CFS):	
	Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a	
	combination of other signs and symptoms:	
	Which are nearly constant and so severe as to restrict routine daily activities almost completely and which	
	may occasionally preclude self-care	
	Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level,	
	or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year	
	Which are nearly constant and restrict routine daily activities to 50 to 75 percent of the pre-illness level, or;	
	which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total du-	
	ration per year	
	Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level,	
	or; which wax and wane, resulting in periods of incapacitation of at least two but less than four weeks total	
	duration per year	
	tion per year, or; symptoms controlled by continuous medicationmultion per year and wane but result in periods of incapacitation of at least one but less than two weeks total duration per year, or; symptoms controlled by continuous medication	
	Note: For the purpose of evaluating this disability, the condition will be considered incapacitating only while it	
	requires bed rest and treatment by a physician.	

§4.88c Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19, 1968.

	Rat- ing
For 1 year after date of inactivity, following active tu- berculosis	100
Thereafter: Rate residuals under the specific body	

Following the total rating for the 1 year period after date of inactivity, the schedular evaluation for residuals of nonpulmonary tuberculosis, i.e., ankylosis, surgical removal of a part, etc., will be assigned under the appropriate diagnostic code for the residual preceded by the diagnostic code for tuberculosis of the body part affected. For example, tuberculosis of the hip joint with residual ankylosis would be coded 5001–5250. Where there are existing residuals of pulmonary and nonpulmonary conditions, the evaluations for residual separate functional impairment may be combined.

Where there are existing pulmonary and nonpulmonary conditions, the total rating for the 1 year, after attainment of inactivity, may not be applied to both conditions during the same period. However, the total rating during the 1-year period for the pulmonary or for the nonpulmonary condition will be utilized, combined with evaluation for residuals of the condition not covered by the 1-year total evaluation, so as to allow any additional benefit provided during such period.

[34 FR 5062, Mar. 11, 1969. Redesignated at 59 FR 60902, Nov. 29, 1994]

§ 4.89 Ratings for inactive nonpulmonary tuberculosis in effect on August 19, 1968.

Public Law 90-493 repealed section 356 of title 38, United States Code which provided graduated ratings for inactive tuberculosis. The repealed section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90-493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For use in rating cases in which the protective provisions of Pub. L. 90-493 apply, the former evaluations are retained in this section.

	Rat- ing
For 2 years after date of inactivity, following active tuberculosis, which was clinically identified during	
service or subsequently	100
Thereafter, for 4 years, or in any event, to 6 years after date of inactivity	50
Thereafter, for 5 years, or to 11 years after date of inactivity	30
Thereafter, in the absence of a schedular compen-	
sable permanent residual	0

Following the total rating for the 2-year period after date of inactivity, the schedular evaluation for residuals of nonpulmonary tuberculosis, *i.e.*, ankylosis, surgical removal of a part, etc., if in excess of 50 percent or 30 percent will be assigned under the appropriate diagnostic code for the specific residual preceded by the diagnostic code for tuberculosis of the body part affected. For example, tuberculosis of the hipjoint with residual ankylosis would be coded 5001–5250.

The graduated ratings for nonpulmonary tuberculosis will not be combined with residuals of nonpulmonary tuberculosis unless the graduated rating and the rating for residual disability cover separate functional losses, e.g., graduated ratings for tuberculosis of the kidney and residuals of tuberculosis of the spine. Where there are existing pulmonary and nonpulmonary conditions, the graduated evaluation for the pulmonary, or for the nonpulmonary, condition will be utilized, combined with evaluations for residuals of the condition not covered by the graduated evaluation utilized, so as to provide the higher evaluation over such period.

The ending dates of all graduated ratings of nonpulmonary tuberculosis will be controlled by the date of attainment of inactivity.

These ratings are applicable only to veterans with nonpulmonary tuberculosis active on or after October 10, 1949.

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 43 FR 45361, Oct. 2, 1978]

THE RESPIRATORY SYSTEM

§ 4.96 Special provisions regarding evaluation of respiratory conditions.

(a) Rating coexisting respiratory conditions. Ratings under diagnostic codes 6600 through 6817 and 6822 through 6847 will not be combined with each other. Where there is lung or pleural involvement, ratings under diagnostic codes 6819 and 6820 will not be combined with each other or with diagnostic codes 6600 through 6817 or 6822 through 6847. A single rating will be assigned under the diagnostic code which reflects the predominant disability with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation. However, in cases protected by the provisions of Pub. L. 90-493, the graduated ratings of 50 and 30 percent for inactive tuberculosis will not be elevated.

(b) Rating "protected" tuberculosis cases. Public Law 90-493 repealed section 356 of title 38, United States Code which had provided graduated ratings for inactive tuberculosis. The repealed

section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90–493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For application in rating cases in which the protective provisions of Pub. L. 90–493 apply the former evaluations pertaining to pulmonary tuberculosis are retained in §4.97.

- (c) Special monthly compensation. When evaluating any claim involving complete organic aphonia, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, there are other conditions in this section which under certain circumstances also establish entitlement to special monthly compensation.
- (d) Special provisions for the application of evaluation criteria for diagnostic codes 6600, 6603, 6604, 6825–6833, and 6840–6845. (1) Pulmonary function tests (PFT's) are required to evaluate these conditions except:
- (i) When the results of a maximum exercise capacity test are of record and are 20 ml/kg/min or less. If a maximum exercise capacity test is not of record, evaluate based on alternative criteria.
- (ii) When pulmonary hypertension (documented by an echocardiogram or cardiac catheterization), cor pulmonale, or right ventricular hypertrophy has been diagnosed.
- (iii) When there have been one or more episodes of acute respiratory failure.
- (iv) When outpatient oxygen therapy is required.

- (2) If the DLCO (SB) (Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method) test is not of record, evaluate based on alternative criteria as long as the examiner states why the test would not be useful or valid in a particular case.
- (3) When the PFT's are not consistent with clinical findings, evaluate based on the PFT's unless the examiner states why they are not a valid indication of respiratory functional impairment in a particular case.
- (4) Post-bronchodilator studies are required when PFT's are done for disability evaluation purposes except when the results of pre-bronchodilator pulmonary function tests are normal or when the examiner determines that post-bronchodilator studies should not be done and states why.
- (5) When evaluating based on PFT's, use post-bronchodilator results in applying the evaluation criteria in the rating schedule unless the post-bronchodilator results were poorer than the pre-bronchodilator results. In those cases, use the pre-bronchodilator values for rating purposes.
- (6) When there is a disparity between the results of different PFT's (FEV-1 (Forced Expiratory Volume in one second), FVC (Forced Vital Capacity), etc.), so that the level of evaluation would differ depending on which test result is used, use the test result that the examiner states most accurately reflects the level of disability.
- (7) If the FEV-1 and the FVC are both greater than 100 percent, do not assign a compensable evaluation based on a decreased FEV-1/FVC ratio.

(Authority: 38 U.S.C. 1155)

[34 FR 5062, Mar. 11, 1969, as amended at 61 FR 46727, Sept. 5, 1996; 71 FR 52459, Sept. 6, 2006]

$\S 4.97$ Schedule of ratings—respiratory system.

		Rating
	DISEASES OF THE NOSE AND THROAT	
6502	Septum, nasal, deviation of: Traumatic only,	
	With 50-percent obstruction of the nasal passage on both sides or complete obstruction on one side	10
6504	Nose, loss of part of, or scars:	
	Exposing both nasal passages	30
	Loss of part of one ala, or other obvious disfigurement	10

		Rating
Note:	Or evaluate as DC 7800, scars, disfiguring, head, face, or neck.	
6511 6512	Sinusitis, frontal, chronic. Sinusitis, maxillary, chronic. Sinusitis, sphenoid, chronic. General Rating Formula for Sinusitis (DC's 6510 through 6514): Following radical surgery with chronic osteomyelitis, or; near constant sinusitis characterized by headaches, pain and tenderness of affected sinus, and purulent discharge or crusting after repeated surgeries Three or more incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; more than six non-incapacitating episodes per year of sinusitis characterized by headaches, pain, and purulent discharge or crusting One or two incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; three to six non-incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; three to six non-incapacitating episodes per year of sinusitis characterized by headaches, pain, and purulent discharge or crusting	50
	Detected by X-ray only	0
6515	Note: An incapacitating episode of sinusitis means one that requires bed rest and treatment by a physician. Laryngitis, tuberculous, active or inactive. Rate under §§ 4.88c or 4.89, whichever is appropriate.	
6516	Laryngitis, chronic: Hoarseness, with thickening or nodules of cords, polyps, submucous infiltration, or pre-malignant changes on biopsy	30
6518	Hoarseness, with inflammation of cords or mucous membrane	10 1100
	Rate the residuals of partial laryngectomy as laryngitis (DC 6516), aphonia (DC 6519), or stenosis of larynx (DC 6520).	
6519	Aphonia, complete organic: Constant inability to communicate by speech Constant inability to speak above a whisper	¹ 100 60
	Note: Evaluate incomplete aphonia as laryngitis, chronic (DC 6516).	
6520	Larynx, stenosis of, including residuals of laryngeal trauma (unilateral or bilateral): Forced expiratory volume in one second (FEV-1) less than 40 percent of predicted value, with Flow-Volume Loop compatible with upper airway obstruction, or; permanent tracheostomy	100 60 30 10
6521	Pharynx, injuries to:	
	Stricture or obstruction of pharynx or nasopharynx, or; absence of soft palate secondary to trauma, chemical burn, or granulomatous disease, or; paralysis of soft palate with swallowing difficulty (nasal regurgitation) and speech impairment	50
6522	Allergic or vasomotor rhinitis: With polyps Without polyps, but with greater than 50-percent obstruction of nasal passage on both sides or complete ob-	30
6523	struction on one side Bacterial rhinitis:	10
	Rhinoscleroma With permanent hypertrophy of turbinates and with greater than 50-percent obstruction of nasal passage on both sides or complete obstruction on one side	50 10
6524	Granulomatous rhinitis: Wegener's granulomatosis, lethal midline granuloma	100
	Other types of granulomatous infection	20
	DISEASES OF THE TRACHEA AND BRONCHI	
6600	Bronchitis, chronic: FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy FEV-1 of 40 to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	100 60 30
6601	predicted Bronchiectasis:	10
	With incapacitating episodes of infection of at least six weeks total duration per year	100

		Ra
	With incapacitating episodes of infection of four to six weeks total duration per year, or; near constant findings of cough with purulent sputum associated with anorexia, weight loss, and frank hemoptysis and requiring antibiotic usage almost continuously	
	With incapacitating episodes of infection of two to four weeks total duration per year, or; daily productive cough with sputum that is at times purulent or blood-tinged and that requires prolonged (lasting four to six weeks) antibiotic usage more than twice a year	
	Intermittent productive cough with acute infection requiring a course of antibiotics at least twice a year Or rate according to pulmonary impairment as for chronic bronchitis (DC 6600).	
	Note: An incapacitating episode is one that requires bedrest and treatment by a physician.	
602	Asthma, bronchial:	
002	FEV-1 less than 40-percent predicted, or; FEV-1/FVC less than 40 percent, or; more than one attack per week with episodes of respiratory failure, or; requires daily use of systemic (oral or parenteral) high dose corticosteroids or immuno-suppressive medications	
	FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; at least monthly visits to a physician for required care of exacerbations, or; intermittent (at least three per year) courses of systemic (oral or parenteral) corticosteroids	
	FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; daily inhalational or oral bron-chodilator therapy, or; inhalational anti-inflammatory medication	
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; intermittent inhalational or oral bronchodilator therapy	
	Note: In the absence of clinical findings of asthma at time of examination, a verified history of asthmatic attacks must be of record.	
6603	Emphysema, pulmonary: FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy. FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent	
604	predicted	
	FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy. FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	
	DISEASES OF THE LUNGS AND PLEURA—TUBERCULOSIS	
704	Ratings for Pulmonary Tuberculosis Entitled on August 19, 1968	
	Tuberculosis, pulmonary, chronic, far advanced, active	
	Tuberculosis, pulmonary, chronic, minimal, active	
	Tuberculosis, pulmonary, chronic, active, advancement unspecified	
721	Tuberculosis, pulmonary, chronic, far advanced, inactive.	
22	Tuberculosis, pulmonary, chronic, moderately advanced, inactive.	
23	Tuberculosis, pulmonary, chronic, minimal, inactive.	
724	Tuberculosis, pulmonary, chronic, inactive, advancement unspecified. General Rating Formula for Inactive Pulmonary Tuberculosis: For two years after date of inactivity, following	
	General Rating Formula for Inactive Pulmonary Tuberculosis: For two years after date of inactivity, following active tuberculosis, which was clinically identified during service or subsequently	
	Thereafter for four years, or in any event, to six years after date of inactivity	
	Thereafter, for five years, or to eleven years after date of inactivity	
	Following far advanced lesions diagnosed at any time while the disease process was active, minimum Following moderately advanced lesions, provided there is continued disability, emphysema, dyspnea on exertion, impairment of health, etc	

		Rating
treated bero treated bero 1 to Vete (Note (inaction)	(1): The 100-percent rating under codes 6701 through 6724 is not subject to a requirement of precedent hospital trent. It will be reduced to 50 percent for failure to submit to examination or to follow prescribed treatment upon ont to that effect from the medical authorities. When a veteran is placed on the 100-percent rating for inactive tuculosis, the medical authorities will be appropriately notified of the fact, and of the necessity, as given in footnote 38 U.S.C. 1156 (and formerly in 38 U.S.C. 356, which has been repealed by Public Law 90–493), to notify the errans Service Center in the event of failure to submit to examination or to follow treatment. (2): The graduated 50-percent and 30-percent ratings and the permanent 30 percent and 20 percent ratings for titve pulmonary tuberculosis are not to be combined with ratings for other respiratory disabilities. Following acoplasty the rating will be for removal of ribs combined with the rating for collapsed lung. Resection of the ribs dent to thoracoplasty will be rated as removal.	
	Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968	
6730	Tuberculosis, pulmonary, chronic, active	100
6731	findings of a stationary or retrogressive lesion. Tuberculosis, pulmonary, chronic, inactive: Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600). Rate thoracoplasty as removal of ribs under DC 5297. Note: A mandatory examination will be requested immediately following notification that active tuberculosis	
6732	evaluated under DC 6730 has become inactive. Any change in evaluation will be carried out under the provisions of § 3.105(e). Pleurisy, tuberculous, active or inactive: Rate under §§ 4.88c or 4.89, whichever is appropriate.	
	NONTUBERCULOUS DISEASES	
6817	Pulmonary Vascular Disease: Primary pulmonary hypertension, or; chronic pulmonary thromboembolism with evidence of pulmonary hypertension, right ventricular hypertrophy, or cor pulmonale, or; pulmonary hypertension secondary to other obstructive disease of pulmonary arteries or veins with evidence of right ventricular hypertrophy or cor pulmonale	100
	Chronic pulmonary thromboembolism requiring anticoagulant therapy, or; following inferior vena cava surgery without evidence of pulmonary hypertension or right ventricular dysfunction Symptomatic, following resolution of acute pulmonary embolism Asymptomatic, following resolution of pulmonary thromboembolism	60 30 0
	Note: Evaluate other residuals following pulmonary embolism under the most appropriate diagnostic code, such as chronic bronchitis (DC 6600) or chronic pleural effusion or fibrosis (DC 6844), but do not combine that evaluation with any of the above evaluations.	
	Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	100
6820	Neoplasms, benign, any specified part of respiratory system. Evaluate using an appropriate respiratory analogy.	
	Bacterial Infections of the Lung	
	Actinomycosis. Nocardiosis. Chronic lung abscess. General Rating Formula for Bacterial Infections of the Lung (diagnostic codes 6822 through 6824): Active infection with systemic symptoms such as fever, night sweats, weight loss, or hemoptysis Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600).	100
	Interstitial Lung Disease	
6825 6826 6827 6828	Desquamative interstitial pneumonitis. Pulmonary alveolar proteinosis.	

0000	Don't induced address of the said file and file and	Rating
6829 6830	Drug-induced pulmonary pneumonitis and fibrosis. Radiation-induced pulmonary pneumonitis and fibrosis.	
6831		
6832)	
6833	Asbestosis.	
	General Rating Formula for Interstitial Lung Disease (diagnostic codes 6825 through 6833): Forced Vital Capacity (FVC) less than 50-percent predicted, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption with cardiorespiratory limitation, or; cor pulmonale or pulmonary hypertension, or; requires outpatient oxygen therapy	100
	FVC of 65- to 74-percent predicted, or; DLCO (SB) of 56- to 65-percent predicted	30 10
	Mycotic Lung Disease	
6834	Histoplasmosis of lung.	
	Coccidioidomycosis.	
6836		
6837 6838		
6839		
0000	General Rating Formula for Mycotic Lung Disease (diagnostic codes 6834 through 6839):	
	Chronic pulmonary mycosis with persistent fever, weight loss, night sweats, or massive hemoptysis	100
	Chronic pulmonary mycosis requiring suppressive therapy with no more than minimal symptoms	
	such as occasional minor hemoptysis or productive cough	50
	tive cough	30
	Healed and inactive mycotic lesions, asymptomatic	0
	Note: Coccidioidomycosis has an incubation period up to 21 days, and the disseminated phase is ordinarily manifest within six months of the primary phase. However, there are instances of dissemination delayed up to many years after the initial infection which may have been unrecognized. Accordingly, when service connection is under consideration in the absence of record or other evidence of the disease in service, service in southwestern United States where the disease is endemic and absence of prolonged residence in this locality before or after service will be the deciding factor.	
	Restrictive Lung Disease	
6840	Diaphragm paralysis or paresis.	
6841	Spinal cord injury with respiratory insufficiency.	
6842 6843		
6844		
6845		
	General Rating Formula for Restrictive Lung Disease (diagnostic codes 6840 through 6845): FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy FEV-1 of 40 to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40 to	100
	55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	60
	FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65- percent predicted	30
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted	10
	Or rate primary disorder.	
	Note (1): A 100-percent rating shall be assigned for pleurisy with empyema, with or without pleurocutaneous fistula, until resolved.	
	Note (2): Following episodes of total spontaneous pneumothorax, a rating of 100 percent shall be assigned as of the date of hospital admission and shall continue for three months from the first day of the month after hospital discharge.	
	Note (3): Gunshot wounds of the pleural cavity with bullet or missile retained in lung, pain or discomfort on exertion, or with scattered rales or some limitation of excursion of diaphragm or of lower chest expansion shall be rated at least 20-percent disabling. Disabling injuries of shoulder girdle muscles (Groups I to IV) shall be separately rated and combined with ratings for respiratory involvement. Involvement of Muscle Group XXI (DC 5321), however, will not be separately rated.	
6846	Sarcoidosis:	

		Rating
	Cor pulmonale, or; cardiac involvement with congestive heart failure, or; progressive pulmonary disease with fever, night sweats, and weight loss despite treatment	100
	Pulmonary involvement requiring systemic high dose (therapeutic) corticosteroids for control	60
	Pulmonary involvement with persistent symptoms requiring chronic low dose (maintenance) or intermittent corticosteroids	30
	Chronic hilar adenopathy or stable lung infiltrates without symptoms or physiologic impairment	0
	Or rate active disease or residuals as chronic bronchitis (DC 6600) and extra-pulmonary involvement under specific body system involved.	
6847	Sleep Apnea Syndromes (Obstructive, Central, Mixed):	
	Chronic respiratory failure with carbon dioxide retention or cor pulmonale, or; requires tracheostomy	100
	Requires use of breathing assistance device such as continuous airway pressure (CPAP) machine	50
	Persistent day-time hypersomnolence	30
	Asymptomatic but with documented sleep disorder breathing	0

[61 FR 46728, Sept. 5, 1996, as amended at 71 FR 28586, May 17, 2006]

THE CARDIOVASCULAR SYSTEM

§4.100 Application of the evaluation criteria for diagnostic codes 7000-7007, 7011, and 7015–7020.

- (a) Whether or not cardiac hypertrophy or dilatation (documented by electrocardiogram, echocardiogram, or X-ray) is present and whether or not there is a need for continuous medication must be ascertained in all cases.
- (b) Even if the requirement for a 10% (based on the need for continuous medication) or 30% (based on the presence of cardiac hypertrophy or dilatation) evaluation is met, METs testing is required in all cases except:
- (1) When there is a medical contraindication.
- (2) When the left ventricular ejection fraction has been measured and is 50%
- (3) When chronic congestive heart failure is present or there has been more than one episode of congestive heart failure within the past year.
- (4) When a 100% evaluation can be assigned on another basis.
- (c) If left ventricular ejection fraction (LVEF) testing is not of record, evaluate based on the alternative criteria unless the examiner states that the LVEF test is needed in a particular case because the available medical information does not sufficiently reflect the severity of the veteran's cardiovascular disability.

[71 FR 52460, Sept. 6, 2006]

§§ 4.101-4.103 [Reserved]

§4.104 Schedule of ratings—cardiovascular system.

DISEASES OF THE HEART

Rat- ing
100
100

¹ Review for entitlement to special monthly compensation under § 3.350 of this chapter.

38 CFR Ch. I (7-1-17 Edition)

DISEASES OF THE HEART—Continued

		Rat- ing		Rat- ing
	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea,	9	Chronic congestive heart failure, or; work-	
	fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electro-cardiogram, echocardio-		load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100
\	gram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	30	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,	
	continuous medication requiredndocarditis: For three months following cessation of	10	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60
7	therapy for active infection with cardiac in- volvement Thereafter, with endocarditis (documented by findings on physical examination and	100	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-	
,	either echocardiogram, Doppler echo- cardiogram, or cardiac catheterization) re- sulting in:		tion on electro-cardiogram, echocardiogram, or X-ray	30
(Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection		greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10
ı	fraction of less than 30 percent	100	Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
	than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection frac-	60	fraction of less than 30 percent	100
١	tion of 30 to 50 percent	60	of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
١	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30	tion of 30 to 50 percent	60
7002 Pa	greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30
	For three months following cessation of therapy for active infection with cardiac involvement	100	Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10
	Thereafter, with documented pericarditis resulting in: Chronic congestive heart failure, or; work-		NOTE: Evaluate syphilitic aortic aneurysms under DC 7110 (aortic aneurysm).	
	load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or, left ventricular dysfunction with an ejection fraction of less than 30 percent.	100	7005 Arteriosclerotic heart disease (Coronary artery disease): With documented coronary artery disease resulting in:	
ľ	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,	100	Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
,	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60	fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater	100
	greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electro-cardiogram, echocardio-		than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	60
١	gram, or X-rayWorkload of greater than 7 METs but not greater than 10 METs results in dyspnea,	30	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	60
7003 Pe	fatigue, angina, dizziness, or syncope, or; continuous medication requiredericardial adhesions:	10	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30

Department of Veterans Affairs

§4.104

DISEASES OF THE HEART—Continued

greater than 10 METs results in dyspnea,

fatigue, angina, dizziness, or syncope, or; continuous medication required NOTE: If nonservice-connected arteriosclerotic heart disease is superimposed on service-connected valvular or other non-arteriosclerotic heart disease, request a medical opinion as to which condition is

causing the current signs and symptoms.

7006 Myocardial infarction:

During and for three months following myocardial infarction, documented by labora-

Thereafter:

With history of documented myocardial infarction, resulting in:
Chronic congestive heart failure, or; work-

load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection

heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required 7007 Hypertensive heart disease:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent More than one episode of acute congestive

heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

7008 Hyperthyroid heart disease:

Include as part of the overall evaluation for hyperthyroidism under DC 7900. How-ever, when atrial fibrillation is present, hyperthyroidism may be evaluated either under DC 7900 or under DC 7010 (supraventricular arrhythmia), whichever results in a higher evaluation.

7010 Supraventricular arrhythmias:

Rat- ing		Rat- ing
10	Paroxysmal atrial fibrillation or other supraventricular tachycardia, with more than four episodes per year documented by ECG or Holter monitor	30
100	praventricular tachycardia documented by ECG or Holter monitor	10
100	(AICD) in place	100
60	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection frac-	100
30	tion of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or, evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardio-	60
10	gram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	30
100	continuous medication required	10
60	7015 Atrioventricular block: Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
30 10	fraction of less than 30 percent	100
	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60
	tion on electrocardiogram, echocardio- gram, or X-ray	30

38 CFR Ch. I (7-1-17 Edition)

DISEASES OF THE HEART—Continued

	Rat- ing		Rat- ing
Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication or a pacemaker required	10	Workload greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10
ventricular block associated with a supraventricular arrhythmia or pathological bradycardia should be submitted to the Director, Compensation Service. Simple delayed P-R conduction time, in the absence of other evidence of cardiac disease, is not a disability.		for implantation or reimplantation	100
7016 Heart valve replacement (prosthesis): For indefinite period following date of hospital admission for valve replacement	100	NOTE: Evaluate implantable Cardioverter-Defibrillators (AICD's) under DC 7011. 7019 Cardiac transplantation:	
Thereafter: Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or;		For an indefinite period from date of hospital admission for cardiac transplantation Thereafter: Chronic congestive heart failure, or; work-	100
left ventricular dysfunction with an ejection fraction of less than 30 percent	100	load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100
of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	60	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-		tion of 30 to 50 percent	60 30
tion on electrocardiogram, echocardio- gram, or X-ray	30	the date of hospital admission for cardiac trans- plantation. One year following discharge, the ap- propriate disability rating shall be determined by mandatory VA examination. Any change in evalua-	
fatigue, angina, dizziness, or syncope, or; continuous medication required	10	tion based upon that or any subsequent examina- tion shall be subject to the provisions of §3.105(e) of this chapter.	
the date of hospital admission for valve replace- ment. Six months following discharge, the appro- priate disability rating shall be determined by man- datory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.		7020 Cardiomyopathy: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent More than one episode of acute congestive	100
7017 Coronary bypass surgery: For three months following hospital admission for surgery Thereafter:	100	heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100	tion of 30 to 50 percent	60
More than one episode of acute congestive heart failure in the past year, or, workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,		tion on electrocardiogram, echocardio- gram, or X-ray	30
angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60	fatigue, angina, dizziness, or syncope, or; continuous medication required	10
greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-		and isolated systolic hypertension): Diastolic pressure predominantly 130 or more	60
tion on electrocardiogram, echocardiogram, or X-ray	30	Diastolic pressure predominantly 120 or more	40

Department of Veterans Affairs

§4.104

DISEASES OF THE HEART—Continued

	Rat- ing		Rat- ing
Diastolic pressure predominantly 110 or more, or; systolic pressure predominantly 200 or more	20	NoTE (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor, if applicable. NOTE (3): A rating of 100 percent shall be assigned as of the date of hospital admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. 7112 Aneurysm, any small artery:	<u> </u>
means that the diastolic blood pressure is predominantly 90mm. or greater, and isolated systolic hypertension means that the systolic blood pressure is predominantly 160mm. or greater with a diastolic blood pressure of less than 90mm.		Asymptomatic evaluate according to body system affected. Following surgery, evaluate residuals under the body system affected.	0
NOTE (2): Evaluate hypertension due to aortic insufficiency or hyperthyroidism, which is usually the isolated systolic type, as part of the condition causing it rather than by a separate evaluation. NOTE (3): Evaluate hypertension separately from hypertensive heart disease and other types of heart disease.		7113 Arteriovenous fistula, traumatic: With high output heart failure Without heart failure but with enlarged heart, wide pulse pressure, and tachycardia Without cardiac involvement but with edema, stasis dermatitis, and either ulcer-	100 60
7110 Aortic aneurysm: If five centimeters or larger in diameter, or; if symptomatic, or; for indefinite period from date of hospital admission for surgical		ation or cellulitis: Lower extremity	50 40 30
correction (including any type of graft insertion) Precluding exertion Evaluate residuals of surgical correction according to organ systems affected.	100 60	Upper extremity	100
NOTE: A rating of 100 percent shall be assigned as of the date of admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.		Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; either persistent coldness of the extremity or ankle/brachial index of 0.5 or less	60
7111 Aneurysm, any large artery: If symptomatic, or; for indefinite period from date of hospital admission for surgical correction	100	sence of hair, dystrophic nails) or ankle/ brachial index of 0.7 or less	40 20
Following surgery: Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	100	NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The normal index is 1.0 or greater. NOTE (2): Evaluate residuals of aortic and large arterial bypass surgery or arterial graft as arterio-	20
brachial index of 0.5 or less	60	sclerosis obliterans. NOTE (3): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.	
brachial index of 0.7 or less	40	7115 Thrombo-angiitis obliterans (Buerger's Disease): Ischemic limb pain at rest, and; either deep	
NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The normal index is 1.0 or greater.		ischemic ulcers or ankle/brachial index of 0.4 or less	100

38 CFR Ch. I (7-1-17 Edition)

DISEASES OF THE HEART—Continued

DISEASES OF THE HEART—Continued

	Rat- ing		Rat- ing
Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, absence of hair, dystrophic nails) or ankle/ brachial index of 0.7 or less	40	Note: For purposes of this section, a characteristic attack of erythromelalgia consists of burning pain in the hands, feet, or both, usually bilateral and symmetrical, with increased skin temperature and redness, occurring at warm ambient temperatures. These evaluations are for the disease as a whole, regardless of the number of extremities involved. 7120 Varicose veins: With the following findings attributed to the effects of varicose veins: Massive board-like edema with constant pain at rest Persistent edema or subcutaneous induration, stasis pigmentation or eczema, and persistent ulceration Persistent edema and stasis pigmentation or eczema, with or without intermittent ulcer-	100
combine (under §4.25), using the bilateral factor (§4.26), if applicable.		ation Persistent edema, incompletely relieved by	40
7117 Raynaud's syndrome: With two or more digital ulcers plus autoamputation of one or more digits and history of characteristic attacks	100	elevation of extremity, with or without be- ginning stasis pigmentation or eczema Intermittent edema of extremity or aching and fatique in leg after prolonged standing	20
With two or more digital ulcers and history of characteristic attacks	60	or walking, with symptoms relieved by elevation of extremity or compression ho-	10
Characteristic attacks occurring at least daily	40	siery Asymptomatic palpable or visible varicose veins	0
times a week Characteristic attacks occurring one to three times a week NOTE: For purposes of this section, characteristic attacks consist of sequential color changes of the digits of one or more extremities lasting minutes to hours, sometimes with pain and paresthesias, and precipitated by exposure to cold or by emotional upsets. These evaluations are for the disease as a whole, regardless of the number of extremities in-	10	Note: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable. 7121 Post-phlebitic syndrome of any etiology: With the following findings attributed to venous disease: Massive board-like edema with	100
volved or whether the nose and ears are involved. 7118 Angioneurotic edema: Attacks without laryngeal involvement last-		constant pain at rest	100
ing one to seven days or longer and oc- curring more than eight times a year, or; attacks with laryngeal involvement of any		tion	60
duration occurring more than twice a year Attacks without laryngeal involvement last- ing one to seven days and occurring five to eight times a year, or; attacks with la-	40	without intermittent ulceration Persistent edema, incompletely re- lieved by elevation of extremity, with or without beginning stasis	40
ryngeal involvement of any duration oc- curring once or twice a year	20 10	pigmentation or eczema	20
7119 Erythromelalgia: Characteristic attacks that occur more than once a day, last an average of more than two hours each, respond poorly to treatment, and that restrict most routine daily		vation of extremity or compression hosiery	10 0
activities	100	NOTE: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.	
routine daily activities	60	7122 Cold injury residuals:	
Characteristic attacks that occur daily or more often but that respond to treatment Characteristic attacks that occur less than daily but at least three times a week and	30		
daily but at least three times a week and that respond to treatment	10		

DISEASES OF THE HEART—Continued

DISEASES OF THE HEART—Continued		
	Rat- ing	
With the following in affected parts: Arthralgia or other pain, numbness, or cold sensitivity plus two or more of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis)	30	

Arthraigia or other pain, numbness, or cold sensitivity plus tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, or X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis)

Arthralgia or other pain, numbness, or cold sensitivity

NOTE (1): Separately evaluate amputations of fingers or toes, and complications such as squamous cell carcinoma at the site of a cold injury scar or peripheral neuropathy, under other diagnostic codes. Separately evaluate other disabilities that have been diagnosed as the residual effects of cold injury, such as Raynaud's phenomenon, muscle atrophy, etc., unless they are used to support an evaluation under diagnostic code 7122.

NOTE (2): Evaluate each affected part (e.g., hand, foot, ear, nose) separately and combine the ratings in accordance with §§ 4.25 and 4.26.

7123 Soft tissue sarcoma (of vascular origin)

NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.

(Authority: 38 U.S.C. 1155)

[62 FR 65219, Dec. 11, 1997, as amended at 63 FR 37779, July 14, 1998; 71 FR 52460, Sept. 6, 2006; 79 FR 2100, Jan. 13, 2014]

THE DIGESTIVE SYSTEM

§ 4.110 Ulcers.

Experience has shown that the term "peptic ulcer" is not sufficiently specific for rating purposes. Manifest differences in ulcers of the stomach or duodenum in comparison with those at an anastomotic stoma are sufficiently recognized as to warrant two separate graduated descriptions. In evaluating the ulcer, care should be taken that the findings adequately identify the particular location.

§ 4.111 Postgastrectomy syndromes.

There are various postgastrectomy symptoms which may occur following anastomotic operations of the stomach. When present, those occurring during or immediately after eating and known as the "dumping syndrome" are characterized by gastrointestinal complaints and generalized symptoms simulating hypoglycemia; those occurring from 1 to 3 hours after eating usually present definite manifestations of hypoglycemia.

§ 4.112 Weight loss.

For purposes of evaluating conditions in §4.114, the term "substantial weight loss" means a loss of greater than 20 percent of the individual's baseline weight, sustained for three months or longer; and the term "minor weight loss" means a weight loss of 10 to 20 percent of the individual's baseline weight, sustained for three months or longer. The term "inability to gain weight" means that there has been substantial weight loss with inability to regain it despite appropriate therapy. "Baseline weight" means the average weight for the two-year-period preceding onset of the disease.

(Authority: 38 U.S.C. 1155) [66 FR 29488, May 31, 2001]

§ 4.113 Coexisting abdominal conditions.

There are diseases of the digestive system, particularly within the abdomen, which, while differing in the site of pathology, produce a common disability picture characterized in the main by varying degrees of abdominal distress or pain, anemia and disturbances in nutrition. Consequently, certain coexisting diseases in this area, as indicated in the instruction under the title "Diseases of the Digestive System," do not lend themselves to distinct and separate disability evaluations without violating the fundarelating mental principle pyramiding as outlined in §4.14.

§ 4.114 Schedule of ratings—digestive system.

Ratings under diagnostic codes 7301 to 7329, inclusive, 7331, 7342, and 7345 to 7348 inclusive will not be combined

with each other. A single evaluation will be assigned under the diagnostic code which reflects the predominant disability picture, with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation.

Rating

7200 Mouth, injuries of. Rate as for disfigurement and impairment of function of mastication. 7201 Lips, injuries of. Rate as for disfigurement of face. 7202 Tongue, loss of whole or part: With inability to communicate by speech	
function of mastication. 7201 Lips, injuries of. Rate as for disfigurement of face. 7202 Tongue, loss of whole or part: With inability to communicate by speech	7200 Mouth, injuries of.
Rate as for disfigurement of face. 7202 Tongue, loss of whole or part: With inability to communicate by speech	
7202 Tongue, loss of whole or part: With inability to communicate by speech	7201 Lips, injuries of.
With inability to communicate by speech	
One-half or more	
With marked speech impairment	
Permitting passage of liquids only, with marked impairment of general health	
Permitting passage of liquids only, with marked impairment of general health	
impairment of general health	
Moderate 7204 Esophagus, spasm of (cardiospasm). If not amenable to dilation, rate as for the degree of obstruction (stricture). 7205 Esophagus, diverticulum of, acquired. Rate as for obstruction (stricture). 7301 Peritoneum, adhesions of: Severe; definite partial obstruction shown by X-ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension Mild NOTE: Ratings for adhesions will be considered when there is history of operative or other traumatic or infectious (intraabdominal) proceess, and at least two of the following: disturbance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year averaging 10 days in duration; or with continuous moderate manifestations	impairment of general health
for tamenable to dilation, rate as for the degree of obstruction (stricture). Feronagus, diverticulum of, acquired. Rate as for obstruction (stricture). Feronagus, diverticulum of, acquired. Rate as for obstruction (stricture). Feronagus, diverticulum of, acquired. Rate as for obstruction (stricture). Feronagus, diverticulum of, acquired. Rate as for obstruction of screen colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain	
If not amenable to dilation, rate as for the degree of obstruction (stricture). 7205 Esophagus, diverticulum of, acquired. Rate as for obstruction (stricture). 7301 Peritoneum, adhesions of: Severe; definite partial obstruction shown by X-ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage. Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain	
gree of obstruction (stricture). 7205 Esophagus, diverticulum of, acquired. Rate as for obstruction (stricture). 7301 Peritoneum, adhesions of: Severe; definite partial obstruction shown by X-ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension	
Rate as for obstruction (stricture). 7301 Peritoneum, adhesions of: Severe; definite partial obstruction shown by X-ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain	
7301 Peritoneum, adhesions of: Severe; definite partial obstruction shown by X-ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain	
Severe; definite partial obstruction shown by X-ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension Mild	
ray, with frequent and prolonged episodes of severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain	
severe colic distension, nausea or vomiting, following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain	
following severe peritonitis, ruptured appendix, perforated ulcer, or operation with drainage Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension Mild NoTE: Ratings for adhesions will be considered when there is history of operative or other traumatic or infectious (intraabdominal) process, and at least two of the following: disturbance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomitting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or twice	
perforated ulcer, or operation with drainage Moderately severe; parifal obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension Mild NOTE: Ratings for adhesions will be considered when there is history of operative or other traumatic or infectious (intraabdominal) process, and at least two of the following: disturbance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or twice yearly	
Moderately severe; partial obstruction manifested by delayed motility of barium meal and less frequent and less prolonged episodes of pain	
less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension Mild	Moderately severe: partial obstruction mani-
less frequent and less prolonged episodes of pain Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension Mild	fested by delayed motility of barium meal and
Moderate; pulling pain on attempting work or aggravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension	less frequent and less prolonged episodes of
gravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension	
sional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or abdominal distension	Moderate; pulling pain on attempting work or ag-
stipation (perhaps alternating with diarrhea) or abdominal distension	signal enisodes of colic pain pausea con-
abdominal distension Mild Mild MOTE: Ratings for adhesions will be considered when there is history of operative or other traumatic or infectious (intraabdominal) proc- ess, and at least two of the following: disturb- ance of motility, actual partial obstruction, re- flex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of defi- nite impairment of health Moderately severe; less than severe but with im- pairment of health manifested by anemia and weight loss; or recurrent incapacitating epi- sodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symp- toms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or twice yearly	
Mild NOTE: Ratings for adhesions will be considered when there is history of operative or other traumatic or infectious (intraabdominal) process, and at least two of the following: disturbance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year	
when there is history of operative or other traumatic or infectious (intraabdominal) process, and at least two of the following: disturbance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health	
traumatic or infectious (intraabdominal) process, and at least two of the following: disturbance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year	NOTE: Ratings for adhesions will be considered
ess, and at least two of the following: disturbance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health	when there is history of operative or other
ance of motility, actual partial obstruction, reflex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomitting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health Moderately severe; less than severe but with impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or twice yearly	traumatic or infectious (intraabdominal) proc-
flex disturbances, presence of pain. 7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health Moderately severe; less than severe but with impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or tvice yearly	
7304 Ulcer, gastric. 7305 Ulcer, duodenal: Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health Moderately severe; less than severe but with impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or twice yearly	
Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations	
Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health Moderately severe; less than severe but with impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or twice yearly	
ulcer therapy, periodic vomiting, recurrent hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health	,
hematemesis or melena, with manifestations of anemia and weight loss productive of definite impairment of health	
of anemia and weight loss productive of defi- nite impairment of health	hematemesis or melena, with manifestations
Moderately severe; less than severe but with impairment of health manifested by anemia and weight loss; or recurrent incapacitating episodes averaging 10 days or more in duration at least four or more times a year	of anemia and weight loss productive of defi-
pairment of health manifested by anemia and weight loss; or recurrent incapacitating eph- sodes averaging 10 days or more in duration at least four or more times a year	
weight loss; or recurrent incapacitating epi- sodes averaging 10 days or more in duration at least four or more times a year	
sodes averaging 10 days or more in duration at least four or more times a year	
at least four or more times a year Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations Mild; with recurring symptoms once or twice yearly	
Moderate; recurring episodes of severe symptoms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations	
toms two or three times a year averaging 10 days in duration; or with continuous moderate manifestations	
days in duration; or with continuous moderate manifestations	toms two or three times a year averaging 10
manifestations	
yearly	
7306 Ulcer, marginal (gastrojejunal):	
	7306 Ulcer, marginal (gastrojejunal):

	Rat- ing
Pronounced; periodic or continuous pain unrelieved by standard ulcer therapy with periodic vomiting, recurring melena or	
hematemesis, and weight loss. Totally inca-	100
pacitating	100
nounced and less continuous symptoms with	
definite impairment of health	60
Moderately severe; intercurrent episodes of ab-	
dominal pain at least once a month partially or	
completely relieved by ulcer therapy, mild and transient episodes of vomiting or melena	40
Moderate; with episodes of recurring symptoms	
several times a year	20
Mild; with brief episodes of recurring symptoms	
once or twice yearly	10
'307 Gastritis, hypertrophic (identified by gastroscope):	
Chronic; with severe hemorrhages, or large ul-	
cerated or eroded areas	60
Chronic; with multiple small eroded or ulcerated	
areas, and symptoms	30
Chronic; with small nodular lesions, and symptoms	10
Gastritis, atrophic.	"
A complication of a number of diseases, includ-	
ing pernicious anemia.	
Rate the underlying condition.	
'308 Postgastrectomy syndromes:	
Severe; associated with nausea, sweating, cir- culatory disturbance after meals, diarrhea,	
hypoglycemic symptoms, and weight loss with	
malnutrition and anemia	60
Moderate; less frequent episodes of epigastric	
disorders with characteristic mild circulatory symptoms after meals but with diarrhea and	
weight loss	40
Mild; infrequent episodes of epigastric distress	
with characteristic mild circulatory symptoms	
or continuous mild manifestations	20
7309 Stomach, stenosis of. Rate as for gastric ulcer.	
'310 Stomach, injury of, residuals.	
Rate as peritoneal adhesions.	
7311 Residuals of injury of the liver:	
Depending on the specific residuals, separately	
evaluate as adhesions of peritoneum (diag- nostic code 7301), cirrhosis of liver (diagnostic	
code 7312), and chronic liver disease without	
cirrhosis (diagnostic code 7345).	
7312 Cirrhosis of the liver, primary biliary cirrhosis,	
or cirrhotic phase of sclerosing cholangitis:	
Generalized weakness, substantial weight loss, and persistent jaundice, or; with one of the fol-	
lowing refractory to treatment: ascites, hepatic	
encephalopathy, hemorrhage from varices or	
portal gastropathy (erosive gastritis)	100
History of two or more episodes of ascites, he- patic encephalopathy, or hemorrhage from	
varices or portal gastropathy (erosive gas-	
tritis), but with periods of remission between	
attacks	70
History of one episode of ascites, hepatic	
encennalonathy or nemormane from varices	50
encephalopathy, or hemorrhage from varices or portal gastropathy (erosive gastritis)	l
or portal gastropathy (erosive gastritis) Portal hypertension and splenomegaly, with	
or portal gastropathy (erosive gastritis) Portal hypertension and splenomegaly, with weakness, anorexia, abdominal pain, malaise,	
or portal gastropathy (erosive gastritis) Portal hypertension and splenomegaly, with	30

	Rat-		Rat-
	ing		ing
NOTE: For evaluation under diagnostic code		Symptomatic with diarrhea, anemia and inability	0/
7312, documentation of cirrhosis (by biopsy or imaging) and abnormal liver function tests		to gain weight	20
must be present.		predominant disability, rate under diagnostic	
7314 Cholecystitis, chronic:		code 7301.	
Severe; frequent attacks of gall bladder colic	30	7329 Intestine, large, resection of:	
Moderate; gall bladder dyspepsia, confirmed by X-ray technique, and with infrequent attacks		With severe symptoms, objectively supported by	
(not over two or three a year) of gall bladder		examination findings	4
colic, with or without jaundice	10	With moderate symptoms With slight symptoms	2
Mild	0	Note: Where residual adhesions constitute the	
7315 Cholelithiasis, chronic.		predominant disability, rate under diagnostic	
Rate as for chronic cholecystitis.		code 7301.	
7316 Cholangitis, chronic. Rate as for chronic cholecystitis.		7330 Intestine, fistula of, persistent, or after attempt	
7317 Gall bladder, injury of.		at operative closure:	
Rate as for peritoneal adhesions.		Copious and frequent, fecal discharge	10
7318 Gall bladder, removal of:		Constant or frequent, fecal discharge	6
With severe symptoms	30	Slight infrequent, fecal discharge Healed; rate for peritoneal adhesions.	30
With mild symptoms Nonsymptomatic	10 0	7331 Peritonitis, tuberculous, active or inactive:	
Spleen, disease or injury of.	O	Active	10
See Hemic and Lymphatic Systems.		Inactive: See §§ 4.88b and 4.89.	
7319 Irritable colon syndrome (spastic colitis, mu-		7332 Rectum and anus, impairment of sphincter	
cous colitis, etc.):		control:	
Severe; diarrhea, or alternating diarrhea and constipation, with more or less constant ab-		Complete loss of sphincter control	10
dominal distress	30	Extensive leakage and fairly frequent involuntary	6
Moderate; frequent episodes of bowel disturb-	00	bowel movements Occasional involuntary bowel movements, ne-	0
ance with abdominal distress	10	cessitating wearing of pad	3
Mild; disturbances of bowel function with occa-	_	Constant slight, or occasional moderate leakage	1
sional episodes of abdominal distress	0	Healed or slight, without leakage	
'321 Amebiasis: Mild gastrointestinal disturbances, lower abdom-		7333 Rectum and anus, stricture of:	
inal cramps, nausea, gaseous distention,		Requiring colostomy	10
chronic constipation interrupted by diarrhea	10	Great reduction of lumen, or extensive leakage	5
Asymptomatic	0	Moderate reduction of lumen, or moderate con-	3
NOTE: Amebiasis with or without liver abscess is		stant leakage	3
parallel in symptomatology with ulcerative colitis and should be rated on the scale provided		Severe (or complete), persistent	5
for the latter. Similarly, lung abscess due to		Moderate, persistent or frequently recurring	3
amebiasis will be rated under the respiratory		Mild with constant slight or occasional moderate	
system schedule, diagnostic code 6809.		leakage	1
7322 Dysentery, bacillary.		7335 Ano, fistula in.	
Rate as for ulcerative colitis 7323 Colitis, ulcerative:		Rate as for impairment of sphincter control.	
Pronounced; resulting in marked malnutrition,		7336 Hemorrhoids, external or internal: With persistent bleeding and with secondary	
anemia, and general debility, or with serious		anemia, or with fissures	2
complication as liver abscess	100	Large or thrombotic, irreducible, with excessive	
Severe; with numerous attacks a year and mal-		redundant tissue, evidencing frequent	
nutrition, the health only fair during remissions Moderately severe; with frequent exacerbations	60 30	recurrences	1
Moderate; with infrequent exacerbations	10	Mild or moderate	
7324 Distomiasis, intestinal or hepatic:		7337 Pruritus ani.	
Severe symptoms	30	Rate for the underlying condition. 7338 Hernia, inquinal:	
Moderate symptoms	10	Large, postoperative, recurrent, not well sup-	
Mild or no symptoms	0	ported under ordinary conditions and not read-	
'325 Enteritis, chronic. Rate as for irritable colon syndrome.		ily reducible, when considered inoperable	6
7326 Enterocolitis, chronic.		Small, postoperative recurrent, or unoperated ir-	
Rate as for irritable colon syndrome.		remediable, not well supported by truss, or not	_
327 Diverticulitis.		readily reducible	3
Rate as for irritable colon syndrome, peritoneal		Postoperative recurrent, readily reducible and well supported by truss or belt	1
adhesions, or colitis, ulcerative, depending upon the predominant disability picture.		Not operated, but remediable	'
7328 Intestine, small, resection of:		Small, reducible, or without true hernia protru-	
With marked interference with absorption and		sion	
nutrition, manifested by severe impairment of		Note: Add 10 percent for bilateral involvement,	
health objectively supported by examination		provided the second hernia is compensable.	
findings including material weight loss	60	This means that the more severely disabling	
With definite interference with absorption and nutrition, manifested by impairment of health		hernia is to be evaluated, and 10 percent, only, added for the second hernia, if the latter	
objectively supported by examination findings		is of compensable degree.	
including definite weight loss	40	7339 Hernia, ventral, postoperative:	

	Rat- ing		Rat- ing
Massive, persistent, severe diastasis of recti muscles or extensive diffuse destruction or weakening of muscular and fascial support of abdominal wall so as to be inoperable	100	Intermittent fatigue, malaise, and anorexia, or, incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least one week, but less than two weeks, during the	_
Small, not well supported by belt under ordinary conditions, or healed ventral hernia or post-operative wounds with weakening of abdominal wall and indication for a supporting belt	20	past 12-month period Nonsymptomatic NOTE (1): Evaluate sequelae, such as cirrhosis or malignancy of the liver, under an appro-	10 0
Wounds, postoperative, healed, no disability, belt not indicated	0	priate diagnostic code, but do not use the same signs and symptoms as the basis for evaluation under DC 7354 and under a diagnostic code for sequelae. (See § 4.14.).	
7342 Visceroptosis, symptomatic, marked	10 100	NOTE (2): For purposes of evaluating conditions under diagnostic code 7345, "incapacitating episode" means a period of acute signs and symptoms severe enough to require bed rest	
yond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other thera- peutic procedure. Six months after discontinu- ance of such treatment, the appropriate dis-		and treatment by a physician. NOTE (3): Hepatitis B infection must be confirmed by serologic testing in order to evaluate it under diagnostic code 7345. 7346 Hernia hiatal:	
ability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no		Symptoms of pain, vomiting, material weight loss and hematemesis or melena with moderate anemia; or other symptom combinations pro- ductive of severe impairment of health	60
local recurrence or metastasis, rate on residu- als. 7344 Benign neoplasms, exclusive of skin growths:		Persistently recurrent epigastric distress with dysphagia, pyrosis, and regurgitation, accom- panied by substernal or arm or shoulder pain, productive of considerable impairment of	
Evaluate under an appropriate diagnostic code, depending on the predominant disability or the specific residuals after treatment.		health With two or more of the symptoms for the 30 percent evaluation of less severity	30 10
7345 Chronic liver disease without cirrhosis (including hepatitis B, chronic active hepatitis, autoimmune hepatitis, hemochromatosis, drug-induced hepatitis, etc., but excluding bile duct disorders and hepatitis C):		7347 Pancreatitis: With frequently recurrent disabling attacks of abdominal pain with few pain free intermissions and with steatorrhea, malabsorption, diarrhea and severe malnutrition	100
Near-constant debilitating symptoms (such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain)	100	With frequent attacks of abdominal pain, loss of normal body weight and other findings show- ing continuing pancreatic insufficiency be-	
Daily fatigue, malaise, and anorexia, with sub- stantial weight loss (or other indication of mal- nutrion), and hepatomegally, or; incapacitating		tween acute attacks	60
episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav- ing a total duration of at least six weeks during the past 12-month period, but not occurring		mission between attacks	30 10
constantly	60	be confirmed as resulting from pancreatitis by appropriate laboratory and clinical studies. NOTE 2: Following total or partial pancreatectomy, rate under above, symptoms, minimum rating 30 percent. 7348 Vagotomy with pyloroplasty or gastroenterostomy:	
ing a total duration of at least four weeks, but less than six weeks, during the past 12-month period	40	Followed by demonstrably confirmative post- operative complications of stricture or con- tinuing gastric retention	40
weight loss or hepatomegaly), requiring dietary restriction or continuous medication, or; inca- pacitating episodes (with symptoms such as		With symptoms and confirmed diagnosis of alka- line gastritis, or of confirmed persisting diar- rhea	30 20
fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav- ing a total duration of at least two weeks, but less than four weeks, during the past 12-		NOTE: Rate recurrent ulcer following complete vagotomy under diagnostic code 7305, min- imum rating 20 percent; and rate dumping	20
month period	l 20	syndrome under diagnostic code 7308. 7351 Liver transplant: For an indefinite period from the date of hospital admission for transplant surgery	100
		Minimum	30

Rating

NOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for transplant surgery and shall continue. One year following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.

7354 Hepatitis C (or non-A, non-B hepatitis):

With serologic evidence of hepatitis C infection and the following signs and symptoms due to hepatitis C infection:

Near-constant debilitating symptoms (such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain)

Daily fatigue, malaise, and anorexia, with substantial weight loss (or other indication of malnutrition), and hepatomegaly, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least six weeks during the past 12-month period, but not occurring constantly

Daily fatigue, malaise, and anorexia, with minor weight loss and hepatomegaly, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least four weeks, but less than six weeks, during the past 12-month period

Intermittent fatigue, malaise, and anorexia, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least one week, but less than two weeks, during the past 12-month period......

Nonsymptomatic ...

NOTE (1): Evaluate sequelae, such as cirrhosis or malignancy of the liver, under an appropriate diagnostic code, but do not use the same signs and symptoms as the basis for evaluation under DC 7354 and under a diagnostic code for sequelae. (See § 4.14.).

NOTE (2): For purposes of evaluating conditions under diagnostic code 7354, "incapacitating episode" means a period of acute signs and symptoms severe enough to require bed rest and treatment by a physician.

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 34 FR 5063, Mar. 11, 1969; 40 FR 42540, Sept. 15, 1975; 41 FR 11301, Mar. 18, 1976; 66 FR 29488, May 31, 2001]

THE GENITOURINARY SYSTEM

§4.115 Nephritis.

Albuminuria alone is not nephritis, nor will the presence of transient albumin and casts following acute febrile illness be taken as nephritis. The glomerular type of nephritis is usually preceded by or associated with severe infectious disease: the onset is sudden. and the course marked by red blood cells, salt retention, and edema; it may clear up entirely or progress to a chronic condition. The nephrosclerotic type, originating in hypertension or arteriosclerosis, develops slowly, with minimum laboratory findings, and is associated with natural progress. Separate ratings are not to be assigned for disability from disease of the heart and any form of nephritis, on account of the close interrelationships of cardiovascular disabilities. If, however, absence of a kidney is the sole renal disability, even if removal was required because of nephritis, the absent kidney and any hypertension or heart disease will be separately rated. Also, in the event that chronic renal disease has progressed to the point where regular dialysis is required, any coexisting hypertension or heart disease will be separately rated.

[41 FR 34258, Aug. 13, 1976, as amended at 59 FR 2527, Jan. 18, 1994]

§4.115a Ratings of the genitourinary system—dysfunctions.

Diseases of the genitourinary system generally result in disabilities related to renal or voiding dysfunctions, infections, or a combination of these. The following section provides descriptions of various levels of disability in each of these symptom areas. Where diagnostic codes refer the decisionmaker to these specific areas dysfunction, only the predominant area of dysfunction shall be considered for rating purposes. Since the areas of dysfunction described below do not cover all symptoms resulting from genitourinary diseases, specific diagnoses may include a description of symptoms assigned to that diagnosis.

§4.115b

	Rat- ing			Rat- ing
Renal dysfunction: Requiring regular dialysis, or precluding more than sedentary activity from one of the fol-		L	ong-term drug therapy, 1-2 hospitalizations per year and/or requiring intermittent intensive management	1(
lowing: persistent edema and albuminuria; or, BUN more than 80mg%; or, creatinine more than 8mg%; or, markedly decreased function of kidney or other organ systems, estpecially		[59 F	FR 2527, Jan. 18, 1994; 59 FR 10676, M	
cardiovascularPersistent edema and albuminuria with BUN 40	100		15b Ratings of the genitouri	inary
to 80mg%; or, creatinine 4 to 8mg%; or, generalized poor health characterized by lethargy, weakness, anorexia, weight loss, or limitation			system—diagnoses.	
of exertion	80			Rat- ing
nite decrease in kidney function; or, hyper- tension at least 40 percent disabling under di- agnostic code 7101	60		Note: When evaluating any claim involving loss or loss of use of one or	
Albumin constant or recurring with hyaline and granular casts or red blood cells; or, transient			more creative organs, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special	
or slight edema or hypertension at least 10 percent disabling under diagnostic code 7101 Albumin and casts with history of acute nephritis;	30		monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement	
or, hypertension non-compensable under diagnostic code 7101	0		to special monthly compensation; however, there are other conditions in	
Voiding dysfunction: Rate particular condition as urine leakage, frequency, or obstructed voiding			this section which under certain cir- cumstances also establish entitlement to special monthly compensation.	
Continual Urine Leakage, Post Surgical Urinary Diversion, Urinary Incontinence, or Stress Incontinence:		7500	Kidney, removal of one: Minimum evaluation	30
Requiring the use of an appliance or the wearing of absorbent materials which must be changed			Or rate as renal dysfunction if there is nephritis, infection, or pathology of the other.	
more than 4 times per day Requiring the wearing of absorbent materials	60	7501		
which must be changed 2 to 4 times per day Requiring the wearing of absorbent materials which must be changed less than 2 times per	40	7502		
dayUrinary frequency:	20	7504	Pyelonephritis, chronic: Rate as renal dysfunction or urinary tract infection, whichever is predomi-	
Daytime voiding interval less than one hour, or; awakening to void five or more times per night Daytime voiding interval between one and two	40	7505	nant. Kidney, tuberculosis of:	
hours, or; awakening to void three to four times per night	20		Rate in accordance with §§ 4.88b or 4.89, whichever is appropriate.	
Daytime voiding interval between two and three hours, or; awakening to void two times per	10	7507	Nephrosclerosis, arteriolar: Rate according to predominant symptoms as renal dysfunction, hyper-	
night Obstructed voiding: Urinary retention requiring intermittent or contin-	10		tension or heart disease. If rated under the cardiovascular schedule,	
uous catheterization	30		however, the percentage rating which would otherwise be assigned will be elevated to the next higher evalua-	
slow or weak stream, decreased force of stream) with any one or combination of the fol- lowing:		7508	tion. Nephrolithiasis:	
 Post void residuals greater than 150 cc. Uroflowmetry; markedly diminished peak flow rate (less than 10 cc/sec). 			Rate as hydronephrosis, except for re- current stone formation requiring one or more of the following:	
Recurrent urinary tract infections secondary to obstruction.			 diet therapy drug therapy invasive or non-invasive proce- 	
Stricture disease requiring periodic dilatation every 2 to 3 months Obstructive symptomatology with or without stric-	10	7509	dures more than two times/year Hydronephrosis:	3
ture disease requiring dilatation 1 to 2 times per year	0		Severe; Rate as renal dysfunction. Frequent attacks of colic with infection	_
Urninary tract infection: Poor renal function: Rate as renal dysfunction. Poor renal function: Rate as renal dysfunction.			(pyonephrosis), kidney function impaired Frequent attacks of colic, requiring catheter drainage	2
Recurrent symptomatic infection requiring drain- age/frequent hospitalization (greater than two			Only an occasional attack of colic, not infected and not requiring catheter drainage	10

Department of Veterans Affairs

	§ 4	. 1	1	5	b
--	-----	-----	---	---	---

		Rat- ing		Rat- ing
	Ureterolithiasis: Rate as hydronephrosis, except for recurrent stone formation requiring one or more of the following: 1. diet therapy 2. drug therapy 3. invasive or non-invasive procedures more than two times/year Ureter, stricture of: Rate as hydronephrosis, except for recurrent stone formation requiring one or more of the following: 1. diet therapy 2. drug therapy 3. invasive or non-invasive procedures more than two times/year	30	Note—Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local reocurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant.	3
etiol 7515	Cystitis, chronic, includes interstitial and all logies, infectious and non-infectious: Bladder, calculus in, with symptoms interng with function:		tem: Rate as voiding dysfunction or renal dysfunction, whichever is predominant. 7530 Chronic renal disease requiring regular dialysis:	
	Rate as voiding dysfunction Bladder, fistula of: Rate as voiding dysfunction or urinary tract infection, whichever is predominant. Postoperative, suprapubic cystotomy	100	Rate as renal dysfunction. 7531 Kidney transplant: Following transplant surgery Thereaffer: Rate on residuals as renal dysfunction, minimum rating Note—The 100 percent evaluation shall	10
	Bladder, injury of: Rate as voiding dysfunction. Urethra, stricture of:		be assigned as of the date of hospital admission for transplant surgery and	
7519	Rate as voiding dysfunction. Urethra, fistual of: Rate as voiding dysfunction.		shall continue with a mandatory VA examination one year following hos- pital discharge. Any change in eval- uation based upon that or any subse-	
7520	Multiple urethroperineal fistulae Penis, removal of half or more Or rate as voiding dysfunction.	100 30	quent examination shall be subject to the provisions of §3.105(e) of this chapter.	
	Penis removal of glans Or rate as voiding dysfunction.	20	7532 Renal tubular disorders (such as renal glycosurias, aminoacidurias, renal tubular acidosis,	
201	Testis, atrophy complete:. Both—20 ¹		Fanconi's syndrome, Bartter's syndrome, related disorders of Henle's loop and proximal or distal nephron function, etc.): Minimum rating for symptomatic condi-	
7524	One—01 Testis, removal:. Both—301 One—01		tion	2
	Note: In cases of the removal of one testis as the result of a service-incurred injury or disease, other than an undescended or congenitally undeveloped testis, with the absence or nonfunctioning of the other testis unrelated to service, an evaluation of 30 percent will be assigned for the service-connected testicular loss. Testis, underscended, or congenitally undeveloped is not a ratable disability.			
7525	Epididymo-orchitis, chronic only: Rate as urinary tract infection. For tubercular infections: Rate in accordance with §§ 4.88b or 4.89, whichever is appropriate.			
	Prostate gland injuries, infections, hyper-			
trop	hy, postoperative residuals: Rate as voiding dysfunction or urinary tract infection, whichever is predomi-			
7528	nant. Malignant neoplasms of the genitourinary sys-			
		100		

		Rat- ing
ease	Or rate as renal dysfunction. Cystic diseases of the kidneys (polycystic disease, uremic medullary cystic disease, Medullary nge kidney, and similar conditions): Rate as renal dysfunction.	
	Atherosclerotic renal disease (renal artery stessor atheroembolic renal disease): Rate as renal dysfunction.	
age	Toxic nephropathy (antibotics, radiocontrast nts, nonsteroidal anti-inflammatory agents, vy metals, and similar agents): Rate as renal dysfunction.	
7536	,	
7537	Interstitial nephritis: Rate as renal dysfunction.	
7538	Papillary necrosis: Rate as renal dysfunction.	
7539	Renal amyloid disease: Rate as renal dysfunction.	
7540 rena	Disseminated intravascular coagulation with al cortical necrosis: Rate as renal dysfunction.	
	,	
7542	,	

 $^{^{\}rm 1}\,\text{Review}$ for entitlement to special monthly compensation under § 3.350 of this chapter.

[59 FR 2527, Jan. 18, 1994; 59 FR 14567, Mar. 29, 1994, as amended at 59 FR 46339, Sept. 8, 1994]

GYNECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST

§ 4.116 Schedule of ratings—gynecological conditions and disorders of the breast.

		Rating
	Note 1: Natural menopause, primary	
	amenorrhea, and pregnancy and child- birth are not disabilities for rating pur- poses. Chronic residuals of medical or	
	poses. Chronic residuals of medical or	
	surgical complications of pregnancy may	
	be disabilities for rating purposes. Note 2: When evaluating any claim involv-	
	ing loss or loss of use of one or more	
	creative organs or anatomical loss of	
	one or both breasts, refer to §3.350 of	
	this chapter to determine whether the veteran may be entitled to special	
	monthly compensation. Footnotes in the	
	schedule indicate conditions which po-	
	tentially establish entitlement to special	
	monthly compensation; however, almost any condition in this section might, under	
	certain circumstances, establish entitle-	
	ment to special monthly compensation.	
	Vulva, disease or injury of (including	
	vaginitis). Vagina, disease or injury of.	
	Cervix, disease or injury of.	
	Uterus, disease, injury, or adhesions of.	
7614 F	Fallopian tube, disease, injury, or adhesions cluding pelvic inflammatory disease (PID)).	
7615 (Ovary, disease, injury, or adhesions of.	
	Rating Formula for Disease, Injury, or Ad-	
	ns of Female Reproductive Organs (diag-	
nostic	codes 7610 through 7615): Symptoms not controlled by continuous	
	treatment	30
	Symptoms that require continuous treat-	
	ment	10
	Symptoms that do not require continuous treatment	ا ر
	Uterus and both ovaries, removal of, com-	
plete:	For three months after removal	1 100
	Thereafter	150
7618 l	Uterus, removal of, including corpus:	
	For three months after removal	1100
7619 (Thereafter	1 30
7019	For three months after removal	1100
	Thereafter:	
	Complete removal of both ovaries	1 30
	Removal of one with or without partial removal of the other	10
7620 (Ovaries, atrophy of both, complete	1 20
7621 l	Uterus, prolapse:	
	Complete, through vagina and introitus	50
7622 l	IncompleteUterus, displacement of:	30
	With marked displacement and frequent or	
	continuous menstrual disturbances	30
7000 [With adhesions and irregular menstruation	10
7623 F	Pregnancy, surgical complications of: With rectocele or cystocele	50
	With relaxation of perineum	10
7624 F	Fistula, rectovaginal:	
	Vaginal fecal leakage at least once a day	1
	requiring wearing of pad Vaginal fecal leakage four or more times	100
	per week, but less than daily, requiring	

Rating

¹50

	Vaginal fecal leakage one to three times
	per week requiring wearing of pad
	Vaginal fecal leakage less than once a week
	Without leakage
7625	Fistula, urethrovaginal:
020	Multiple urethrovaginal fistulae
	Requiring the use of an appliance or the
	wearing of absorbent materials which must be changed more than four times
	per day
	Requiring the wearing of absorbent materials which must be changed two to four
	times per day
	rials which must be changed less than two times per day
7626	Breast, surgery of:
020	
	Following radical mastectomy: Both
	One
	Following modified radical mastectomy:
	Both
	One
	Following simple mastectomy or wide loca
	excision with significant alteration of size or form:
	Both
	One
	Following wide local excision without sig- nificant alteration of size or form:
	Both or one
	Note: For VA purposes:
	(1) Radical mastectomy means
	removal of the entire breast, un- derlying pectoral muscles, and regional lymph nodes up to the
	coracoclavicular ligament
	(2) Modified radical mastectomy means removal of the entire
	breast and axillary lymph nodes (in continuity with the breast)
	Pectoral muscles are left intact. (3) Simple (or total) mastectomy
	means removal of all of the breast tissue, nipple, and a
	small portion of the overlying skin, but lymph nodes and mus
	cles are left intact
	(4) Wide local excision (including
	partial mastectomy lumpectomy, tylectomy
	segmentectomy, and quadrantectomy) means re-
	moval of a portion of the breastissue
7627	Malignant neoplasms of gynecological sys-

	Rating
Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals. 7628 Benign neoplasms of the gynecological system or breast. Rate according to impairment in	
function of the urinary or gynecological systems, or skin.	
7629 Endometriosis:	
Lesions involving bowel or bladder con- firmed by laparoscopy, pelvic pain or heavy or irregular bleeding not controlled by treatment, and bowel or bladder	
symptoms	50
Pelvic pain or heavy or irregular bleeding	
not controlled by treatment Pelvic pain or heavy or irregular bleeding	30
requiring continuous treatment for control Note: Diagnosis of endometriosis must be substantiated by laparoscopy.	10

 $^{^{\}rm 1} \mbox{Review}$ for entitlement to special monthly compensation under $\S\,3.350$ of this chapter.

[60 FR 19855, Apr. 21, 1995, as amended at 67 FR 6874, Feb. 14, 2002; 67 FR 37695, May 30, 2002]

THE HEMIC AND LYMPHATIC SYSTEMS

$\$\,4.117\,$ Schedule of ratings—hemic and lymphatic systems.

		Rating
meg	Anemia, hypochromic-microcytic and paloblastic, such as iron-deficiency and per-	
	Hemoglobin 5gm/100ml or less, with find- ings such as high output congestive heart failure or dyspnea at rest	100
	Hemoglobin 7gm/100ml or less, with find- ings such as dyspnea on mild exertion, cardiomegaly, tachycardia (100 to 120 beats per minute) or syncope (three epi-	
	sodes in the last six months) Hemoglobin 8gm/100ml or less, with find- ings such as weakness, easy fatigability,	70
	headaches, lightheadedness, or short- ness of breath	30
	ings such as weakness, easy fatigability or headaches	10
	tomatic	0
	Evaluate complications of pernicious anemia, sentia or peripheral neuropathy, separately.	such as
7702	Agranulocytosis, acute: Requiring bone marrow transplant, or; re- quiring transfusion of platelets or red cells at least once every six weeks, or;	

mune:

	Rating
Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months	60 30 10
NOTE: The 100 percent rating for bone marrow to shall be assigned as of the date of hospital admiss shall continue with a mandatory VA examinat months following hospital discharge. Any change uation based upon that or any subsequent exar shall be subject to the provisions of §3.105(e) chapter.	ion and ion six in eval- nination
7703 Leukemia: With active disease or during a treatment phase Otherwise rate as anemia (code 7700) or aplastic anemia (code 7716), whichever would result in the greater benefit.	100
NOTE: The 100 percent rating shall continue beyond is sation of any surgical, radiation, antineoplastic therapy or other therapeutic procedures. Six mont discontinuance of such treatment, the appropriate crating shall be determined by mandatory VA exam Any change in evaluation based upon that or any quent examination shall be subject to the provis § 3.105(e) of this chapter. If there has been no recrate on residuals.	chemo- hs after lisability nination. subse- sions of
7704 Polycythemia vera: During periods of treatment with myelosuppressants and for three months following cessation of myelosuppressant therapy	100 40 10 s, stroke

NOTE: Rate complications such as systemic infections with encapsulated bacteria separately.

Platelet count of less than 20,000, with ac-

tive bleeding, requiring treatment with medication and transfusions

Platelet count between 20,000 and 70,000,

Stable platelet count between 70,000 and

Stable platelet count of 100,000 or more,

100,000, without bleeding ...

without bleeding

7706 Splenectomy

not requiring treatment, without bleeding

NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.

		Rating
7710	Adenitis, tuberculous, active or inactive. Rate under §§ 4.88c or 4.89 of this part, whichever is appropriate.	
7714	Sickle cell anemia: With repeated painful crises, occurring in skin, joints, bones or any major organs caused by hemolysis and sickling of red blood cells, with anemia, thrombosis and	
	infarction, with symptoms precluding even light manual labor	100
	light manual laborFollowing repeated hemolytic sickling cri-	60
	ses with continuing impairment of health Asymptomatic, established case in remis- sion, but with identifiable organ impair-	30
	ment	10

NOTE: Sickle cell trait alone, without a history of directly attributable pathological findings, is not a ratable disability. Cases of symptomatic sickle cell trait will be forwarded to the Director, Compensation Service, for consideration under § 3.321(b)(1) of this chapter.

7715 Non-Hodgkin's lymphoma:
With active disease or during a treatment phase

NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be dtermined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.

7716 Aplastic anemia: Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or; infections recurring at least once every

six weeks

Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months

100

60

30

10

NOTE: The 100 percent rating for bone marrow transplant shall be assigned as of the date of hospital admission and shall continue with a mandatory VA examination six months following hospital discharge. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.

7717 AL amyloidosis (primary amyloidosis) 100

[60 FR 49227, Sept. 22, 1995, as amended at 77 FR 6467, Feb. 8, 2012; 79 FR 2100, Jan. 13, 2014]

THE SKIN

§ 4.118 Schedule of ratings—skin.

A veteran whose scars were rated by VA under a prior version of diagnostic codes 7800, 7801, 7802, 7803, 7804, or 7805,

100

70

30

0

as in effect before October 23, 2008, may request review under diagnostic codes 7800, 7801, 7802, 7804, and 7805, irrespective of whether his or her disability has worsened since the last review. VA will review that veteran's disability rating to determine whether the veteran may be entitled to a higher disability rating under diagnostic codes 7800, 7801, 7802, 7804, and 7805. A request for review pursuant to this rulemaking will be treated as a claim for an increased rating for purposes of determining the effective date of an increased rating awarded as a result of such review; however, in no case will the award be effective before October 23, 2008

	Rat- ing
7800 Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or other disfigurement of the head, face, or neck:	
With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement	80
With visible or palpable tissue loss and either gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement	50
With visible or palpable tissue loss and ei- ther gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with two or three characteristics of disfigurement	30
With one characteristic of disfigurement Note (1):The 8 characteristics of disfigurement, for purposes of evaluation under § 4.118, are:	10
Scar 5 or more inches (13 or more cm.) in length.	
Scar at least one-quarter inch (0.6 cm.) wide at widest part.	
Surface contour of scar elevated or depressed on palpation.	
Scar adherent to underlying tissue. Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.).	
Skin texture abnormal (irregular, atrophic, shiny, scaly, etc.) in an area exceeding six square inches (39 sq. cm.).	
Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.).	
Skin indurated and inflexible in an area ex-	

ceeding six square inches (39 sq. cm.).

	Rat- ing
Note (2): Rate tissue loss of the auricle under DC 6207 (loss of auricle) and ana- tomical loss of the eye under DC 6061	
(anatomical loss of both eyes) or DC 6063 (anatomical loss of one eye), as appropriate.	
Note (3): Take into consideration unretouched color photographs when evaluating under these criteria.	
Note (4): Separately evaluate disabling effects other than disfigurement that are associated with individual scar(s) of the head, face, or neck, such as pain, instability, and residuals of associated muscle or nerve injury, under the appropriate diagnostic code(s) and apply § 4.25 to com-	
bine the evaluation(s) with the evaluation assigned under this diagnostic code.	
Note (5): The characteristic(s) of disfigure- ment may be caused by one scar or by multiple scars; the characteristic(s) re- quired to assign a particular evaluation need not be caused by a single scar in order to assign that evaluation.	
7801 Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck, that are deep and nonlinear:	
Area or areas of 144 square inches (929 sq. cm.) or greater Area or areas of at least 72 square inches	40
(465 sq. cm.) but less than 144 square inches (929 sq. cm.)	30
(77 sq. cm.) but less than 72 square inches (465 sq. cm.)	20
Area or areas of at least 6 square inches (39 sq. cm.) but less than 12 square inches (77 sq. cm.)	10
Note (1): A deep scar is one associated with underlying soft tissue damage.	
Note (2): If multiple qualifying scars are present, or if a single qualifying scar affects more than one extremity, or a single qualifying scar affects one or more extremities and either the anterior portion or posterior portion of the trunk, or both, or a single qualifying scar affects both the anterior portion and the posterior portion of the trunk, assign a separate evaluation for each affected extremity based on the total area of the qualifying scars that affect that extremity, assign a separate evaluation based on the total area of the qualifying scars that affect the anterior portion of the trunk, and assign a separate evaluation based on the total area of the qualifying scars that affect the posterior portion of the trunk. The midaxillary line on each side separates the anterior and posterior portions of the trunk. Combine the separate evaluations under §4.25. Qualifying scars are scars that are nonlinear, deep, and are not located on the head, face, or neck.	

not of the head, face, or neck, that are superficial

Area or areas of 144 square inches (929 sq. cm.) or greater

10

and nonlinear:

	Rat- ing		Rat- ing
Note (1): A superficial scar is one not associated with underlying soft tissue damage Note (2): If multiple qualifying scars are present, or if a single qualifying scar affects more than one extremity, or a single qualifying scar affects one or more extremities and either the anterior portion or posterior portion of the trunk, or both, or a single qualifying scar affects both the anterior portion and the posterior portion of the trunk, assign a separate evaluation for each affected extremity based on the total area of the qualifying scars that affect that extremity, assign a separate evaluation based on the total area of the qualifying scars that affect the anterior portion of the trunk, and assign a separate evaluation based on the total area of the qualifying scars that affect the posterior portion of the trunk. The midaxillary line on each side separates the anterior and posterior portions of the trunk. Combine the separate evaluations under § 4.25. Qualifying scars are scars that are nonlinear, superficial, and are not located on the head, face, or neck.	···g	Less than 5 percent of the entire body or less than 5 percent of exposed areas affected, and; no more than topical therapy required during the past 12-month period Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805), depending upon the predominant disability. 7807 American (New World) leishmaniasis (mucocutaneous, espundia): Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or dermatitis (DC 7806), depending upon the predominant disability. Note: Evaluate non-cutaneous (visceral) leishmaniasis under DC 6301 (visceral leishmaniasis). 7808 Old World leishmaniasis (cutaneous, Oriental sore): Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC's, 7801, 7802, 7803, 7804, or 7805), or dermatitis (DC 7806), depending upon the predominant disability.	0
7804 Scar(s), unstable or painful:. Five or more scars that are unstable or painful Three or four scars that are unstable or painful One or two scars that are unstable or painful Note (1): An unstable scar is one where, for any reason, there is frequent loss of covering of skin over the scar. Note (2): If one or more scars are both unstable and painful, add 10 percent to the evaluation that is based on the total number of unstable or painful scars Note (3): Scars evaluated under diagnostic codes 7800, 7801, 7802, or 7805 may also receive an evaluation under this diagnostic code, when applicable 7805 Scars, other (including linear scars) and other effects of scars evaluated under diagnostic codes 7800, 7801, 7802, and 7804: Evaluate any disabling effect(s) not considered in a rating provided under diagnostic codes 7800—04 under an appropriate diagnostic code. 7806 Dermatitis or eczema. More than 40 percent of the entire body or more than 40 percent of exposed areas affected, or; constant or near-constant systemic therapy such as corticosteroids or other immunosuppressive drugs required during the past 12-month period 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected, or; 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected, or; 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected, or; 20 to 40 percent of exposed areas affected, or; 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected, or; 20 to 40 percent of exposed areas affected, or; 20 to 40 percent of exposed areas affected, or 20 to 40 percent of exposed areas affected, or 20 to 40 percent of exposed areas affected, or 20 to 40 percent of exposed areas affected, or 20 to 40 percent of exposed areas affected, or 20 to 40 percent of exposed areas affected, or 20 to 40 percent of exposed areas affected, or 20 to 40 percent of exposed areas affected, or 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas a	30 20 10	Note: Evaluate non-cutaneous (visceral) leishmaniasis under DC 6301 (visceral) leishmaniasis). 7809 Discoid lupus erythematosus or subacute cutaneous lupus erythematosus: Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or dermatitis (DC 7806), depending upon the predominant disability. Do not combine with ratings under DC 6350. 7811 Tuberculosis luposa (lupus vulgaris), active or inactive: Rate under §§ 4.88c or 4.89, whichever is appropriate. 7813 Dermatophytosis (ringworm: of body, tinea corporis; of head, tinea capitis; of feet, tinea pedis; of beard area, tinea barbae; of nails, tinea unguium; of inguinal area (jock itch), tinea cruris): Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or dermatitis (DC 7806), depending upon the predominant disability. 7815 Bullous disorders (including pemphigus vulgaris, pemphigus (hailey-Hailey), and porphyria cutanea tarda): More than 40 percent of the entire body or more than 40 percent of exposed areas affected, or; constant or near-constant	
systemic therapy such as corticosteroids or other immunosuppressive drugs required for a total duration of six weeks or more, but not constantly, during the past 12-month period	30	systemic therapy such as corticosteroids or other immunosuppressive drugs required during the past 12-month period 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected, or; systemic therapy such as corticosteroids or other immunosuppressive drugs required for a total duration of six weeks or more, but not constantly, during the past 12-month period	60 30

		Rat- ing		Rat- ing
	At least 5 percent, but less than 20 percent,	9	Any extent of involvement of the skin, and;	"'Y
	of the entire body, or at least 5 percent,		systemic therapy such as therapeutic	
	but less than 20 percent, of exposed		doses of corticosteroids, immuno-	
	areas affected, or; intermittent systemic		suppressive retinoids, PUVA (psoralen	
	therapy such as corticosteroids or other		with long-wave ultraviolet-A light) or UVB	
	immunosuppressive drugs required for a		(ultraviolet-B light) treatments, or electron	
	total duration of less than six weeks dur-		beam therapy required for a total duration	
	ing the past 12-month period	10	of six weeks or more, but not constantly,	
	Less than 5 percent of the entire body or		during the past 12-month period	30
	exposed areas affected, and; no more		Any extent of involvement of the skin, and;	-
	than topical therapy required during the		systemic therapy such as therapeutic	
	past 12-month period	0	doses of corticosteroids, immuno-	
	Or rate as disfigurement of the head, face,	U	suppressive retinoids, PUVA (psoralen	
			with long-wave ultraviolet-A light) or UVB	
	or neck (DC 7800) or scars (DC's 7801,		(ultraviolet-B light) treatments, or electron	
	7802, 7803, 7804, or 7805), depending		beam therapy required for a total duration	
	upon the predominant disability.		of less than six weeks during the past 12-	
816	Psoriasis:			10
	More than 40 percent of the entire body or		month period	10
	more than 40 percent of exposed areas		Any extent of involvement of the skin, and;	
	affected, or; constant or near-constant		no more than topical therapy required dur-	
	systemic therapy such as corticosteroids		ing the past 12-month period	(
	or other immunosuppressive drugs re-		7818 Malignant skin neoplasms (other than malig-	
	quired during the past 12-month period	60	nant melanoma):	
	20 to 40 percent of the entire body or 20 to		Rate as disfigurement of the head, face, or	
	40 percent of exposed areas affected, or;		neck (DC 7800), scars (DC's 7801, 7802,	
	systemic therapy such as corticosteroids		7803, 7804, or 7805), or impairment of	
	or other immunosuppressive drugs re-		function.	
	quired for a total duration of six weeks or		Note: If a skin malignancy requires therapy	
	more, but not constantly, during the past		that is comparable to that used for sys-	
	12-month period	30	temic malignancies, i.e., systemic chemo-	
	At least 5 percent, but less than 20 percent,		therapy, X-ray therapy more extensive	
	of the entire body, or at least 5 percent,		than to the skin, or surgery more exten-	
	but less than 20 percent, of exposed		sive than wide local excision, a 100-per-	
	areas affected, or; intermittent systemic		cent evaluation will be assigned from the	
	therapy such as corticosteroids or other		date of onset of treatment, and will con-	
	immunosuppressive drugs required for a		tinue, with a mandatory VA examination	
	total duration of less than six weeks dur-		six months following the completion of	
	ing the past 12-month period	10	such antineoplastic treatment, and any	
	Less than 5 percent of the entire body or		change in evaluation based upon that or	
	exposed areas affected, and; no more		any subsequent examination will be sub-	
	than topical therapy required during the		ject to the provisions of §3.105(e) of this	
	past 12-month period	0	chapter. If there has been no local recur-	
	Or rate as disfigurement of the head, face,	U	rence or metastasis, evaluation will then	
	or neck (DC 7800) or scars (DC's 7801,		be made on residuals. If treatment is con-	
	7802, 7803, 7804, or 7805), depending		fined to the skin, the provisions for a 100-	
			percent evaluation do not apply.	
017	upon the predominant disability.		7819 Benign skin neoplasms:	
817	Exfoliative dermatitis (erythroderma):		Rate as disfigurement of the head, face, or	
	Generalized involvement of the skin, plus		neck (DC 7800), scars (DC's 7801, 7802,	
	systemic manifestations (such as fever,		7803, 7804, or 7805), or impairment of	
	weight loss, and hypoproteinemia), and;		function.	
	constant or near-constant systemic ther-		7820 Infections of the skin not listed elsewhere (in-	
	apy such as therapeutic doses of		cluding bacterial, fungal, viral, treponemal and	
	corticosteroids, immunosuppressive		parasitic diseases):	
	retinoids, PUVA (psoralen with long-wave		• /	
	ultraviolet-A light) or UVB (ultraviolet-B		Rate as disfigurement of the head, face, or	
	light) treatments, or electron beam ther-		neck (DC 7800), scars (DC's 7801, 7802,	
	apy required during the past 12-month pe-		7803, 7804, or 7805), or dermatitis (DC	
	riod	100	7806), depending upon the predominant	
	Generalized involvement of the skin without		disability.	
	systemic manifestations, and; constant or		7821 Cutaneous manifestations of collagen-vas-	
	near-constant systemic therapy such as		cular diseases not listed elsewhere (including	
	therapeutic doses of corticosteroids, im-		scleroderma, calcinosis cutis, and dermato-	
	munosuppressive retinoids, PUVA		myositis):	
	(psoralen with long-wave ultraviolet-A		More than 40 percent of the entire body or	
	light) or UVB (ultraviolet-B light) treat-		more than 40 percent of exposed areas	
	ments, or electron beam therapy required		affected, or; constant or near-constant	
	during the past 12-month period	60	systemic therapy such as corticosteroids	
			or other immunosuppressive drugs re-	
			guired during the past 12-month period	6

	Rat- ing		Rat- ing
20 to 40 percent of the entire body or 20 to	miy_	With localized or episodic cutaneous in-	ıııy
40 percent of exposed areas affected, or; systemic therapy such as conticosteroids		volvement and intermittent systemic medi- cation, such as immunosuppressive	
or other immunosuppressive drugs re- quired for a total duration of six weeks or		retinoids, required for a total duration of less than six weeks during the past 12-	
more, but not constantly, during the past		month period	10
12-month period	30	No more than topical therapy required dur-	
At least 5 percent, but less than 20 percent,		ing the past 12-month period	0
of the entire body, or at least 5 percent,		7825 Urticaria:	
but less than 20 percent, of exposed areas affected, or; intermittent systemic		Recurrent debilitating episodes occurring at	
therapy such as corticosteroids or other		least four times during the past 12-month period despite continuous immuno-	
immunosuppressive drugs required for a		suppressive therapy	60
total duration of less than six weeks dur-		Recurrent debilitating episodes occurring at	
ing the past 12-month period Less than 5 percent of the entire body or	10	least four times during the past 12-month	
exposed areas affected, and; no more		period, and; requiring intermittent sys-	
than topical therapy required during the		temic immunosuppressive therapy for	30
past 12-month period	0	control Recurrent episodes occurring at least four	30
Or rate as disfigurement of the head, face,		times during the past 12-month period,	
or neck (DC 7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805), depending		and; responding to treatment with antihis-	
upon the predominant disability.		tamines or sympathomimetics	10
7822 Papulosquamous disorders not listed else-		7826 Vasculitis, primary cutaneous:	
where (including lichen planus, large or small		Recurrent debilitating episodes occurring at	
plaque parapsoriasis, pityriasis lichenoides et		least four times during the past 12-month period despite continuous immuno-	
varioliformis acuta (PLEVA), lymphomatoid papulosus, and pityriasis rubra pilaris (PRP)):		suppressive therapy	60
More than 40 percent of the entire body or		Recurrent debilitating episodes occurring at	
more than 40 percent of exposed areas		least four times during the past 12-month	
affected, and; constant or near-constant		period, and; requiring intermittent sys-	
systemic medications or intensive light therapy required during the past 12-month		temic immunosuppressive therapy for control	30
period	60	Recurrent episodes occurring one to three	00
20 to 40 percent of the entire body or 20 to	00	times during the past 12-month period,	
40 percent of exposed areas affected, or;		and; requiring intermittent systemic im-	
systemic therapy or intensive light therapy		munosuppressive therapy for control	10
required for a total duration of six weeks or more, but not constantly, during the		Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801,	
past 12-month period	30	7802, 7803, 7804, or 7805), depending	
At least 5 percent, but less than 20 percent,		upon the predominant disability.	
of the entire body, or at least 5 percent,		7827 Erythema multiforme; Toxic epidermal	
but less than 20 percent, of exposed areas affected, or; systemic therapy or in-		necrolysis:	
tensive light therapy required for a total		Recurrent debilitating episodes occurring at least four times during the past 12-month	
duration of less than six weeks during the		period despite ongoing immuno-	
past 12-month period	10	suppressive therapy	60
Less than 5 percent of the entire body or exposed areas affected, and; no more		Recurrent episodes occurring at least four	
than topical therapy required during the		times during the past 12-month period,	
past 12-month period	0	and; requiring intermittent systemic im- munosuppressive therapy	30
Or rate as disfigurement of the head, face,		Recurrent episodes occurring during the	00
or neck (DC 7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805), depending		past 12-month period that respond to	
upon the predominant disability.		treatment with antihistamines or	
7823 Vitiligo:		sympathomimetics, or; one to three epi-	
With exposed areas affected	10	sodes occurring during the past 12-month period requiring intermittent systemic im-	
With no exposed areas affected	0	munosuppressive therapy	10
7824 Diseases of keratinization (including icthyoses, Darier's disease, and palmoplantar keratoderma):		Or rate as disfigurement of the head, face,	
With either generalized cutaneous involve-		or neck (DC 7800) or scars (DC's 7801,	
ment or systemic manifestations, and;		7802, 7803, 7804, or 7805), depending	
constant or near-constant systemic medi-		upon the predominant disability. 7828 Acne:	
cation, such as immunosuppressive retinoids, required during the past 12-		Deep acne (deep inflamed nodules and pus-	
month period	60	filled cysts) affecting 40 percent or more	
With either generalized cutaneous involve-	00	of the face and neck	30
ment or systemic manifestations, and;		Deep acne (deep inflamed nodules and pus-	
intermittent systemic medication, such as		filled cysts) affecting less than 40 percent	
immunosuppressive retinoids, required for a total duration of six weeks or more, but		of the face and neck, or; deep acne other than on the face and neck	10
		man on the lace and neck	10
not constantly, during the past 12-month		Superficial acne (comedones, papules,	

		Det		Da
		Rat- ing		Ra in
	Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805), depending upon the predominant disability.		Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic nervous system, cardiovascular, or	
7829	Chloracne: Deep acne (deep inflamed nodules and pus- filled cysts) affecting 40 percent or more		astrointestinal symptoms Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	10
	of the face and neck	30	Tachycardia, tremor, and increased pulse pres-	
	Deep acne (deep inflamed nodules and pus- filled cysts) affecting less than 40 percent of the face and neck, or; deep acne other		Sure or blood pressure Tachycardia, which may be intermittent, and tremor, or; continuous medication required for con-	;
	than on the face and neck	10	trol	
	Superficial acne (comedones, papules, pustules, superficial cysts) of any extent Or rate as disfigurement of the head, face,	0	NOTE (1): If disease of the heart is the predomi- nant finding, evaluate as hyperthyroid heart dis- ease (DC 7008) if doing so would result in a	
	or neck (DC 7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805), depending		higher evaluation than using the criteria above. NOTE (2): If ophthalmopathy is the sole finding,	
7830	upon the predominant disability. Scarring alopecia:		evaluate as field vision, impairment of (DC 6080); diplopia (DC 6090); or impairment of	
. 000	Affecting more than 40 percent of the scalp	20	central visual acuity (DC 6061-6079).	
	Affecting 20 to 40 percent of the scalp	10 0	7901 Thyroid gland, toxic adenoma of Thyroid enlargement, tachycardia (more than 100	
7831	Affecting less than 20 percent of the scalp Alopecia areata:	U	beats per minute), eye involvement, muscular	
	With loss of all body hair	10	weakness, loss of weight, and sympathetic nervous system, cardiovascular, or gastro-	
7000	With loss of hair limited to scalp and face	0	intestinal symptoms	1
632	Hyperhidrosis: Unable to handle paper or tools because of moisture, and unresponsive to therapy	30	Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	
7833	Able to handle paper or tools after therapy Malignant melanoma:	0	Tachycardia, tremor, and increased pulse pres- sure or blood pressure	
	Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805), disfigurement of the head,		or, or; continuous medication required for control	
	face, or neck (DC 7800), or impairment of function (under the appropriate body system).		NOTE (1): If disease of the heart is the predominant finding, evaluate as hyperthyroid heart dis-	
	Note: If a skin malignancy requires therapy		ease (DC 7008) if doing so would result in a higher evaluation than using the criteria above.	
	that is comparable to that used for sys-		NOTE (2): If ophthalmopathy is the sole finding,	
	temic malignancies, <i>i.e.</i> , systemic chemotherapy, X-ray therapy more extensive		evaluate as field vision, impairment of (DC 6080); diplopia (DC 6090); or impairment of	
	than to the skin, or surgery more exten-		central visual acuity (DC 6061–6079).	
	sive than wide local excision, a 100-per- cent evaluation will be assigned from the		7902 Thyroid gland, nontoxic adenoma of	
	date of onset of treatment, and will con-		With disfigurement of the head or neck	
	tinue, with a mandatory VA examination		Without disfigurement of the head or neck NOTE: If there are symptoms due to pressure on	
	six months following the completion of		adjacent organs such as the trachea, larynx, or	
	such antineoplastic treatment, and any change in evaluation based upon that or		esophagus, evaluate under the diagnostic code	
	any subsequent examination will be sub-		for disability of that organ, if doing so would re- sult in a higher evaluation than using this diag-	
	ject to the provisions of §3.105(e). If there		nostic code.	
	has been no local recurrence or metas- tasis, evaluation will then be made on re-		7903 Hypothyroidism	
	siduals. If treatment is confined to the		Cold intolerance, muscular weakness, cardio- vascular involvement, mental disturbance (de-	
	skin, the provisions for a 100-percent		mentia, slowing of thought, depression),	
	evaluation do not apply.		bradycardia (less than 60 beats per minute),	
Aut	chority: 38 U.S.C. 1155)		and sleepiness	1
	-	E0440	weight gainFatigability, constipation, and mental sluggishness	
Sept	FR 49596, July 31, 2002; 67 FR 58448, 5. 16, 2002; 73 FR 54710, Oct. 23, 2008; Jan. 20, 2012]		Fatigability, consupation, and mental stuggistness Fatigability, or; continuous medication required for control	
.o.r.o,	Juli. 20, 2012]		7904 Hyperparathyroidism	
	THE ENDOCRINE SYSTEM		Generalized decalcification of bones, kidney stones, gastrointestinal symptoms (nausea, vomiting, anorexia, constipation, weight loss, or	
§ 4.1	19 Schedule of ratings—endo	crine	peptic ulcer), and weakness	1
			Continuous medication required for control	
		Rat- ing	NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular residuals or as endocrine dysfunction.	

	Rat- ing		Rat- ing
Marked neuromuscular excitability (such as con- vulsions, muscular spasms (tetany), or laryn- geal stridor) plus either cataract or evidence of		Note (1): An Addisonian "crisis" consists of the rapid onset of peripheral vascular collapse (with acute hypotension and shock), with findings	
increased intracranial pressure (such as papilledema)	100	that may include: anorexia; nausea; vomiting; dehydration; profound weakness; pain in abdo-	
Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area)		men, legs, and back; fever; apathy, and de- pressed mentation with possible progression to coma, renal shutdown, and death.	
plus either cataract or evidence of increased intracranial pressure	60	NOTE (2): An Addisonian "episode," for VA purposes, is a less acute and less severe event	
Continuous medication required for control	10	than an Addisonian crisis and may consist of anorexia, nausea, vomiting, diarrhea, dehydra- tion, weakness, malaise, orthostatic hypo-	
tension, weakness, and enlargement of pituitary or adrenal gland	100	tension, or hypoglycemia, but no peripheral vascular collapse.	
Loss of muscle strength and enlargement of pituitary or adrenal gland	60	NOTE (3): Tuberculous Addison's disease will be evaluated as active or inactive tuberculosis. If inactive, these evaluations are not to be com-	
With striae, obesity, moon face, glucose intoler- ance, and vascular fragility	30	bined with the graduated ratings of 50 percent or 30 percent for non-pulmonary tuberculosis	
NOTE: With recovery or control, evaluate as residuals of adrenal insufficiency or cardio-		specified under §4.88b. Assign the higher rating.	
vascular, psychiatric, skin, or skeletal complications under appropriate diagnostic code.		7912 Pluriglandular syndrome Evaluate according to major manifestations.	
7908 Acromegaly Evidence of increased intracranial pressure (such		7913 Diabetes mellitus Requiring more than one daily injection of insulin,	
as visual field defect), arthropathy, glucose in- tolerance, and either hypertension or cardio-	100	restricted diet, and regulation of activities (avoidance of strenuous occupational and rec- reational activities) with episodes of	
megaly Arthropathy, glucose intolerance, and hypertension	100	ketoacidosis or hypoglycemic reactions requir- ing at least three hospitalizations per year or	
Enlargement of acral parts or overgrowth of long bones, and enlarged sella turcica	30	weekly visits to a diabetic care provider, plus ei- ther progressive loss of weight and strength or	
7909 Diabetes insipidus Polyuria with near-continuous thirst, and more	30	complications that would be compensable if separately evaluated	100
than two documented episodes of dehydration requiring parenteral hydration in the past year	100	Requiring insulin, restricted diet, and regulation of activities with episodes of ketoacidosis or hypo-	
Polyuria with near-continuous thirst, and one or two documented episodes of dehydration re-		glycemic reactions requiring one or two hos- pitalizations per year or twice a month visits to a diabetic care provider, plus complications that	
quiring parenteral hydration in the past year Polyuria with near-continuous thirst, and one or	60	would not be compensable if separately evaluated	60
more episodes of dehydration in the past year not requiring parenteral hydration	40	Requiring insulin, restricted diet, and regulation of activities	40
Polyuria with near-continuous thirst	20	Requiring insulin and restricted diet, or; oral hypo- glycemic agent and restricted diet	20
Hypofunction) Four or more crises during the past year	60	Manageable by restricted diet only NOTE (1): Evaluate compensable complications of	10
Three crises during the past year, or; five or more episodes during the past year	40	diabetes separately unless they are part of the criteria used to support a 100 percent evalua-	
One or two crises during the past year, or; two to four episodes during the past year, or; weak-		tion. Noncompensable complications are con- sidered part of the diabetic process under diag- nostic code 7913.	
ness and fatigability, or; corticosteroid therapy required for control	20	NOTE (2): When diabetes mellitus has been con- clusively diagnosed, do not request a glucose	
		tolerance test solely for rating purposes. 7914 Neoplasm, malignant, any specified part of the	
		endocrine system	100
		yond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinu-	
		ance of such treatment, the appropriate dis- ability rating shall be determined by mandatory VA examination. Any change in evaluation	
		based upon that or any subsequent examina- tion shall be subject to the provisions of	
		§3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	
		7915 Neoplasm, benign, any specified part of the en- docrine system rate as residuals of endocrine dys- function.	

	Ŗat-
	ing
7916 Hyperpituitarism (prolactin secreting pituitary dysfunction) 7917 Hyperaldosteronism (benign or malignant) 7918 Pheochromocytoma (benign or malignant) 7918 Pheochromocytoma (benign or malignant) NOTE: Evaluate diagnostic codes 7916, 7917, and 7918 as malignant or benign neoplasm as appropriate. 7919 C-cell hyperplasia of the thyroid NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	100

[61 FR 20446, May 7, 1996]

NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

§ 4.120 Evaluations by comparison.

Disability in this field is ordinarily to be rated in proportion to the impairment of motor, sensory or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, injury to the skull, etc. In rating disability from the conditions in the preceding sentence refer to the appropriate schedule. In rating peripheral nerve injuries and their residuals, attention should be given to the site and character of the injury, the relative impairment in motor function, trophic changes, or sensory disturbances.

§ 4.121 Identification of epilepsy.

When there is doubt as to the true nature of epileptiform attacks, neurological observation in a hospital adequate to make such a study is necessary. To warrant a rating for epilepsy, the seizures must be witnessed or verified at some time by a physician. As to frequency, competent, consistent lay testimony emphasizing convulsive and immediate post-convulsive characteristics may be accepted. The frequency of seizures should be ascertained under the ordinary conditions of life (while not hospitalized).

§ 4.122 Psychomotor epilepsy.

The term psychomotor epilepsy refers to a condition that is characterized by seizures and not uncommonly by a chronic psychiatric disturbance as well.

(a) Psychomotor seizures consist of episodic alterations in conscious control that may be associated with automatic states, generalized convulsions, random motor movements (chewing, lip smacking, fumbling), hallucinatory phenomena (involving taste, smell, sound, vision), perceptual illusions (deja vu, feelings of loneliness, strangeness, macropsia, micropsia, dreamy states), alterations in thinking (not open to reason), alterations in memory, abnormalities of mood or affect (fear, alarm, terror, anger, dread, wellbeing), and autonomic disturbances (sweating, pallor, flushing of the face, visceral phenomena such as nausea, vomiting, defecation, a rising feeling of warmth in the abdomen). Automatic states or automatisms are characterized by episodes of irrational, irrelevant. disjointed. unconventional. asocial, purposeless though seemingly coordinated and purposeful, confused or inappropriate activity of one to several minutes (or, infrequently, hours) duration with subsequent amnesia for the seizure. Examples: A person of high social standing remained seated, muttered angrily, and rubbed the arms of his chair while the National Anthem was being played; an apparently normal person suddenly disrobed in public; a man traded an expensive automobile for an antiquated automobile in poor mechanical condition and after regaining conscious control, discovered that he had signed an agreement to pay an additional sum of money in the trade. The seizure manifestations of psychomotor epilepsy vary from patient to patient and in the same patient from seizure to seizure.

(b) A chronic mental disorder is not uncommon as an interseizure manifestation of psychomotor epilepsy and may include psychiatric disturbances extending from minimal anxiety to severe personality disorder (as distinguished from developmental) or almost complete personality disintegration (psychosis). The manifestations of a chronic mental disorder associated

with psychomotor epilepsy, like those of the seizures, are protean in character.

§4.123 Neuritis, cranial or peripheral.

Neuritis, cranial or peripheral, characterized by loss of reflexes, muscle atrophy, sensory disturbances, and constant pain, at times excruciating, is to be rated on the scale provided for injury of the nerve involved, with a maximum equal to severe, incomplete, paralysis. See nerve involved for diagnostic code number and rating. The maximum rating which may be assigned for neuritis not characterized by organic changes referred to in this section will be that for moderate, or with sciatic nerve involvement, for moderately severe, incomplete paralysis.

§ 4.124 Neuralgia, cranial or peripheral.

Neuralgia, cranial or peripheral, characterized usually by a dull and intermittent pain, of typical distribution so as to identify the nerve, is to be rated on the same scale, with a maximum equal to moderate incomplete paralysis. See nerve involved for diagnostic code number and rating. Tic douloureux, or trifacial neuralgia, may be rated up to complete paralysis of the affected nerve.

§4.124a Schedule of ratings—neurological conditions and convulsive disorders.

[With the exceptions noted, disability from the following diseases and their residuals may be rated from 10 percent to 100 percent in proportion to the impairment of motor, sensory, or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, etc., referring to the appropriate bodily system of the schedule. With partial loss of use of one or more extremities from neurological lesions, rate by comparison with the mild, moderate, severe, or complete paralysis of peripheral nerves]

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM

	Rat- ing
8000 Encephalitis, epidemic, chronic: As active febrile disease	100

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

	Rat- ing
Rate residuals, minimum	10
Brain, new growth of:	
8002 Malignant	100
NOTE: The rating in code 8002 will be continued	
for 2 years following cessation of surgical,	
chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized,	
the rating will be made on neurological residu-	
als according to symptomatology.	
Minimum rating	30
8003 Benign, minimum	60
Rate residuals, minimum	10
8004 Paralysis agitans:	
Minimum rating	30
8005 Bulbar palsy	100
8007 Brain, vessels, embolism of.	
8008 Brain, vessels, thrombosis of. 8009 Brain, vessels, hemorrhage from:	
, , , , , , , , , , , , , , , , , , , ,	
Rate the vascular conditions under Codes 8007 through 8009, for 6 months	100
Rate residuals, thereafter, minimum	10
8010 Myelitis:	
Minimum rating	10
8011 Poliomyelitis, anterior:	
As active febrile disease	100
Rate residuals, minimum	10
8012 Hematomyelia:	
For 6 months	100
Rate residuals, minimum	10
8013 Syphilis, cerebrospinal.	
8014 Syphilis, meningovascular.	
8015 Tabes dorsalis.	
NOTE: Rate upon the severity of convulsions, pa-	
ralysis, visual impairment or psychotic involve- ment, etc.	
8017 Amyotrophic lateral sclerosis	100
NOTE: Consider the need for special monthly	100
compensation.	
8018 Multiple sclerosis:	
Minimum rating	30
8019 Meningitis, cerebrospinal, epidemic:	
As active febrile disease	100
Rate residuals, minimum	10
8020 Brain, abscess of:	
As active disease	100
Rate residuals, minimum	10
Spinal cord, new growths of:.	
8021 Malignant	100
Note: The rating in code 8021 will be continued for 2 years following cessation of surgical.	
for 2 years following cessation of surgical, chemotherapeutic or other treatment modality.	
At this point, if the residuals have stabilized,	
the rating will be made on neurological residu-	
als according to symptomatology.	
Minimum rating	30
8022 Benign, minimum rating	60
Rate residuals, minimum	10
8023 Progressive muscular atrophy:	
Minimum rating	30
8024 Syringomyelia:	-
Minimum rating	30
COOF Management and the cooperation	
8025 Myasthenia gravis: Minimum rating	30

Department of Veterans Affairs

§4.124a

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

ing

ORGANIC DISEASES OF THE CENTRAL NERVOU	S
System—Continued	

NOTE: It is required for the minimum ratings for residuals under diagnostic codes 8000–8025, that there be ascertainable residuals. Determinations as to the presence of residuals not capable of objective verification, i.e., headaches, dizziness, fatigability, must be approached on the basis of the diagnosis recorded; subjective residuals will be accepted when consistent with the disease and not more likely attributable to other disease or no disease. It is of exceptional importance that when ratings in excess of the prescribed minimum ratings are assigned, the diagnostic

codes utilized as bases of evaluation be cited in addition to the codes identifying the diag-

8045 Residuals of traumatic brain injury (TBI):

There are three main areas of dysfunction that may result from TBI and have profound effects on functioning: cognitive (which is common in varying degrees after TBI), emotional/behavioral, and physical. Each of these areas of dysfunction may require evaluation.

Cognitive impairment is defined as decreased memory, concentration, attention, and executive functions of the brain. Executive functions are goal setting, speed of information processing, planning, organizing, prioritizing, self-monitoring, problem solving, judgment, decision making, spontaneity, and flexibility in changing actions when they are not productive. Not all of these brain functions may be affected in a given individual with cognitive impairment, and some functions may be affected more severely than others. In a given individual, symptoms may fluctuate in severity from day to day. Evaluate cognitive impairment under the table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified."

Subjective symptoms may be the only residual of TBI or may be associated with cognitive impairment or other areas of dys function. Evaluate subjective symptoms that are residuals of TBI, whether or not they are part of cognitive impairment, under the subjective symptoms facet in the table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified." However, separately evaluate any residual with a distinct diagnosis that may be evaluated under another diagnostic code, such as migraine headache or Meniere's disease, even if that diagnosis is based on subjective symptoms, rather than under the "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified" table.

Evaluate emotional/behavioral dysfunction under § 4.130 (Schedule of ratings—mental disorders) when there is a diagnosis of a mental disorder. When there is no diagnosis of a mental disorder, evaluate emotional/behavioral symptoms under the criteria in the table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified.".

Evaluate physical (including neurological) dysfunction based on the following list, under an appropriate diagnostic code: Motor and sensory dysfunction, including pain, of the extremities and face; visual impairment; hearing loss and tinnitus; loss of sense of smell and taste; seizures; gait, coordination, and balance problems; speech and other communication difficulties, including aphasia and related disorders, and dysarthria; neurogenic bladder; neurogenic bowel; cranial nerve dysfunctions; autonomic nerve dysfunctions; and endocrine dysfunctions.

The preceding list of types of physical dysfunction does not encompass all possible residuals of TBI. For residuals not listed here that are reported on an examination, evaluate under the most appropriate diagnostic code. Evaluate each condition separately, as long as the same signs and symptoms are not used to support more than one evaluation, and combine under \$4.25 the evaluations for each separately rated condition. The evaluation assigned based on the "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified" table will be considered the evaluation for a single condition for purposes of combining with other disability evaluations.

Consider the need for special monthly compensation for such problems as loss of use of an extremity, certain sensory impairments, erectile dysfunction, the need for aid and attendance (including for protection from hazards or dangers incident to the daily environment due to cognitive impairment), being housebound, etc.

38 CFR Ch. I (7-1-17 Edition)

ing

§4.124a

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

	Rat- ing
Evaluation of Cognitive Impairment and Subjective Symptoms	

The table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified" contains 10 important facets of TBI related to cognitive impairment and subjective symptoms. It provides criteria for levels of impairment for each facet, as appropriate, ranging from 0 to 3, and a 5th level, the highest level of impairment, labeled "total." However, not every facet has every level of severity. The Consciousness facet, for example, does not provide for an impairment level other than "total," since any level of impaired consciousness would be totally disabling. Assign a 100-percent evaluation if "total" is the level of evaluation for one or more facets. If no facet is evaluated as "total," assign the overall percentage evaluation based on the level of the highest facet as follows: 0 = 0 percent; 1 = 10 percent; 2 = 40 percent; and 3 = 70 percent. For example, assign a 70 percent evaluation if 3 is the highest level of evaluation for any facet.

Note (1): There may be an overlap of manifestations of conditions evaluated under the table titled "Evaluation Of Cognitive Impairment And Other Residuals Of TBI Not Otherwise Classified" with manifestations of a comorbid mental or neurologic or other physical disorder that can be separately evaluated under another diagnostic code. In such cases, do not assign more than one evaluation based on the same manifestations. If the manifestations of two or more conditions cannot be clearly separated, assign a single evaluation under whichever set of diagnostic criteria allows the better assessment of overall impaired functioning due to both conditions. However, if the manifestations are clearly separatele, assign a separate evaluation for each condition.

Note (2): Symptoms listed as examples at certain evaluation levels in the table are only examples and are not symptoms that must be present in order to assign a particular evaluation.

Note (3): "Instrumental activities of daily living" refers to activities other than self-care that are needed for independent living, such as meal preparation, doing housework and other chores, shopping, traveling, doing laundry, being responsible for one's own medications, and using a telephone. These activities are distinguished from "Activities of daily living," which refers to basic self-care and includes bathing or showering, dressing, eating, getting in or out of bed or a chair, and using the toilet.

Note (4): The terms "mild," "moderate," and "severe" TBI, which may appear in medical records, refer to a classification of TBI made at, or close to, the time of injury rather than to the current level of functioning. This classification does not affect the rating assigned under diagnostic code

ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

Note (5): A veteran whose residuals of TBI are rated under a version of §4.124a, diagnostic code 8045, in effect before Octoagricult code 50-5, in short school 50-5 ber 23, 2008 may request review under diagnostic code 8045, irrespective of whether his or her disability has worsened since the last review. VA will review that veteran's disability rating to determine whether the veteran may be entitled to a higher disability rating under diagnostic code 8045. A request for review pursuant to this note will be treated as a claim for an increased rating for purposes of determining the effective date of an increased rating awarded as a result of such review however, in no case will the award be effective before October 23, 2008. For the purposes of determining the effective date of an increased rating awarded as a result of such review, VA will apply 38 CFR 3.114, if applicable..

8046 Cerebral arteriosclerosis:

Purely neurological disabilities, such as hemiplegia, cranial nerve paralysis, etc., due to cerebral arteriosclerosis will be rated under the diagnostic codes dealing with such specific disabilities, with citation of a hyphenated diagnostic code (e.g., 8046–8207).

Purely subjective complaints such as headache, dizziness, tinnitus, insomnia and irritability, recognized as symptomatic of a properly diagnosed cerebral arteriosclerosis, will be rated 10 percent and no more under diagnostic code 9305. This 10 percent rating will not be combined with any other rating for a disability due to cerebral or generalized arteriosclerosis. Ratings in excess of 10 percent for cerebral arteriosclerosis under diagnostic code 9305 are not assignable in the absence of a diagnosis of multi-infarct dementia with cerebral arteriosclerosis.

NOTE: The ratings under code 8046 apply only when the diagnosis of cerebral arteriosclerosis is substantiated by the entire clinical picture and not solely on findings of retinal arteriosclerosis.

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
Memory, attention, con- centration, executive functions.	0	No complaints of impairment of memory, attention, concentration, or executive functions.

§4.124a

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
	2	A complaint of mild loss of memory (such as having difficulty following a conversation, recalling recent conversations, remembering names of new acquaintances, or finding words, or often misplacing items), attention, concentration, or executive functions, but without objective evidence on testing. Objective evidence on testing of mild impairment of memory, attention, concentration, or executive functions resulting in mild functional impairment. Objective evidence on testing of moderate impairment of memory, attention, concentration, or executive functions resulting in moderate functional impairment.	Social interaction	Total	Moderately severely impaired judgment. For even routine and familiar decisions, occasionally unable to identify, understand, and weigh the alternatives, understand the consequences of choices, and make a reasonable decision. Severely impaired judgment. For even routine and familiar decisions, usually unable to identify, understand, and weigh the alternatives, understand the consequences of choices, and make a reasonable decision. For example, unable to determine appropriate clothing for current weather conditions or judge when to avoid dangerous situations or activities.
	Total	Objective evidence on testing of severe im-		1	tinely appropriate. Social interaction is oc-
		pairment of memory, attention, concentra- tion, or executive func-		2	casionally inappro- priate. Social interaction is fre-
		tions resulting in se- vere functional impair- ment.		3	quently inappropriate. Social interaction is inappropriate most or all of
Judgment	0	Normal.			the time.
·	2	Mildly impaired judgment. For complex or unfamiliar decisions, occasionally unable to identify, understand, and weigh the alternatives, understand the consequences of choices, and make a reasonable decision. Moderately impaired judgment. For complex or unfamiliar decisions,	Orientation	0 1 2	Always oriented to person, time, place, and situation. Occasionally disoriented to one of the four aspects (person, time, place, situation) of orientation. Occasionally disoriented to two of the four aspects (person, time, place, situation) of orientation or often dis-
		usually unable to iden- tify, understand, and weigh the alternatives, understand the con- sequences of choices, and make a reason- able decision, although has little difficulty with simple decisions.		3 Total	oriented to one aspect of orientation. Often disoriented to two or more of the four aspects (person, time, place, situation) of orientation. Consistently disoriented to two or more of the four aspects (person, time, place, situation) of orientation.

38 CFR Ch. I (7-1-17 Edition)

§4.124a

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Level of im-pair-ment Facets of cognitive impairment and other residuals of TBI not otherwise classified Criteria Motor activity (with intact Motor activity normal. motor and sensory sys-Motor activity normal most of the time, but mildly slowed at times due to apraxia (inability to perform pre-viously learned motor activities, despite normal motor function). Motor activity mildly decreased or with moderate slowing due to apraxia. 3 Motor activity moderately decreased due to apraxia. Motor activity severely Total decreased due to apraxia. Visual spatial orientation 0 Normal. Mildly impaired. Occa-sionally gets lost in un-familiar surroundings, has difficulty reading maps or following directions. Is able to use assistive devices such as GPS (global positioning system). Moderately impaired. Usually gets lost in unfamiliar surroundings, has difficulty reading maps, following directions, and judging distance. Has difficulty using assistive devices such as GPS (global positioning system). Moderately severely impaired. Gets lost even in familiar sur-roundings, unable to use assistive devices such as GPS (global positioning system).
Severely impaired. May be unable to touch or Total name own body parts when asked by the ex-aminer, identify the rel-ative position in space of two different objects, or find the way

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
Subjective symptoms	0	Subjective symptoms that do not interfere with work; instrumental activities of daily living; or work, family, or other close relationships. Examples are: mild or occasional headaches, mild anxiety.
	1	Three or more subjective symptoms that mildly interfere with work; instrumental activities of daily living; or work, family, or other close relationships. Examples of findings that might be seen at this level of impairment are: intermittent dizziness, daily mild to moderate headaches, tinnitus, frequent insomnia, hypersensitivity to sound, hypersensitivity to light.
	2	Three or more subjective symptoms that moderately interfere with work; instrumental activities of daily living; or work, family, or other close relationships. Examples of findings that might be seen at this level of impairment are: marked fatigability, blurred or double vision, headaches requiring rest periods during most days.

from one room to another in a familiar envi-

§4.124a

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	
Neurobehavioral effects	1 2 2	One or more neurobehavioral effects that do not interfere with workplace interaction. Examples of neurobehavioral effects are: Irritability, impulsivity, unpredictability, lack of motivation, verbal aggression, belligerence, apathy, lack of empathy, lack of cooperation, inflexibility, and impaired awareness of disability. Any of these effects may range from slight to severe, although verbal and physical aggression are likely to have a more serious impact on workplace interaction and social interaction than some of the other effects. One or more neurobehavioral effects that occasionally interfere with workplace interaction, or both but do not preclude them. One or more neurobehavioral effects that frequently interfere with workplace interaction, social interaction, or both but do not preclude them. One or more neurobehavioral effects that frequently interfere with workplace interaction, social interaction, or both but do not preclude them. One or more neurobehavioral effects that interfere with workplace interaction, or both but do not preclude them. One or more neurobehavioral effects that interfere with or preclude them. One or more neurobehavioral effects that interfere with or preclude them. One or more neurobehavioral effects that interfere with or preclude interaction, social interaction, social interaction, or both on most	Consciousness	2	either by spoken I guage, written lan guage, written lan guage, or both, m than occasionally less than half of the time, or to comprehend spoken Is guage, written lan guage, or both, m than occasionally less than half of the time. Can general communicate com ideas. Inability to communicate ither by spoken I guage, written lan guage, or both, at least half of the time to the tor to comprehend ken language, written land the tor to comprehend ken language, or both least half of the time than the time than the tor to comprehend the staff of the time than the time than the tor the time than the time that the time than the time than the time than the time than the time that the time th	of
Communication	0	days or that occasion- ally require supervision for safety of self or others. Able to communicate by spoken and written	MISCELLAI	VEOUS	such as vegetative state, minimally responsive state, co	e-
		language (expressive communication), and to comprehend spoken and written language.				Rat-

38 CFR Ch. I (7-1-17 Edition)

§4.124a

MISCELLANEOUS DISEASES—Continued

	Rat- ing
With characteristic prostrating attacks occurring	
on an average once a month over last several	
months	3
With characteristic prostrating attacks averaging	
one in 2 months over last several months	1
With less frequent attacks	
8103 Tic, convulsive:	_
Severe	3
Moderate	1
Mild	
NOTE: Depending upon frequency, severity, mus- cle groups involved.	
8104 Paramyoclonus multiplex (convulsive state,	
myoclonic type):	
Rate as tic; convulsive; severe cases	6
8105 Chorea, Sydenham's:	
Pronounced, progressive grave types	10
Severe	8
Moderately severe	5
Moderate	3
Mild	1
NOTE: Consider rheumatic etiology and com-	
plications.	
8106 Chorea, Huntington's.	
Rate as Sydenham's chorea. This, though a fa-	
milial disease, has its onset in late adult life,	
and is considered a ratable disability.	
8107 Athetosis, acquired.	
Rate as chorea.	
8108 Narcolepsy.	
Rate as for epilepsy, petit mal.	

DISEASES OF THE CRANIAL NERVES

	Rat- ing
Disability from lesions of peripheral portions of first, second, third, fourth, sixth, and eighth nerves will be rated under the Organs of Special Sense. The ratings for the cranial nerves are for unilateral involvement; when bilateral, combine but without the bilateral factor. Fifth (trigeminal) cranial nerve 8205 Paralysis of:	
Complete Incomplete, severe	50 30
Incomplete, severe	10
NOTE: Dependent upon relative degree of sensory manifestation or motor loss.	
8305 Neuritis.	
8405 Neuralgia.	
NOTE: Tic douloureux may be rated in accord- ance with severity, up to complete paralysis. Seventh (facial) cranial nerve	
8207 Paralysis of:	30
CompleteIncomplete, severe	20
Incomplete, moderate	10
NOTE: Dependent upon relative loss of innervation of facial muscles.	
8307 Neuritis.	
8407 Neuralgia.	
Ninth (glossopharyngeal) cranial nerve. 8209 Paralysis of:	
Complete	30
Incomplete, severe	20
Incomplete, moderate	10

DISEASES OF THE CRANIAL NERVES—Continued

		Rat- ing
N	OTE: Dependent upon relative loss of ordinary sensation in mucous membrane of the pharynx, fauces, and tonsils.	
8309	Neuritis.	
8409	Neuralgia.	
Т	enth (pneumogastric, vagus) cranial nerve.	
8210	Paralysis of:	
С	complete	50
In	ncomplete, severe	30
In	ncomplete, moderate	10
N	IOTE: Dependent upon extent of sensory and	
	motor loss to organs of voice, respiration,	
	pharynx, stomach and heart.	
8310	Neuritis.	
	Neuralgia.	
Е	leventh (spinal accessory, external branch) cra-	
	nial nerve.	
	Paralysis of:	
	complete	30
	ncomplete, severe	20
	ncomplete, moderate	10
N	OTE: Dependent upon loss of motor function of	
	sternomastoid and trapezius muscles.	
	Neuritis.	
	Neuralgia.	
	welfth (hypoglossal) cranial nerve.	
	Paralysis of:	
	complete	50
	ncomplete, severe	30
	ncomplete, moderate	10
N	IOTE: Dependent upon loss of motor function of	
0010	tongue.	
	Neuritis.	
0412	Neuralgia.	

DISEASES OF THE PERIPHERAL NERVES

0.1.1.1.1.1	Rat	ing
Schedule of ratings	Major	Minor
The term "incomplete paralysis," with this and other peripheral nerve injuries, indicates a degree of lost or impaired function substantially less than the type picture for complete paralysis given with each nerve, whether due to varied level of the nerve lesion or to partial regeneration. When the involvement is wholly sensory, the rating should be for the mild, or at most, the moderate degree. The ratings for the peripheral nerves are for unilateral involvement; when bilateral, combine with application of the bilateral factor. Upper radicular group (fifth and sixth cervicals)		
8510 Paralysis of: Complete; all shoulder and elbow movements lost or severely affected, hand and wrist movements not affected	70 50 40 20	60 40 30 20

DISEASES OF THE PERIPHERAL NERVES— Continued

DISEASES OF THE PERIPHERAL NERVES—Continued

Schedule of ratings	Rating		Rating Schodulo of ratings		Schedule of ratings		ing
Scriedule of ratings	Major	Minor	Scriedule of fattings	Major	Mino		
8610 Neuritis. 8710 Neuralgia.			8614 Neuritis. 8714 Neuralgia.				
Middle radicular group			NOTE: Lesions involving only "dissocia	ation of e	xtenso		
B511 Paralysis of:			communis digitorum" and "paralysis sor communis digitorum," will not e	below the	exten		
Complete; adduction, abduction and			erate rating under code 8514.	xceeu iii	e mou		
rotation of arm, flexion of elbow, and			•				
extension of wrist lost or severely af-			The median nerve				
fected	70	60	8515 Paralysis of:				
Incomplete:			Complete; the hand inclined to the ulnar side, the index and middle fin-				
Severe	50	40	gers more extended than normally,				
Moderate Mild	40 20	30 20	considerable atrophy of the muscles				
3611 Neuritis.	20	20	of the thenar eminence, the thumb				
3711 Neuralgia.			in the plane of the hand (ape hand);				
-			pronation incomplete and defective, absence of flexion of index finger				
Lower radicular group			and feeble flexion of middle finger,				
B512 Paralysis of:			cannot make a fist, index and mid-				
Complete; all intrinsic muscles of			dle fingers remain extended; cannot				
hand, and some or all of flexors of wrist and fingers, paralyzed (sub-			flex distal phalanx of thumb, defec- tive opposition and abduction of the				
stantial loss of use of hand)	70	60	thumb, at right angles to palm; flex-				
Incomplete:			ion of wrist weakened; pain with				
Severe	50	40	trophic disturbances	70	(
Moderate	40	30	Incomplete:				
Mild	20	20	Severe	50 30	4		
3612 Neuritis.			ModerateMild	10	2		
3712 Neuralgia.			8615 Neuritis.	10	i '		
All radicular groups			8715 Neuralgia.				
3513 Paralysis of:			The ulnar nerve				
Complete	90	80	8516 Paralysis of:				
Incomplete:			Complete; the "griffin claw" deformity,				
Severe	70	60	due to flexor contraction of ring and				
Moderate	40	30	little fingers, atrophy very marked in dorsal interspace and thenar and				
Mild	20	20	hypothenar eminences; loss of ex-				
3613 Neuritis. 3713 Neuralgia.			tension of ring and little fingers can-				
3713 Neuraigia.			not spread the fingers (or reverse),				
The musculospiral nerve (radial nerve)			cannot adduct the thumb; flexion of wrist weakened	60	5		
3514 Paralysis of:			Incomplete:	60			
Complete; drop of hand and fingers,			Severe	40	3		
wrist and fingers perpetually flexed, the thumb adducted falling within the			Moderate	30	2		
line of the outer border of the index			Mild	10	1		
finger; can not extend hand at wrist,			8616 Neuritis.				
extend proximal phalanges of fin-			8716 Neuralgia.				
gers, extend thumb, or make lateral			Musculocutaneous nerve				
movement of wrist; supination of hand, extension and flexion of elbow			8517 Paralysis of:				
weakened, the loss of synergic mo-			Complete; weakness but not loss of				
tion of extensors impairs the hand			flexion of elbow and supination of forearm	30	2		
grip seriously; total paralysis of the			Incomplete:	30	-		
triceps occurs only as the greatest	70	00	Severe	20	2		
rarity Incomplete:	70	60	Moderate	10	-		
Severe	50	40	Mild	0			
Moderate	30	20	8617 Neuritis.				
Mild	20	20	8717 Neuralgia.				
-		_,	Circumflex nerve				
			8518 Paralysis of:				
			Complete; abduction of arm is impos- sible, outward rotation is weakened;				
			muscles supplied are deltoid and				
			teres minor	50	_		

§4.124a

DISEASES OF THE PERIPHERAL NERVES— Continued

Schedule of ratings		Rating		
		Major	Minor	
Inc	complete:			
	Severe	30	20	
	Moderate	10	10	
	Mild	0	(
8618	Neuritis.			
8718	Neuralgia.			
	Long thoracic nerve			
8519	Paralysis of:			
Co	emplete; inability to raise arm above			
	shoulder level, winged scapula de-			
	formity	30	20	
Inc	complete:			
	Severe	20		
	Moderate	10		
	Mild	0	1 (
	OTE: Not to be combined with lost mot der level.	ion abov	e shoul-	
8619	Neuritis.			
8719	Neuralgia.			
	OTE: Combined nerve injuries should erence to the major involvement, or intent, consider radicular group ratings.			
1				

	F
Sciatic nerve	
8520 Paralysis of: Complete; the foot dangles and drops, no active movement possible of muscles below the knee, flexion of knee weakened or (very rarely) lost Incomplete: Severe, with marked muscular atrophy	
8720 Neuralgia.	
External popliteal nerve (common peroneal)	
8521 Paralysis of: Complete; foot drop and slight droop of first phalanges of all toes, cannot dorsiflex the foot, extension (dorsal flexion) of proximal phalanges of toes lost; abduction of foot lost, adduction weakened; anesthesia covers entire dorsum of foot and toes	
Incomplete: Severe Moderate	
Mild	

		Rating
8621	Neuritis.	
8721	Neuralgia.	
Mus	culocutaneous nerve (superficial peroneal)	
8522	Paralysis of:	
	omplete; eversion of foot weakened complete:	30
	Severe	20
	Moderate Mild	10
8622	Neuritis.	,
8722	Neuralgia.	
Ant	erior tibial nerve (deep peroneal)	
8523	Paralysis of:	
	omplete; dorsal flexion of foot lost	30
In	complete:	
	Severe Moderate	20
	Mild	'(
8623	Neuritis.	
8723	Neuralgia.	
I	nternal popliteal nerve (tibial)	
8524	Paralysis of:	
C	omplete; plantar flexion lost, frank adduction of foot impossible, flexion	
	and separation of toes abolished; no	
	muscle in sole can move; in lesions of the nerve high in popliteal fossa,	
	plantar flexion of foot is lost	40
In	complete:	
	Severe	30
	Moderate Mild	20
8624	Neuritis.	
8724	Neuralgia.	
	Posterior tibial nerve	
8525	Paralysis of:	
C	omplete; paralysis of all muscles of	
	sole of foot, frequently with painful paralysis of a causalgic nature; toes	
	cannot be flexed; adduction is weak-	
ln.	ened; plantar flexion is impaired	30
III	complete: Severe	20
	Moderate	10
	Mild	10
8625 8725	Neuritis. Neuralgia.	
	-	
8526	Anterior crural nerve (femoral) Paralysis of:	
	omplete; paralysis of quadriceps ex-	
	tensor muscles	40
In	complete: Severe	0/
	Moderate	30 20
	Mild	10

§4.124a

		Rating
8626	Neuritis.	
8726	Neuralgia.	
	Internal saphenous nerve	
8527	Paralysis of:	
S	evere to complete	10
M	lild to moderate	0
8627	Neuritis.	
8727	Neuralgia.	
	Obturator nerve	
8528	Paralysis of:	
S	evere to complete	10
M	lild or moderate	0
8628	Neuritis.	
8728	Neuralgia.	
Ex	ternal cutaneous nerve of thigh	
8529	Paralysis of:	
S	evere to complete	10
M	lild or moderate	0
8629	Neuritis.	
8729	Neuralgia.	
	Ilio-inguinal nerve	
8530	Paralysis of:	
S	evere to complete	10
M	lild or moderate	0
8630	Neuritis.	
8730	Neuralgia.	
	Soft-tissue sarcoma (of neurogenic	
•	in)	100
N	OTE: The 100 percent rating will be co	ntinued

NOTE: The 100 percent rating will be continued for 6 months following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. At this point, if there has been no local recurrence or metastases, the rating will be made on residuals.

THE EPILEPSIES

	Rat- ing
A thorough study of all material in §§ 4.121 and 4.122 of the preface and under the ratings for epilepsy is necessary prior to any rating action. 8910 Epilepsy, grand mal. Rate under the general rating formula for major seizures.	
8911 Epilepsy, petit mal.	

THE EFFECT OILS CONTINUES	
	Rat- ing
Rate under the general rating formula for minor seizures.	
NOTE (1): A major seizure is characterized by the generalized tonic-clonic convulsion with	
unconsciousness. NOTE (2): A minor seizure consists of a brief interruption in consciousness or conscious	
control associated with staring or rhythmic blinking of the eyes or nodding of the head ("pure" petit mal), or sudden jerking move- ments of the arms, trunk, or head (myoclonic type) or sudden loss of postural control	
(akinetic type).General Rating Formula for Major and Minor Epileptic Seizures:	
Averaging at least 1 major seizure per month over the last year	100
months over the last year; or more than 10 minor seizures weekly	80
Averaging at least 1 major seizure in 4 months over the last year; or 9–10 minor seizures per week	60
At least 1 major seizure in the last 6 months or 2 in the last year; or averaging at least 5 to 8 minor seizures weekly	40
At least 1 major seizure in the last 2 years; or at least 2 minor seizures in the last 6	20
months A confirmed diagnosis of epilepsy with a history of seizures	10
NOTE (1): When continuous medication is shown necessary for the control of epilepsy, the minimum evaluation will be 10 percent. This rating will not be combined with any other rating for epilepsy.	
Note (2): In the presence of major and minor seizures, rate the predominating type. Note (3): There will be no distinction between	
diurnal and nocturnal major seizures. 8912 Epilepsy, Jacksonian and focal motor or sensory.	
8913 Epilepsy, diencephalic. Rate as minor seizures, except in the presence of major and minor seizures, rate the predominating type.	
8914 Epilepsy, psychomotor. Major seizures: Psychomotor seizures will be rated as major	
seizures under the general rating formula when characterized by automatic states and/or generalized convulsions with un- consciousness.	
Minor seizures:	
Psychomotor seizures will be rated as minor seizures under the general rating formula when characterized by brief transient epi- sodes of random motor movements, hallu- cinations, perceptual illusions, abnormali- ties of thinking, memory or mood, or auto-	
nomic disturbances.	
Mental Disorders in Epilepsies: A nonpsychotic	organic

THE EPILEPSIES—Continued

Mental Disorders in Epilepsies: A nonpsychotic organic brain syndrome will be rated separately under the appropriate diagnostic code (e.g., 9304 or 9326). In the absence of a diagnosis of non-psychotic organic psychiatric disturbance (psychotic, psychoneurotic or personality disorder) if diagnosed and shown to be secondary to or directly associated with epilepsy will be rated separately. The psychotic or psychroneurotic disorder will be rated under the appropriate diagnostic code. The personality disorder will be rated as a dementia (e.g., diagnostic code 9304 or 9326).

§4.125

Epilepsy and Unemployability: (1) Rating specialists must bear in mind that the epileptic, although his or her seizures are controlled, may find employment and rehabilitation difficult of attainment due to employer reluctance to the hiring of the

(2) Where a case is encountered with a definite history of unemployment, full and complete development should be un-dertaken to ascertain whether the epilepsy is the determining factor in his or her inability to obtain employment.

(3) The assent of the claimant should first be obtained for

(a) The assent of the calman should hist be obtained in open ission to conduct this economic and social survey. The purpose of this survey is to secure all the relevant facts and data necessary to permit of a true judgment as to the reason for his or her unemployment and should include information

Occupations prior and subsequent to service;

(b) Occupations prior and subsequent to service;
(c) Places of employment and reasons for termination;
(d) Wages received;
(e) Number of seizures.
(4) Upon completion of this survey and current examination, the case should have rating board consideration. Where in the judgment of the rating board the veteran's unemployability is due to epilepsy and jurisdiction is not vested in that body by reason of schedular evaluations, the case should be substituted to the Compensation Service or the Director. Pension mitted to the Compensation Service or the Director, Pension and Fiduciary Service.

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 40 FR 42540, Sept. 15, 1975; 41 FR 11302, Mar. 18, 1976; 43 FR 45362, Oct. 2, 1978; 54 FR 4282, Jan. 30, 1989; 54 FR 49755, Dec. 1, 1989; 55 FR 154, Jan. 3, 1990; 56 FR 51653, Oct. 15, 1991; 57 FR 24364, June 9, 1992; 70 FR 75399, Dec. 20, 2005; 73 FR 54705, Sept. 23, 2008; 73 FR 69554, Nov. 19, 2008; 76 FR 78824, Dec. 20, 2011; 79 FR 2100, Jan. 13, 2014]

MENTAL DISORDERS

§ 4.125 Diagnosis of mental disorders.

(a) If the diagnosis of a mental disorder does not conform to DSM-5 or is not supported by the findings on the examination report, the rating agency shall return the report to the examiner to substantiate the diagnosis. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association (2013), is incorporated by reference into this section with the approval of the Director of the Federal Register under 5 U.S.C. 552(a) and 1 CFR part 51. To enforce any edition other than that specified in this section, the Department of Veterans Affairs must publish notice of change in the FEDERAL REGISTER and the material must be available to the public. All approved material is available from the American Psychiatric Association, 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901, 703-907-7300, http://www.dsm5.org. It is also available for inspection at the Office of Regulation Policy and Management, Department of Veterans Affairs, 810 Vermont Avenue NW., Room 1068,

Washington, DC 20420. It is also available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this information at NARA, call 202–741–6030 or go to http://www.archives.gov/federal register/ code of federal regulations/ ibr publications.html.

(b) If the diagnosis of a mental disorder is changed, the rating agency shall determine whether the new diagnosis represents progression of the prior diagnosis, correction of an error in the prior diagnosis, or development of a new and separate condition. If it is not clear from the available records what the change of diagnosis represents, the rating agency shall return the report to the examiner for a determination.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996, as amended at 79 FR 45099, Aug. 4, 2014]

§4.126 Evaluation of disability from mental disorders.

- (a) When evaluating a mental disorder, the rating agency shall consider the frequency, severity, and duration of psychiatric symptoms, the length of remissions, and the veteran's capacity for adjustment during periods of remission. The rating agency shall assign an evaluation based on all the evidence of record that bears on occupational and social impairment rather than solely on the examiner's assessment of the level of disability at the moment of the examination.
- (b) When evaluating the level of disability from a mental disorder, the rating agency will consider the extent of social impairment, but shall not assign an evaluation solely on the basis of social impairment.
- (c) Neurocognitive disorders shall be evaluated under the general rating formula for mental disorders; neurologic deficits or other impairments stemming from the same etiology (e.g., a head injury) shall be evaluated separately and combined with the evaluation for neurocognitive disorders (see § 4.25).
- (d) When a single disability has been diagnosed both as a physical condition and as a mental disorder, the rating

§4.130

agency shall evaluate it using a diagnostic code which represents the dominant (more disabling) aspect of the condition (see § 4.14).

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996, as amended at 79 FR 45099, Aug. 4, 2014]

§4.127 Intellectual disability (intellectual developmental disorder) and personality disorders.

Intellectual disability (intellectual developmental disorder) and personality disorders are not diseases or injuries for compensation purposes, and, except as provided in §3.310(a) of this chapter, disability resulting from them may not be service-connected. However, disability resulting from a mental disorder that is superimposed upon intellectual disability (intellectual developmental disorder) or a personality disorder may be service-connected.

(Authority: 38 U.S.C. 1155) [79 FR 45100, Aug. 4, 2014]

§ 4.128 Convalescence ratings following extended hospitalization.

If a mental disorder has been assigned a total evaluation due to a continuous period of hospitalization lasting six months or more, the rating agency shall continue the total evaluation indefinitely and schedule a mandatory examination six months after the veteran is discharged or released to nonbed care. A change in evaluation based on that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.

(Authority: 38 U.S.C. 1155) [61 FR 52700, Oct. 8, 1996]

§4.129 Mental disorders due to traumatic stress.

When a mental disorder that develops in service as a result of a highly stressful event is severe enough to bring about the veteran's release from active military service, the rating agency shall assign an evaluation of not less than 50 percent and schedule an examination within the six month period following the veteran's discharge to determine whether a change in evaluation is warranted.

(Authority: 38 U.S.C. 1155) [61 FR 52700, Oct. 8, 1996]

§4.130 Schedule of ratings-Mental disorders.

The nomenclature employed in this portion of the rating schedule is based upon the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (see §4.125 for availability information). Rating agencies must be thoroughly familiar with this manual to properly implement the directives in §4.125 through §4.129 and to apply the general rating formula for mental disorders in §4.130. The schedule for rating for mental disorders is set forth as follows:

9201 Schizophrenia

9202 [Removed] 9203 [Removed]

[Removed]

[Removed]

Delusional disorder

Other specified and unspecified schizophrenia spectrum and other psychotic disorders

9211 Schizoaffective disorder

Delirium

9301 Major or mild neurocognitive disorder due to HIV or other infections

9304 Major or mild neurocognitive disorder due to traumatic brain injury

9305 Major or mild vascular neurocognitive disorder

9310 Unspecified neurocognitive disorder

9312 Major or mild neurocognitive disorder due to Alzheimer's disease

9326 Major or mild neurocognitive disorder due to another medical condition or substance/medication-induced major or mild neurocognitive disorder

9327 [Removed]

9400 Generalized anxiety disorder

9403 Specific phobia; social anxiety disorder (social phobia)

9404 Obsessive compulsive disorder

9410 Other specified anxiety disorder

9411 Posttraumatic stress disorder

Panic disorder and/or agoraphobia 9412

Unspecified anxiety disorder

identity disorder dissociative 9416 Dissociative

9417 Depersonalization/Derealization disorder

9421 Somatic symptom disorder

Other specified somatic symptom and related disorder

9423 Unspecified somatic symptom and related disorder

§4.130

38 CFR Ch. I (7-1-17 Edition)

9424 Conversion disorder (functional neuro- logical symptom disorder)	9433 Persistent depressive disorder (dysthymia)
9425 Illness anxiety disorder	9434 Major depressive disorder
9431 Cyclothymic disorder	9435 Unspecified depressive disorder
9432 Bipolar disorder	9440 Chronic adjustment disorder

GENERAL RATING FORMULA FOR MENTAL DISORDERS

	Rating
Total occupational and social impairment, due to such symptoms as: gross impairment in thought processes or communication; persistent delusions or hallucinations; grossly inappropriate behavior; persistent danger of hurting self or others; intermittent inability to perform activities of daily living (including maintenance of minimal personal hygiene); disorientation to time or place; memory loss for names of close relatives, own occupation, or own name. Occupational and social impairment, with deficiencies in most areas, such as work, school, family relations, judgment, thinking, or mood, due to such symptoms as: suicidal ideation; obsessional rituals which interfere with routine activities; speech intermittently illogical, obscure, or irrelevant; near-continuous panic or depression affecting	100
the ability to function independently, appropriately and effectively; impaired impulse control (such as unprovoked irritability with periods of violence); spatial disorientation; neglect of personal appearance and hygiene; difficulty in adapting to stressful circumstances (including work or a worklike setting); inability to establish and maintain effective relationships. Occupational and social impairment with reduced reliability and productivity due to such symptoms as: flattened affect; circumstantial, circumlocutory, or stereotyped speech; panic attacks more than once a week; difficulty in un-	70
derstanding complex commands, impairment of short- and long-term memory (e.g., retention of only highly learned material, forgetting to complete tasks); impaired judgment; impaired abstract thinking; disturbances of motivation and mood; difficulty in establishing and maintaining effective work and social relationships. Occupational and social impairment with occasional decrease in work efficiency and intermittent periods of inability to perform occupational tasks (although generally functioning satisfactorily, with routine behavior, self-care, and	50
conversation normal), due to such symptoms as: depressed mood, anxiety, suspiciousness, panic attacks (weekly or less often), chronic sleep impairment, mild memory loss (such as forgetting names, directions, recent events). Occupational and social impairment due to mild or transient symptoms which decrease work efficiency and ability to	30
perform occupational tasks only during periods of significant stress, or symptoms controlled by continuous medication.	10
A mental condition has been formally diagnosed, but symptoms are not severe enough either to interfere with occupational and social functioning or to require continuous medication.	0

9520 Anorexia nervosa 9521 Bulimia nervosa

RATING FORMULA FOR EATING DISORDERS

	Rating
Self-induced weight loss to less than 80 percent of expected minimum weight, with incapacitating episodes of at	
least six weeks total duration per year, and requiring hospitalization more than twice a year for parenteral nutrition or tube feeding.	100
Self-induced weight loss to less than 85 percent of expected minimum weight with incapacitating episodes of six or	
more weeks total duration per year.	60
Self-induced weight loss to less than 85 percent of expected minimum weight with incapacitating episodes of more than two but less than six weeks total duration per year.	30
Binge eating followed by self-induced vomiting or other measures to prevent weight gain, or resistance to weight gain even when below expected minimum weight, with diagnosis of an eating disorder and incapacitating episodes of up to two weeks total duration per year.	10
Binge eating followed by self-induced vomiting or other measures to prevent weight gain, or resistance to weight	
gain even when below expected minimum weight, with diagnosis of an eating disorder but without incapacitating	_
episodes.	1 0

Note 1: An incapacitating episode is a period during which bed rest and treatment by a physician are required.

Note 2: Ratings under diagnostic codes 9201 to 9440 will be evaluated using the General Rating Formula for Mental Disorders. Ratings under diagnostic codes 9520 and 9521 will be evaluated using the General Rating Formula for Eating Disorders.

Pt. 4, App. A

20

30

Department of Veterans Affairs

(Authority: 38 U.S.C. 1155) [79 FR 45100, Aug. 4, 2014]

DENTAL AND ORAL CONDITIONS

§ 4.149 [Reserved]

		9908 Condyloid process, loss of, one or both sides	30
§ 4.149 [Reserved]		9909 Coronoid process, loss of:	
		Bilateral	20
§ 4.150 Schedule of ratings—dental	and	Unilateral	10
oral conditions.		9911 Hard palate, loss of half or more:	
		Not replaceable by prosthesis	30
	Rat-	Replaceable by prosthesis	10
	ing	9912 Hard palate, loss of less than half of:	
0000 Mavilla as mandible absenie esteemuelitie es		Not replaceable by prosthesis	20
9900 Maxilla or mandible, chronic osteomyelitis or		Replaceable by prosthesis	0
osteoradionecrosis of: Rate as osteomyelitis, chronic under diag-		9913 Teeth, loss of, due to loss of substance of	
nostic code 5000.		body of maxilla or mandible without loss of con- tinuity:	
9901 Mandible, loss of, complete, between angles	100	Where the lost masticatory surface cannot	
9902 Mandible, loss of approximately one-half:		be restored by suitable prosthesis:	
Involving temporomandibular articulation	50	Loss of all teeth	40
Not involving temporomandibular articulation	30	Loss of all upper teeth	30
9903 Mandible, nonunion of: Severe	30	Loss of all lower teeth	30
Moderate	10	All upper and lower posterior teeth	
Note-Dependent upon degree of motion	10	missing	20
and relative loss of masticatory function.		All upper and lower anterior teeth	
9904 Mandible, malunion of:		missing	20
Severe displacement	20	All upper anterior teeth missing	10
Moderate displacement	10	All lower anterior teeth missing	10
Slight displacement	0	All upper and lower teeth on one	
NOTE—Dependent upon degree of motion		side missing	10
and relative loss of masticatory function.		Where the loss of masticatory surface can	
9905 Temporomandibular articulation, limited mo-		be restored by suitable prosthesis	0
tion of:		NOTE—These ratings apply only to bone	
Inter-incisal range:		loss through trauma or disease such as	
0 to 10 mm	40	osteomyelitis, and not to the loss of the	
11 to 20 mm	30	alveolar process as a result of periodontal	
21 to 30 mm	20	disease, since such loss is not considered	
31 to 40 mm Range of lateral excursion:	10	disabling.	
0 to 4 mm	10	9914 Maxilla, loss of more than half:	
Note—Ratings for limited inter-incisal move-	10	Not replaceable by prosthesis	100
ment shall not be combined with ratings		Replaceable by prosthesis	50
for limited lateral excursion.		9915 Maxilla, loss of half or less:	
9906 Ramus, loss of whole or part of:		Loss of 25 to 50 percent:	
Involving loss of temporomandibular articu-		Not replaceable by prosthesis	40
lation		Replaceable by prosthesis	30
Bilateral	50	Loss of less than 25 percent:	
Unilateral	30	Not replaceable by prosthesis	20
Not involving loss of temporomandibular ar-		Replaceable by prosthesis	0
ticulation		9916 Maxilla, malunion or nonunion of:	
Bilateral	30	Severe displacement	30
Unilateral	20	Moderate displacement	10
9907 Ramus, loss of less than one-half the sub-		Slight displacement	0
stance of, not involving loss of continuity:			

Bilateral ...

Unilateral

9908 Condyloid process, loss of, one or both sides

[59 FR 2530, Jan. 18, 1994]

APPENDIX A TO PART 4—TABLE OF AMENDMENTS AND EFFECTIVE DATES SINCE 1946

Sec.	Diagnostic code No.	
4.71a	5000	Evaluation February 1, 1962.
	5001	Evaluation March 11, 1969.
	5002	Evaluation March 1, 1963.
	5003	Added July 6, 1950.
	5012	Criterion March 10, 1976.
	5024	Criterion March 1, 1963.
	5025	Added May 7, 1996.
	5051	Added September 22, 1978. Note July 16, 2015.
	5052	Added September 22, 1978. Note July 16, 2015.
	5053	Added September 22, 1978. Note July 16, 2015.